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ABSTRACT
A tr ia l  n a tr iu re t ic  peptide (ANP) has previously been shown to increase 
in t ra c e l lu la r  cGMP levels in isolated rat ven tr icu lar myocytes. Using 
p u r if ie d  ra t  cardiac sarcolemmal membranes, a series of experiments 
was performed to investigate the mechanisms by which th is  occurs. A 
second series of experiments was carried out to investigate the nature 
of ANP degradation by preparations isolated from ra t  heart, lung and 
kidney.
In r a t  cardiac sarcolemmal membranes, ANP produced a 1 .8 -fo ld  
stim ulation of manganese-dependent guanylate cyclase a c t iv i ty ,  with a 
Km of around InM. This a c t iv i ty  was attenuated by the presence of 1 mM 
ATP in the incubation. In the presence of magnesium, guanylate cyclase 
a c t iv i t y  was reduced 20- to 40-fo ld , but was augmented by ATP. Similar  
resu lts  were obtained in the presence of ANP-PNP, a non-hydrolysable 
analogue of ATP.
[125 i ]_ anp binding studies indicated the presence of two 
r e c e p to r /a f f in i ty  states, with K^'s of less than 10 pM, and around 1 
nM fo r  the high and low a f f in i t y  sites respectively. More than 90% of  
these receptors were of the low a f f in i t y  form. Sim ilar results were 
obtained with bovine adrenal cortex membranes, but with MDCK cell  
membranes, only high a f f in i t y  binding sites could be detected.
These experiments indicate that ra t  cardiac sarcolemmal membranes 
possess ANP receptors, at least a proportion of which are coupled to 
guanylate cyclase.
Incubation of [^^^I]-ANP with isolated ra t  ven tr icu lar myocytes, or 
with a cytosolic frac tion  prepared from these c e l ls ,  resulted in i ts
Xlil
rapid degradation. The proteolytic  a c t iv i t y  appeared to be due to the 
action of a soluble metallopeptidase. Incubation of [^^^I]~ANP with a 
cytosolic fraction  prepared from ra t  kidney and lung indicated that  
s im ilar  degradative a c t iv i ty  could be isolated from these tissues.
XIV
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CHAPTER 1
1.1 H istorica l Perspectives
In recent years much evidence has accumulated to suggest that 
mammalian a t r ia  play an important ro le  in body f lu id  homeostasis.
Henry et a l .  (1956) showed that mechanical distension of the a t r ia ,  in 
the absence of volume expansion, e l ic i te d  an increase in diuresis and 
n atr iu re s is ,  w h ils t  Goetz et a l . (1970) demonstrated that acute 
e x tra c e llu la r  f lu id  volume expansion had no e f fe c t  on urine flow when 
a t r ia l  distension was prevented.
Early studies on the morphology of the mammalian heart revealed the 
presence, in a t r ia l  but not ven tricu lar c e l ls ,  of electron dense 
granules which were closely associated with the Golgi complex (Kirsh, 
1956; Jamieson & Palade, 1964). The degree of granulation varied 
according to the s a lt  and water status of the animal, a progressive 
decrease in g ranu larity  being observed with increasing sodium and 
water loading (Marie et a l . . 1976; De Bold, 1979). When injected into  
ra ts ,  extracts of a t r ia l  muscle were shown to produce powerful 
n a tr iu re t ic  and d iu re t ic  responses, and the term " a t r ia l  n a tr iu re t ic  
factor"  (ANF) was used to describe the substance(s) responsible fo r  
th is  e f fe c t  (De Bold et a l . .  1981). Using ce l l  frac tiona tion  studies, 
i t  was soon established that the n a tr iu re t ic  a c t iv i t y  was closely  
associated the presence of the electron dense granules (De Bold,
1982a; Garcia et a l . . 1982). I t  was observed tha t  n a tr iu re t ic  a c t iv i ty  
was not destroyed by boiling (Trippodo et a l . . 1982; Grammer et a l . . 
1983) and that recovery was better from acid extracts than from 
physiological buffers (De Bold, 1982b; De Bold & Flynn et a l . . 1983).
.i
Together with e a r l ie r  experiments which had shown that the electron  
dense granules were able to incorporate [^H]-leucine (Huet & Cantin, 
1974; De Bold & Bencosme, 1975), these observations strongly suggested 
that ANF was proteinaceous in nature.
Since these early  studies much work has been carried  out on the 
biochemistry and physiology of ANF, both in v itro  and in vivo. In the 
remainder of th is  chapter I shall summarise the current information 
concerning the synthesis and structure of ANF, i ts  physiological and 
pharmacological e f fe c ts ,  and the ro le  of cGMP in the action of ANF.
1.2 Nomenclature
ANF is now known to be a peptide and therefore I shall use the term 
ANP ( a t r i a l  n a tr iu re t ic  peptide) to re fe r  to th is  substance. 
Alterations to the length of th is  peptide are denoted by subscripts 
and a lte ra tions  to the amino acid composition are indicated in 
brackets. For example
ANP5_27 (fy^^) re fers  to the amino acid sequence from Ser^ to Arg^7 in 
which Phe® has been replaced by Tyr.
1.3 Structure of ANF and Related Peptides
Early attempts to determine the structure of ra t  ANP resulted in a 
var ie ty  of d i f fe re n t  peptides, ranging in length from 19 to 35 amino 
acid residues (Flynn et a l . . 1983; Atlas et a l . . 1984; Currie et a l . . 
1984a; Gel 1er et a l . . 1984; Mi sono et a l . . 1984ab; Napier et a l . .
1984; Seidah et a l . ,  1984). A il the sequences id e n t if ie d  shared the 
same 18 amino acid core containing two cysteine residues linked by a 
disulphide bridge, and were apparently truncated versions of the same 
peptide. Similar sequences were isolated from human a t r ia  and d iffe red
only in the presence of a methionine residue in place of an isoleucine  
(Kangawa & Matsuo, 1984; Thibault e t  a l . . 1984a). Larger molecular 
weight peptides, which could be converted into the low molecular forms 
by treatment with trypsin  and k a l l ik re in ,  were also isolated (Currie  
et a l . , 1984b). The low molecular weight forms appeared to be derived 
from the carboxyl-termini of the higher molecular weight molecules.
Using olgionucleotide probes derived from known amino acid sequences 
of ra t  ANP, cDNA l ib ra r ie s  were screened fo r  the peptide (Maki et a l . . 
1984; Yamanaka et a l . . 1984). The ANP precursor was determined by the 
id e n t if ic a t io n  of the sequence encoding ANP and by following the N- 
terminus of th is  sequence u n t i l  an area could be id e n t if ie d  as being 
s im ila r  to a c lassic  signal polypeptide sequence (Perlman & Halverson
1983). Prepro-ANP was found to consist of 152-amino acids of which the 
f i r s t  24 constituted the signal sequence (Maki e t  a l . . 1984). Pro-ANP 
is composed of the following 125 amino acids of which the f in a l  28 
residues make up ANP ( f i g  1.1) .  Part of the amino-terminal sequence of 
pro-ANP has substantial homology with the cardiodila t in  peptides 
isolated from pig a t r ia  and shown to possess vaso-relaxant a c t iv i ty  
(Forssmann et a l . . 1983; 1984). I t  is possible that the card iodila tins  
are part of a s im ila r  a t r ia l  peptide in the pig. The f in a l  two 
arginine residues th a t  are encoded fo r  at the C-terminus have never 
been id e n t if ie d  on any ANP fragment as yet isolated, and therefore  
presumably are cleaved very rap id ly  from the primary translation  
product.
Human prepro-ANP has been id en tif ie d  by s im ilar techniques and found 
to consist of 151 amino acids of which the f i r s t  25 residues are the 
signal peptide (Oikawa et a l . . 1984). Human prepro-ANP is 80%
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homologous with the ra t  peptide, the greatest s im ila r i ty  occuring at 
the carboxyl-terminus. The f in a l  28 amino acids, which constitute ANP, 
are identica l except fo r  the replacement in the human peptide of the 
isoleucine residue at position 12 in ra t  ANP with a methionine 
res id u e (f ig .  1 . 1 ) .
The cDNA sequences were used in turn to screen genomic DNA l ib ra r ie s  
fo r  the gene encoding ANP, and the human (Greenberg e t  a l . . 1984;
Nemer et a l . . 1984), mouse (Seidman et a l . . 1984) ra t  (Argentin et 
a l . . 1985), and bovine genes (Vlasuk et a l . ,1986) have been 
characterized. The gene is highly conserved between species and is 
present as a single copy per haploid genome (Seidman et a l . . 1984; 
Argentin et a l . . 1985). The intron-exon structure in a l l  cases 
consists of 3 exons and two introns. The f i r s t  exon encodes the AUG 
i n i t ia t o r  codon, the signal peptide, and f i r s t  16 amino acids of pro- 
ANP, in addition to an untranslated 5' sequence. The second exon 
encodes the sequence up to and including Arg^^S, and the remaing exon 
contains codons fo r the f in a l  amino acid (human) or las t three amino 
acids ( r a t ,  mouse, and bovine), as well as the stop codon and the 3' 
untranslated sequences ( f i g .  1 . 2 ) .
1.4 ANP Gene Expression
1.4.1 Expression of ANP Gene in the Heart
The measurement of ANP mRNA in a t r ia l  tissue has been used to assess 
ANP gene expression under a number of conditions. ANP mRNA levels were 
substan tia lly  lowered (approximately 30% of control leve ls )  in rats  
deprived of water or fed on a low sodium d ie t ,  whereas there was no 
e f fe c t  on transcipt levels in rats on high sodium diets (Tagayanagi et
Figure 1.2
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a l . . 1985). Volume overload produces a small ( less than 2 - fo ld )  
increase in expression (Nemer et a l . . 1987; Lattion et a l . . 1986)
The second intron of the ra t  and human gene contains a consensus 
sequence fo r  a potentia l glucocorticoid receptor-binding s ite  
(Greenberg et a l . . 1984; Argentin et a l . . 1985), ra is ing the 
poss ib lity  that expression of the ANP gene may be regulated by 
glucocorticoids. This is supported by the observation that  
glucorticoids produce a 2- to 3 -fo ld  increase in ANP a t r ia l  mRNA 
levels in the ra t  (Gardener e t  a l . . 1986a; Nemer e t a l . . 1987)
1. 4. 2 Expression of the ANP Gene in Other Tissues
Although secretory vesicles containing ANP have only been found in the 
a t r ia ,  cDNA probes have id e n t if ie d  ANP transcrip ts  in ra t  ven tricu lar  
muscle (Gardener et a l . . 1986b; Takayanagi et a l . . 1987a), a lb e i t  at 
concentrations 100- to 250-fold less than those found in a t r ia l  
t issue. I t  should be noted however that when the re la t iv e  volumes of 
a t r ia l  to ven tr icu lar  tissue are taken into account, the absolute 
level of ANP mRNA is only around 5-fo ld  less in the ven tr ic les .  
Although the levels of ANP detected in ven tr icu lar muscle are some
1,000- to 20 ,000-fo ld  less than in a t r ia  (Nemer et a l . . 1986;
Takayanagi et a l . . 1987a), i t  is possible that the ventr ic les  make a
s ig n if ican t  contribution to plasma levels of ANP by continual 
secretion of the peptide into the blood stream.
The levels of ANP, and ANP mRNA in the ventric les are a lte red  in some 
diseased states and under certa in  experimental conditions. The levels  
of ANP are about 3 - fo ld  higher in the ventric les of spontaneously 
hypertensive ra ts  compared to controls (Takayanagi et a l . . 1987a).
Volume over-load and glucocorticoid administration appear to 
p re fe re n t ia l ly  increase ANP mRNA in ra t  ventr ic les , producing 4- to 
11-fo ld  increases in ven tr icu lar levels compared to 1 .5 -  to 3 3-fo ld  
increases in the a t r ia  (Lattion et a l . , 1986; Nemer e t a l . , 1987). In 
the cardiomyopathic hampster electron dense granules, s im ilar to those 
found in a t r ia ,  have been id e n t if ie d ,  and found to contain 
immunoreactive ANP (Cantin et a l . . 1987; Ding et a l . . 1987).
Transcripts of ANF have also been detected in the lung, anterior
p i tu i ta r y ,  and the aort ic  arch (Gardner et a l . . 1986b).
1.5 Secretion and Processing of ANP
The exact nature of the peptide secreted into the blood stream has yet
to be conclusively determined. Cultures of a t r ia l  and ven tr icu lar  
cardiomyocytes, isolated from newborn rats , secrete only 10 to 20 % of 
ANP as the C-terminal form, the rest being pro-ANP (Glembotski & 
Gibson, 1985; Bloch et a l . , 1985). In contrast, the eluate from the 
perfused ra t  heart contains only the short form of ANF (Currie et a l . ,  
1984c; Lang et a l . . 1985).
In humans, three forms of ANP have been iden tif ied  in the a t r ia .  
Alpha-human ANP (a-hANP) is comprised of the 28 amino acids from the 
carboxyFterminal of the 126 amino acid prohormone gamma-hANP. Beta- 
hANP is an a n t ip a ra l le l  dimer of alpha-hANP, formed by intermolecular 
disulphide bridges (Kangawa & Matsuo, 1984; Nakao et a l . , 1984; 
Needleman et a l . . 1985).  The dimeric form of ANP has only been 
id e n t if ie d  in humans. Alpha-hANP is the major form of the peptide 
found c ircu la ting  in the blood (Miyata et a l . , 1987; Sugawara e t a l . .
1985), although s ig n if ic a n t  levels  of beta-hANP have been detected in
the blood of some subjects (Miyata et a l . , 1987). I t  has recently been 
reported that beta-hANP is converted to alpha-hANP in the human 
c irc u la t io n ,  and that whilst the n a tr iu re t ic  and d iu re t ic  a c t iv ité s  of 
administered beta-hANP have a slower onset, the peptide is more potent 
and has a longer duration of a c t iv i ty  ( Itoh , et a l . . 1988).
1 .6  ANP in Other Tissues
Immunoreactive ANP has been id en tif ie d  in the lung (Gardner et a l . . 
1986b), and b io lo g ic a lly  active ANP has been shown to be released from 
perfused ra t  lung (Gutkowska & S iro is , 1988).
Immunoreactive ANP has also been iden tif ied  in the ao rt ic  arch 
(Gardner et a l . ,  1987), the p i tu ita ry  gland (Samson, 1985), and
several areas of the brain. The highest levels in the brain are found
in the hypothalamus, septum, and midbrain, with smaller amounts in the 
cerebral cortex, o lfac to ry  bulb, thalamus, pons-medulla, and 
hippocampus (Jacobowitz et a l . . 1985). A peptide has recently been 
iso lated from porcine brain which e l ic i t s  n a tr iu re t ic  and d iu re t ic  
responses s im ilar to those observed with ANP (Sudoh et a l . , 1988).
This peptide has been termed BNP (brain n a tr iu re t ic  peptide) and 
cons i ts  of 26 amino acid residues which share 60% homology with ANP. 
BNP may be the major n a tr iu re t ic  peptide in the CNS.
1.7 Physiological Effects
ANP has been shown to have d irec t  actions on a number of d i f fe re n t  
tissues both in vivo and in v i t r o . These actions include the 
re laxation  of preconstricted smooth muscle, a lte ra tions  in renal 
haemodynamics, inh ib it io n  of sodium reabsorption in the co llecting  
tubule of the kidney, and inh ib it io n  both of renin and aldosterone
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re lease . These e ffects  are discussed in more deta il  below.
1. 7.1 Vascular Effects of ANP
The observation that a t r ia l  extracts relaxed preconstricted smooth 
muscle (Deth et a l . . 1982; Currie et a l . . 1983), and the subsequent 
confirmation that both extracted ANP (Garcia et a l . . 1984a) and 
synthesised ANP (At las et  a l . . 1984; Garcia et a l . . 1984b; Cohen & 
Shenk, 1985) acted s im ila r ly ,  suggested that vaso-relaxation may be 
responsible fo r  some of the hypotensive actions of ANP. In general, 
vaso-relaxation is independent of the constrictor, and ANP e f fe c t iv e ly  
antagonizes the actions of noradrenaline, histamine, carbachol, and 
angiotensin I I .  However, variable responses have been reported to KCl 
induced vasoconstriction (Garcia et a l . . 1984a; Rapoport et al 1985; 
B ra tve it  et a l . . 1987). The reasons fo r  th is  discrepancy in the action  
of ANF on KCl-induced vasocontriction are not c lear, but may be due to  
differences in the mechanisms by which these compounds a l te r  
in t ra c e l lu la r  Ca^*. Noradrenaline and angiotensin I I  act both by a 
receptor-mediated stimulation of Ca^^ influx and by the release Ca^* 
from in tra c e llu la r  stores (Deth & Van Breemen, 1977; Van Breemen et  
a l . . 1982). ANP has been shown to in h ib it  agonist-stimulated Ca^* 
in f lu x  and in tra c e llu la r  Ca^* release, but has no e f fe c t  on KCl 
stimulated Ca^* in flux  (Chiu et a l . . 1986; Meisheri et a l . 1986).
The degree of ANP-induced vaso-relaxation is dependent on both the 
analogue of ANP used, and the orig in  of the tissue under 
investigation . In general, ANP is a more e f fec tive  vaso-relaxant in 
a r t e r ia l  than in venous preparations, with the degree of re laxation  
corre la ting  with the number of receptors in the tissue (Cohen &
Schenck 1985). The extension or truncation of the amino-terminal has
l i t t l e  or no e f fe c t  on the vaso-relaxant properties of the peptide 
(Misono et a l . . 1984b; Garcia et a l . . 1985), and deletion of the Tyr^® 
from the carboxyl-terminal is also without e f fe c t .  However, removal 
of Phe2G_Arg27_Tyr28 residues produces a peptide which is 70- to 1000- 
fo ld  less potent at relaxing preconstricted smooth muscle (Sugiyama et  
a l . . 1984; Garcia et a l . . 1985; Wakitani et a l . . 1985; Bratve it  et a l . . 
1987; Budzik et a l . . 1987).
The mechanism of action of ANP as a vaso-relaxant is thought to be 
mediated by increasing in t r a c e l lu l la r  cGMP. ANP induced relaxation has 
been shown to be associated with the formation of cGMP (Rapoport et  
a l . ,  1985; 1986) and ANP has been shown to increase cGMP in several 
smooth muscle preparations (see section 2. 3) .  A recent study however 
has dissociated the vaso-relaxant e ffec ts  of various analogues of ANP 
on preconstricted rabbit aorta from the a b i l i t y  of these analogues to  
ra ise  in tra c e llu la r  cGMP levels in cultured rabbit vascular smooth 
muscle cel ls (VSMC; Budzik et a l . 1987). In th is  study, ANPg_27 (Tyr8 ) 
was unable to increase cGMP in VSCM cultures but was able to 
antagonise the actions of histamine on the aorta preparation. 
Conversely, ANP7.22  ANPy_22(Lys^^) stimulated cGMP to the same 
extent as ANPg_2g, but were 1000- fo ld  less e f fec tive  than ANP5.28  
vaso-relaxants. This study therefore ca l ls  into question the ro le  of 
cGMP as the mediator of ANP's vaso-relaxant action. I t  should however 
be noted that the e ffects  of ANP on in tra c e llu la r  cGMP and 
preconstricted smooth muscle were measured in two d if fe re n t  systems. 
Thus the dissociations reported by Budzik et a l . (1987) may be due to  
differences between th e ir  two preparations. In addition, cGMP levels  
in VSMC ce lls  were measured following prolonged incubations (120 min) 
of peptides with the cel l s .  I t  is therefore possible that the
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differences in the a b i l i t y  of the various peptides to increase 
in t ra c e l lu la r  cGMP in these cel l s may be a result of d i f fe re n t ia l  
in te rn a lisa t io n  and/or degradation.
The e ffe c ts  of other vaso-relaxants, such as acetylcholine, histamine, 
bradykinin and the n itro-vasodilators are also mediated by increases 
in in tra c e l lu la r  cGMP. Acetylcholine, histamine, and bradykinin exert  
th e ir  e f fe c t  by the release of endothelial-derived relaxant factor  
(EDRF) and require the presence of an endothelium ( fo r  review see 
Rapoport & Murad, 1983; Furchgott, 1984). The n itro -vasodila tors  act 
by the formation of n i t r ic  oxide, which in turn increases 
in t r a c e l lu la r  cGMP. There is increasing evidence that EDRF is in fac t  
n i t r i c  oxide (Palmer et a l . . 1987), and hence a l l  these compounds act 
through a common mechanism. In contrast, ANP does not require the 
presence of an intact endothelium (Winquist et a l . ,  1984) and is not 
inh ib ited  by methylene blue, a powerful in h ib ito r  of n i t r i c  oxide 
mediated cGMP accumulation (Rapoport et a l . .  1985; Bratve it  et a l . .
1987). ANP has been shown to increase in tra c e l lu la r  cGMP by 
stim ulation of part icu la te  guanylate cyclase (Winquist et a l . .  1984;
Waldman e t  a l . , 1984), whereas methylene blue only in h ib its  the 
actions of soluble guanylate cyclase. Vaso-relaxation can therefore  
occur by the action of two classes of vasodilator, which act through 
d if fe re n t  mechanisms to increase in tra c e l lu la r  cGMP.
Whilst the studies on isolated vascular preparations are in general 
consistent with ANF being a potent vasodilator, the evidence in vivo j
is fa r  from conclusive. Although some studies have reported that 
administration of ANP results in a decrease in to ta l  peripheral 
resistance (TPR; Ackermann et a l . . 1894; Fujioko e t a l . . 1985; Volpe
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et a l . . 1986), others have reported no change or even an increase 
(Koike et a l . . 1984; Lappe et a l . . 1985). Some of these variations may 
be accounted fo r by d iffe ren t experimental protocols, which make i t  
d i f f i c u l t  to d ire c t ly  compare studies. The most consistent 
observations are with respect to the e ffec ts  of ANP on mean a r te r ia l  
pressure (MAP) and cardiac output (CO). Administration of ANP ( a t r ia l  
extract or various analogues of ANF) in general causes a reduction in 
MAP. The reported decreases in MAP in these studies ranged from 0 to 
25%. The largest reductions were observed in studies on hypertensive 
animals (see table 1 in Peqram et a l . . 1986).
1. 7. 2 Effects of ANP in the Kidney
The observation by De Bold et a l .  (1981) that in jection of ra t  a t r ia l  
extracts into the the ra t  produces a profound n a tr iu re t ic  and d iu re t ic  
response has prompted many investigations into the mechanism by which 
th is  occurs. The renal response both to a t r ia l  extracts and synthetic  
ANP is rapid (1-2 min) and short lived (less than 20 min) (De Bold et  
a l . . 1981; Ackermann et a l . . 1984; Burnett e t  a l . . 1984), and results  
in increases in potassium, calcium, magnesium and phosphate excretion  
as well as sodium and water excretion (Keeler and Azzarolo 1983; 
Burnett et a l . . 1984). ANP increases glomerular f i l t r a t i o n  rate  (GFR; 
Atlas et al 1984; Burnett et a l . .  1984; Camargo et a l . . 1984; Cogan
1986) and reduces inner medullary hypertonicity (Borstein et a l . 1983; 
Sosa et a l . . 1986).
In the isolated perfused ra t  kidney, in the absence of 
vasoconstriction, ANP increases GFR and produces a small increase in 
renal vascular resistance. In contrast, in the presence of 
vasoconstricting agents, ANP produces a net renal vasodilation
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(Camargo et al 1984). The effects  of ANP on GFR appear to be due to 
the d i f fe r e n t ia l  effects  of the peptide on the renal vasculature. ANP 
d ila tes  the arcuate and in te rlobu lar a r te r ie s ,  and the affe ren t  
a r te r io le s  of the glomerulus, but constricts the effe ren t a r te r io les  
of the glomerulus (Camargo et a l . 1984; Maack & K le inert 1986). The 
net resu lt  of th is  is an increase in the glomerular c a p il la ry  
hydraulic pressure, and hence an increase in GFR. The increase in 
renal resistance observed in the isolated perfused kidney is 
presumably due to the absence of any constricting  agents in the 
preparation, and thus the only e f fe c t  of ANP is as a vasoconstrictor 
in the e ffe ren t a r te r io le .  Although i t  has been claimed that these 
changes are s u f f ic ie n t  to account fo r  the observed natr iu res is  (Huang 
et a l . . 1985), the glomerular e ffec ts  only account fo r a 2- to 3 -fo ld  
increase in solute and f lu id  in the d is ta l tubule (Huang et a l . .
1985). Administration of ANP commonly results  in a 10- to 50-fo ld  
increase in na tr iu res is  (Burnett et a l . .1984; Maack et a l . . 1984), and 
therefore other tubular mechanisms must be involved. P a rt ia l  clamping 
of the renal a r te ry ,  which abolishes renal haemodynamic e f fe c ts ,  also 
abolishes the n a tr iu re t ic  actions of ANP (Sosa et a l . . 1986). This 
suggests that ANP-induced natr iu res is  results mainly from the e ffec ts  
of ANP on the renal vasculature, rather than from d irec t tubular 
action. Further evidence in support of the importance of the 
haemodynamic e ffec ts  of ANP is given by the observation that doses of 
ANP which do not increase GFR are s u ff ic ie n t  to induce a 
red is tr ib u t io n  of renal blood flow from the sup erfic ia l to the 
juxtamedullary nephrons (Salazar et a l . .  1986).
Micropuncture studies and isolated perfused tubule experiments have 
fa i le d  to show any e f fe c t  of ANP on sodium transport in the area of
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the nephron from the proximal convoluted tubule to the cort ica l  
collecting  duct (Baum & Toto 1986; Cogan, 1986 Huang et al 1985; Kondo 
et a l . . 1986). Studies on ce lls  isolated from the inner medullary 
collecting  duct indicate that ANP reduces sodium entry into these 
cel l s  by a mechanism which does not involve a d ire c t  e f fe c t  on 
Na^YK^-ATPase (Zeidel et a l . . 1986). Further experiments suggest that  
the mechanism by which th is  occurs most probably involves the 
inh ib it io n  of a sodium channel or a Na*/H* exchanger in the luminal 
membrane (Ze ide l,  1988).
1 . 7 . 3  Effects of ANP on Renin Release
The constant infusion of ANP results in a rapid decrease in renin 
secretion in the normal dog (Maack et a l . . 1984; Burnett et a l . .
1984). However, a recent study in the ra t  fa i le d  to show any ANP- 
stimulated a lte ra tio n s  in plasma renin concentrations (H ira ta  et a l . . 
1987a). Since renin release would be expected to increase as a resu lt  
of the n a tr iu re t ic  and d iurectic  responses e l ic i t e d  in these 
experiments, the absence of a r ise  in plasma renin concentration in 
the ra t  indicates that ANP is also supressing renin release in th is  
preparation.
Decreases in renin release may resu lt  from an increase in the 
concentration of sodium reaching the macula densa, or an increase in 
the hydrostatic pressure at the juxtaglomerular ce lls  l in ing  the 
a ffe re n t a r te r io le .  Since ANP does not lower renin secretion in the 
n o n -f i l te r in g  kidney, i t  is l ik e ly  that ANP in h ib it io n  of renin 
release is through a mechanism involving the macula densa (Opgenorth 
e t a l . . 1986).
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1. 7. 4 Effects of ANP on Aldosterone
As ear ly  as 1959 i t  was noted that stretching the r ig h t  a t r ia  of the 
dog resulted in decreased aldosterone secretion (Anderson et a l ,
1959). Subsequent experiments suggested the p o s s ib i l i ty  that th is  
procedure resulted in the release of an in h ib ito r  of aldosterone 
secretion (Gann & Travis 1964). Since the discovery of ANP much 
atten tion  has been paid to the rç le  of th is  peptide as an antagonist 
of aldosterone secretion. Several reports have shown that ANP and 
re la ted  peptides in h ib i t  basal aldosterone production by adrenal zona 
glomerulosa cel l s ,  and antagonise stimulation by angiotensin I I ,  
dibutyryl cAMP and potassium (Atarashi et a l . . 1984; Chartier et a l . .  
1984; Goodfriend e t  a l . ,  1984). Although the e ffec ts  of ANP on 
stimulated aldosterone secretion are well established, there are 
reports in which ANP fa i le d  to lower basal levels of secretion (eg. 
Naruse et a l . ,  1987).
In vivo studies have shown that infusion of ANP into both the dog and 
the ra t  results in a f a l l  in the plasma aldosterone levels (Maack et  
a l . . 1984; Aguilera 1987; H irata e t  a l . . 1987a). Although th is  may in 
part be due to the decrease in renin secretion, ANP has been shown to 
decrease plasma aldosterone in the r a t ,  in the absence of decreases in 
plasma renin and in the presence of an ACE in h ib ito r  (H ira ta  et a l . . 
1987a). I t  therefore appears l ik e ly  that ANP has a d irect e f fe c t  on 
aldosterone production by the adrenal cortex. The exact point at which 
ANP acts to in h ib i t  aldosterone production is not known, however i t  
appears to be at a point prior to mitochondrial uptake and the 
metabolism of cholesterol (Goodfriend et a l . , 1984).
ANP appears to have no e f fe c t  on glucocorticoid production in the ra t
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or the dog (Atarashi e t  a l . . 1984, Maack e t a l . . 1984), but i t  has 
been reported to in h ib i t  production by the bovine adrenal gland (De 
Lean et al 1984a) and by adrenal tissue obtained from patients with  
Cushing's syndrome (Naruse et a l . . 1987).
1 .8  Summarv
ANP produces na tr iu re s is ,  diuresis and vaso-relaxation under a var ie ty  
of experimental conditions, both in vivo and in v i t r o . The major 
source of ANP in the body is from secretory granules located in the 
a t r ia ,  but ANP transcrip ts  have been id en tif ied  in several other 
t issues, and these may make s ig n if ican t contributions to overall  
l evels.  The in te r-re la tionsh ips  between the d if fe re n t  effects e l ic i te d  
by ANP are complex; which of these e ffec ts  are caused by the primary 
action of ANP, and which are secondary in nature, remains to be 
conclusively established.
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CHAPTER 2
2.1 Guanylate Cvclase and Receptors
In a number of d i f fe re n t  tissues and preparations, ANP has been shown 
to increase in tra c e l lu la r  cGMP production and stimulate guanylate 
cyclase a c t iv i ty .  In addition, ANP receptors, id e n t if ie d  by d irec t  
binding studies and autoradiography, have been shown to be widely 
d istribu ted  in mammalian tissues ( fo r  review see At las,  1986; Genest & 
Cant in, 1988). The following chapter reviews some of information 
curren tly  available concerning guanylate cyclase a c t iv i t y  and its  
re la tionsh ip  to the ANP receptor.
2.1 Guanvlate Cvclase A c tiv ity
Guanylate cyclase is an enzyme which catalizes the formation of cyclic  
guanosine 3 ‘ , 5 ' -monophosphate (cGMP) from GTP. I ts  presence has been 
id e n t if ie d  in almost a l l  cel l  types examined and i ts  a c t iv i ty  can be 
a ttr ib u ted  to at least two isoenzymes, a soluble (cytoso lic )  and a 
p art ic u la te  form. The soluble and part icu la te  isoenzymes coexist in 
most ce l l s ,  although the d is tribu tion  varies from tissue to tissue.  
Soluble guanylate cyclase is the predominant form in the adult l iv e r  
(Kimura & Murad, 1975a) and p la te le ts  (Bohme et a l . . 1974), w hils t the 
major form is pa rt ic u la te  in regenerating and fe ta l  l iv e r  (Kimura & 
Murad 1975b), in te s t in a l  mucosa (De Jonge, 1975) and re t in a l  rod outer 
segments (Fleischman & D e n is e v ic h ,  1979;  Gordis e t  a l . . 1973; 
Krisanan et a l . 1978). In the sea urchin sperm (Gray & Drummond,
1976), Cg ra t  glioma cel l s ,  and B103 ra t  neuroblastoma ce lls  (Sinacore 
et a l . . 1983), guanylate cyclase a c t iv i ty  appears to be exclusively  
due to the p a rt ic u la te  isoenzymes.
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Soluble guanylate cyclase has been purified  to apparent homogeneity 
and appears to ex is t as a haem-containing heterodimer (Gezer et a l . , 
1981b; Gerzer et a l . . 1981c) with an apparent molecular weight of
150,000 (Garber 1979; Lewicki et a l . . 1980; Gerzer et a l . . 1981a).
This form of the enzyme is stimulated by the n itro -vasodila tors  such 
as azides, n i t r i t e ,  n itrog lycerin , and nitroprusside and by the vaso­
re laxant, endothelial-derived relaxant factor (EDRF). Further de ta ils  
on the d is tribu tion  and mechanism of action of soluble guanylate 
cyclase can be found in the review by Waldman & Murad (1987).
Based on i t  so lu b il iza t io n  characteris tics , p a rt ic u la te  guanylate 
cyclase a c t iv i ty  can be subdivided (Waldman & Murad, 1987). One form 
is read ily  so lubilized by detergents, such as Triton X-100, and is a 
glycoprotein with an estimated molecular weight of 300,000 to 400,000 
(Limbird et a l . . 1975; Goldberg & Haddox, 1977). I t  has been highly  
p u rif ied  from lung (Waldman et a l . . 1985; Kuno et a l . , 1986), and SDS 
polyacrylamide gel electrophoresis yields an apparent molecular weight 
of 130,000. I t  is possible that th is  enzyme exists as a dimer in the 
cel l  membrane.
A portion of the p art icu la te  guanylate cyclase a c t iv i t y  in the 
m icrovillus brush border of the in tes tina l mucosa is res is tan t to 
so lu b iliza t io n  by a va r ie ty  of agents including sa l t ,  EDTA, 
detergents, and IM urea (Waldman et a l . . 1986). This s o lu b i l iz a t io n -  
res is tan t form of the enzyme is associated with microtubular and/or 
filamentous structures in the ce l l ,  and appears to be a d if fe re n t  
isoenzyme (Waldman et a l . . 1986).
P art icu la te  guanylate cyclase a c t iv i ty  is not stimulated by n i t r ic  
oxide (Tremblay et a l . . 1985), and u n t i l  recently the heat-stable
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enterotoxin from E. Coll (ST) was the only known b io logical activator  
(F ie ld  et a l . , 1978). ST stimulates only the s o lu b il iz a t io n -re s is ta n t  
form of guanylate cyclase a c t iv i ty  found in in tes tin a l smooth muscle 
preparations (Waldman et a l . . 1986). Recently, ANP has been iden tif ied  
as a potent stimulator of particu la te  guanylate cyclase a c t iv i ty  in 
many tissues, including lung (Kuno et a l . , 1986), adrenal cortex ( 
Waldman et a l . . 1984; Tremblay et a l . . 1986; Takayanagi e t  a l . .
1987b), l iv e r  (Waldman e t  a l . . 1984; Kurose e t a l . . 1987), kidney 
(Waldman et a l . . 1984), testes (Marala & Sharma, 1988), and several 
cultured cel l  lines (Leitman et a l . . 1986). Several of these studies 
have reported ANP stimulation of guanylate cyclase a c t iv i t y  in 
detergent-so lubilized  membranes, which must necessarily preclude the 
presence of the s o lu b il iza t io n -re s is ta n t  form. The s p e c if ic i ty  of ANP 
fo r  the two forms of part icu la te  guanylate cyclase remains to be 
established, although i t  is known that ANP does not stimulate soluble 
guanylate cyclase a c t iv i t y  (Waldman et a l . . 1984; Winquist et a l . . 
1984).
P a rt icu la te  guanylate cyclase a c t iv i ty  has been co -purif ied  with the 
ANP binding sites from solubilized plasma membranes of lung and bovine 
adrenal cortex (Kuno et a l . . 1986; Takayanagi et a l . . 1987b). This has 
led to the suggestion tha t an ANP receptor is an in tegra l part of the 
p art ic u la te  guanylate cyclase molecule. This p o s s ib i l i ty  w i l l  be 
discussed in more d e ta i l  la te r  in th is  chapter (sections 2.4. 2 and 
2 . 4 . 3 )
2.3 ANP Stimulation of In tra c e l lu la r  cGMP Production
ANP has been shown to increase in tra c e l lu la r  cGMP levels  in whole ce l l  
preparations and established ce ll  lines derived from kidney (Tremblay
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et a l . , 1985; Waldman et a l . . 1984; Takeda et a l . .  1986; Inui et a l . . 
1985; Leitman et a l . , 1988), vascular smooth muscle (Rapoport et a l . . 
1986; H irata et a l . . 1984; Hamet et a l . .  1986, Cohen & Schenk, 1985), 
endothelia (Leitman et a l . . 1988), lung (Waldman et a l . , 1984; Leitman 
et a l . . 1988), and mammary gland and te s t is  (Leitman et a l . . 1988).
ANP-induced vaso-relaxation is thought to be mediated through 
increases in in tra c e l lu la r  cGMP (see section 1 . 6 . 1 ) ,  and the e ffec t  of 
ANP on cGMP production has been examined in a number of cultured 
smooth muscle ce ll  l ines. ANP increases in t ra c e l lu la r  cGMP levels in 
bovine aort ic  smooth muscle cel ls (BASM; Scarborough et a l . . 1986; 
Leitman et a l . . 1988), AlO vascular smooth muscle ce lls  (AlO VSMC; 
Nambi et a l . . 1986; Napier et a l . . 1986; Neuser & Bellemann, 1986), 
and primary cultures of ra t  thoracic smooth muscle cel l s (Roubert et 
a l . . 1987). The concentration of ANP required to produce ha lf  maximal 
increases in in tra c e l lu la r  cGMP (ECgQ) ranged from 1 to 200 nM 
(Scarborough et a l . . 1986; Nambi et a l . .1986; Roubert et a l . . 1987). 
ANP has also been shown to raise in tra c e llu la r  cGMP levels in cultured  
bovine aort ic  endothelial cel l s  (BAE), with an ECgg of 0 .3  nM 
(Leitman & Murad 1986; Leitman et a l . . 1988), and in preparations of 
human coronary artery  (Rapoport et a l . . 1986). Although the EC50 
values fo r  ANP show a large degree of var ia t ion , they are in keeping 
with the reported levels of ANP required to produce vaso-relaxation in 
pre-contracted vascular preparations (Budzik et a l . . 1987; Cohen & 
Schenk, 1985; S ch il le r  e t  a l . . 1987).
ANP-induced elevation of in tra c e l lu la r  cGMP concentrations has been 
reported fo r  several renal preparations. ANP augments cGMP levels in 
the glomerulus (Ballerman et a l . , 1985; Tremblay e t a l . . 1985; Takeda
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et a l . . 1986), the cort ica l co llecting  duct (Tremblay e t a l . . 1985; 
Takeda et a l . , 1986), the d is ta l  convoluted tubule (Takeda et a l . . 
1986), and the thick loop of Henle (Tremblay et a l . . 1985). No e f fe c t  
of ANP has been demonstrated in the proximal tubule (Tremblay et a l . . 
1985; Takeda et a l . . 1986). Several studies have demonstrated effects  
of ANP on cGMP levels in cultured ce lls  derived from kidney. Increases
in cGMP levels have been reported in MOCK ce lls  (Leitman et a l . .
1988), LLC-PKi cel l s ( Inu i et a l . . 1985), primary cultures of ra t  
glomerular mesangial ce lls  (Ballerman et a l . . 1985), and cort ica l  
collecting  tubules (Naray-Fejes-Toth et a l . . 1988). The concentrations 
of ANP required to produce h a lf  maximum e ffe c t  (ECgg) are 1 and 10 nM 
fo r  the cort ica l co llecting  tubules and LLC-PKi cel l s respective ly .
ANP has also been shown to elevate cGMP levels in ra t  and rabb it  
ventr icu lar myocytes (Aiton & Cramb, 1985; Cramb et a l . . 1987), ra t  
leydig cel l s (Vlasuk et a l . . 1988; Leitman et a l . . 1988), cultures of 
human lung f ib rob las ts , ra t  mammary e p ith e l ia l  ce l l s ,  and bovine 
kidney (Leitman et a l . . 1988) and osteoblasts (Fletcher et a l . . 1986).
2.4 Localization and P u rif ica tio n  of ANP Receptors
2. 4.1 The Kidney
Autoradiographical studies in the kidney, using [^^^I]-ANP, have shown
labe lling  of a number of d i f fe re n t  regions. The m ajority  of labe lling
is associated with the glomeruli (Bianchi et a l . . 1985; Koseki et 
a l . . 1986a; Carrier  et a l . . 1985; Murphy et a l . . 1985; Mantyh et a l . . 
1986), but binding sites have been iden tif ied  on the outer medullary 
vasa recta (Bianchi et a l . . 1987), the inner medullary co llecting  
duct, (Bianchi et a l . . 1987; Koseki et a l . . 1986a; Mantyh e t a l . .
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1986), the renal arte ry  (Bianchi et a l . . 1985; Koseki et a l . ,1986a: 
Mantyh et a l . . 1986), and the renal pelvis (Koseki et a l . , 1986a).
Using ligand binding techniques, high a f f i n i t y  [^^^I]-ANP binding 
sites  have been demonstrated in renal cort ica l membranes derived from 
ra t  (Napier et a l . . 1984; Hori et a l . . 1985; Maack et a l . . 1987), 
rabb it  (Napier et a l . . 1984), dog (De Lean et a l . . 1985), and man 
(Ishikawa e t  a l . . 1987). Similar binding s ites have also been 
id e n t if ie d  in in tact cel l s  and membranes prepared from the cultured  
kidney e p i th e l ia ,  LLC-PK} (Napier et a l . . 1984; Inui et a l . . 1985).
The estimates of [^^^I]-ANP a f f in i t y  and number of binding sites in 
these preparations show a wide degree of varia t ion , with values for  
the Kb ranging from 50 to 1000 pM, and B ^^ from 15 to 500 fmol/mg 
prote in . The dose response curves for [^^^I]-ANP binding to ra t  and 
rab b it  kidney cortex were biphasic, suggesting the presence of high 
and low a f f i n i t y  receptors with Kq' s of 50 and 500 pM (Napier et a l . . 
1984).
D irect binding studies in ra t  glomerular membranes have id en tif ie d  
the presence of a single population of high a f f in i t y  binding s ites ,  
with a Kq of 27 pM (C arrie r  et a l . . 1985). Similar studies in isolated  
ra t  glomeruli also resulted in the id e n t if ic a t io n  of a single class of 
binding s ite s .  In th is  preparation, however, they were of lower 
a f f i n i t y ,  with a Kq of 220 pM (Ballermann et a l . . 1985). More 
recently , both high and low a f f in i t y  binding sites have been detected 
in p u r i f ie d  glomerular membranes, with K^'s of 5pM and 2.5nM 
respective ly  (Hamada et a l . . 1987). The discrepancies between these 
studies may, in part, be accounted fo r by differences in the 
concentration of [^^^I]-ANP used. In p a rt ic u la r .  Carr ier  et a l . (1985)
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used a very low concentration of radioligand (4.4pM) which would 
almost c e r ta in ly  resu lt  in the fa i lu re  to detect lower a f f in i t y  
binding si tes.
Cultures of mesangial and e p ith e l ia l  ce l ls  isolated from normal ra t  
glomeruli have indicated that the [^^^I]-ANP binding sites are 
confined to the mesangial ce lls  (Ballermann et a l . . 1985). This study 
also showed that the number and a f f i n i t y  of [^^^I]-ANP binding sites  
on ra t  glomeruli can be a ltered by changes in the s a l t  status of the 
animal. Glomeruli isolated from rats fed on a high s a lt  d ie t  have 
approximately four times less binding sites compared to those on a low 
s a lt  d ie t  (426 vs 116 fmol/mg pro te in ),  and this is accompanied by a 
two-fold reduction in the dissociation constant, which decreases from 
940 to 380pM.
P u rif ied  membrane preparations of glomeruli and inner medullary 
c o llec t ing  ducts from ra t  kidney have been p ho toa ff in ity  labelled with  
[125i]_ANP, and subjected to SDS electrophoresis under reducing 
conditions. In th is  study, autoradiographs revealed the specific  
labeling of a single band in both preparations, with an apparent 
molecular weight of 65 kDa (Koseki et a l . , 1986b). A s im ilar  cross- 
l ink ing study on a glomerular membrane preparation which had been 
shown to possess high and low a f f in i t y  ANP receptors, resulted in the 
la b e ll in g  of two bands at 75 kDa and 140 kDa (Hamada et a l . . 1987).
2 . 4 . 2  The Lung
Autoradiographic studies have shown that ANP binding s ites are widely  
d is tr ibu ted  in the ra t  lung. Binding sites have been localized on the 
endothelial and smooth muscle cel l s of the a r te r ie s ,  a r te r io le s ,  veins
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and venules, as well as the endothelial c e l ls  of the a lveo li  (Bianchi 
et a l . . 1985). Direct binding studies have id en t if ie d  ANP receptors in 
membranes prepared from ra t  (Kuno et a l . . 1986), rabb it  (01 ins et a l . . 
1986), and bovine (Ishido et a l . . 1986; Shimonaka et a l . . 1987) lung. 
The Ko fo r  [^^^I]-ANP binding to ra t  and rabb it lung membranes was 280 
and 320 pM respective ly , with the Bmax being 120 and 170 fmol/mg 
protein respective ly  fo r  the two species.
Rat lung ANP receptors have been purified  to apparent homogeneity by a 
combination of a f f i n i t y  and ion exchange chromatography (Kuno et a l . . 
1986). SDS polyacrylamide gel electrophoresis of the purif ied  
preparation, under both reducing and non-reducing conditions, resulted
in a single 120 kDa band. [^^^I]-ANP binding co-purified with
guanylate cyclase a c t iv i ty ,  suggesting that they are part of the same 
molecule.
Shimonaka e t  a l . . (1987) have a f f in i ty -p u r i f ie d  ANP receptors from 
bovine lung and th is  too resulted in the labe lling  of a 140 kDa band, 
as id e n t if ie d  by SDS polyacrylamide gel electrophoresis. In contrast 
to the previous study, th is  was t o ta l ly  converted to a 70 kDa band in 
the presence of reducing agents.
The differences in the sub-unit composition of the ANP receptor 
indicated by these two studies may arise from differences in the 
p u r if ic a t io n  procedures. Kuno et a l .  (1986) noted that they also found
60 to 70 kDa labelled fragments when they carried out SDS
electrophoresis on crude membrane preparations, although these 
disappeared a f te r  p u r if ica t io n  on a GTP a f f i n i t y  column. This 
procedure selects fo r  molecules which possess GTP binding s ites (and 
presumably guanylate cyclase a c t iv i t y ) ,  and therefore ANP receptors
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which are not associated with guanylate cyclase a c t iv i ty  wi l l  not be 
reta ined. I t  appears from studies on purified  ANP receptors isolated  
from bovine adrenal cortex that the 62 kDa fragment results from ANP 
receptors not associated with guanylate cyclase a c t iv i ty  (Takayanagi 
et a l . , 1987b). This is discussed in more d e ta i l  below.
2 . 4 . 3  Adrenal Cortex
[125 i ]„ANP binding s ites have been localized by autoradiography in the 
zona glomerulosa of ra t  (Bianchi et a l . . 1985; Murphy et a l . . 1985; 
Mantyh et a l . . 1986), guinea pig, and man (Mantyh e t a l . . 1986). High 
a f f i n i t y  binding sites are also present on endothelial and smooth 
muscle cel l s of the adrenal co rt ica l a r te r io le s ,  veins, and venules, 
the endothelium of the zona glomerulosa c a p il la r ie s ,  and in small 
numbers on the catecholamine storing cells  of the adrenal medulla 
(Bianchi et a l . . 1985).
D irect binding of [^^^I]-ANP to bovine zona glomerulosa membranes has 
id e n t if ie d  two binding s ites , with Kq ' s fo r ANP of 50pM and 5nM (De 
Lean e t a l . , 1984b). Similar results have been obtained from 
ANP binding studies in solubilized bovine adrenal cortex (BAG) 
membranes (Meloche e t a l . . 1986a).
[125i]_ANp has been cross-linked to i ts  receptor/binding sites in BAG 
membranes, and estimations of receptor size have been made by SDS 
polyacrylamide gel electrophoresis. Several studies have reported the 
la b e ll in g  of a single band under reducing conditions, with an apparent 
molecular weight of 130 kDa (Meloche e t a l . . 1986a; Misono et a l . .
1985; Koseki e t  a l . , 1986b). In contrast. Shinjo et a l .  (1986) 
reported the lab e ll in g  of a 140 kDa band, which t o ta l ly  dissociated
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into 70 kDa fragments in the presence of reducing agents. Takayanagi 
et a l . (1987b) have iden tif ied  two ANP binding s ites in BAG membranes, 
and purif ied  them to apparent homogeneity. Both sites have apparent 
molecular weights of 135 kDa under non reducing conditions, and have 
s im ila r  a f f in i t i e s  for ANP (approximately 60 pM). One of these sites  
is associated w ith guanylate cyclase a c t iv i ty  w h ils t  the other is not. 
The band which possesses guanylate cyclase a c t iv i ty  is not affected by 
reducing agents, w hilst the other can be reduced to a 62 kDa fragment.
Meloche et a l .  (1986b) also observed a 68 kDa band in a f f in i t y -  
labelled BAG membranes, but subsequently reported that th is  band only 
appeared i f  the membranes were acid washed and heated at 100°G 
(Meloche et a l . . 1986a). Meloche et a l .  concluded that the low 
molecular band was due to p a rt ia l  hydrolysis under stringent  
conditions, and subsequently omitted this step from th e ir  p u r if ica t io n  
procedure. A recent report, however, has indicated that a membrane- 
bound acidic metalloendopeptidase on BAG membranes is responsible fo r  
the cleavage of the 140 kDa band into two disulphide-linked 70 kDa 
fragments (Misono, 1988). I t  is therefore possible that the action of 
th is  peptidase is responsible fo r the differences in labe lling  
patterns discussed above.
2. 4 . 4  Vascular Receptors
ANP binding s ite s  have been id en tif ie d  in a number of vascular 
preparations including rabbit aorta (Napier e t  a l . . 1984), ra t  
mesenteric and renal a rte r ies  (S ch if fr in  et a l . . 1985), cultured 
vascular smooth muscle ce lls  from ra t  (H irata e t  a l . , 1984) and bovine 
(Schenk et a l . . 1985) aorta, AlO smooth muscle ce lls  (Napier et a l . .
1986), and cultured bovine aort ic  endothelial ce l ls  (Leitman et a l . .
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1986). Binding in a l l  cases appears to be to a single class of high 
a f f i n i t y  receptors, although the reported Kq values vary from 50pM to 
InM. Cross-linking studies indicate that the m ajority  of these binding 
sites have a Mr of 60 to 70 kDa under reducing conditions (Leitman et 
a l . . 1988).
2 . 4 . 5  Other Tissues
ANP binding sites/receptors have been iden tif ied  in many other tissues  
including various regions of the brain (Quiron e t  a l . , 1986; Quiron, 
1988), the placenta (Sen, 1986), the c i l ia r y  process of the eye 
(Bianchi et a l . . 1986), and p la te le ts  (S ch ifr in , e t  a l . . 1986; fo r  
review see Genest & Cantin 1988).
2 .5  S truc tu re -A ctiv itv  Relationships
Modification of the ANP molecule, p a r t ic u la r ly  by carboxyl terminal 
deletions or disruption of i ts  ring structure, has marked e ffects  on 
the potency of the peptide to e l i c i t  physiological responses (see 
section 1 . 6 . 1) .  The effects of such altera tions on the a b i l i t y  of the 
peptide to displace [^^^I]-ANP have been studied in a number of 
tissues and can be summarised as follows: Deletion of amino acids from 
the amino terminal results in a gradual reduction in the a f f in i t y  of 
the peptide. ANp2_2g is equipotent or almost equipotent to ANPj^28 ' 
whereas ANPg_2g is 3- to 10-fold less potent. ANP7„28 the least  
potent of the amino-terminal deleted peptides, having an a f f in i t y  some 
20-fo ld  less than the 28 amino acid peptide, ANPj^_28 (S c h if fr in  et  
a l . . 1985; De Lean e t a l . . 1985; 01 ins et a l . . 1986). Deletion of 
T y r l^6 from the carboxyl-terminal has l i t t l e  e f fe c t  on binding 
a f f i n i t y  (S c h if f r in  et a l . . 1985; Carrier et a l . . 1985; De Lean
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a l . . 1985). Removal of the tr ip ep tid e , Phe^^-Arg^^-Tyr^®, usually  
results  in a 10- to 100-fold reduction in a f f i n i t y  (S c h if fr in  et a l . . 
1985; 01 ins et a l . . 1986), although as much as an 8000-fold reduction 
in a f f i n i t y  has been reported fo r  the inh ib it ion  of [^^^I]-ANP binding 
to bovine adrenal ce lls  (De Lean et a l . . 1985).
A s im ila r  p ro f i le  of a c t iv i ty  is observed fo r  the stimulation of 
in t ra c e l lu la r  cGMP production, a lb e it  at concentrations some 10- to 
1000- fo ld  higher than those observed in the d irec t binding studies; 
the order of potency being ANPi_2g > ANPg_2g> ANPg_25 (Leitman & Murad 
1986; Nambi et a l . . 1986; Rapoport et a l . . 1986; Roubert et a l . .
1987).
There are however some analogues of ANP which show divergence between 
th e ir  a f f in i t y  fo r  ANP binding sites and th e ir  a b i l i t y  to increase 
in t ra c e l lu la r  cGMP. Scarborough e t  a l .  (1986) showed that while ANP^_ 
23 and ANP4_25 were equipotent at displacing rad io -lab e lled  ANP, the 
l a t t e r  was more than 100- fo ld  less e f fe c tive  than the former at 
augmenting in tra c e l lu la r  cGMP accumulation in BASM cel l s .  S im ilar ly ,  
Leitman and Murad (1986) reported a 6- fo ld  difference in potency 
between ANPg_23 and ANP5_2g to displace of [^^^I]-ANP from cultured  
bovine endothelial cel l s ,  w hilst there was more than a 100- fol d  
d ifference in th e ir  a b i l i t y  to increase cGMP in these cel l s.
A ring-deleted analogue of ANP, ANP4_23 (des-Gln^®-Gly^^)-NH2 , has 
been shown to compete e f fe c t iv e ly  with [^^^I]-ANP fo r  the m ajority of 
binding sites in whole ra t kidney and kidney cortex, with only an 8 - 
fo ld  reduction in a f f in i t y  re la t iv e  to ANPj.28 (Maack et a l . . 1987). 
Ring-deleted ANP is however without e f fe c t  on glomerular f i l t r a t i o n  
ra te ,  sodium and water excretion or vascular resistance in the
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isolated perfused ra t  kidney (Maack et a l . , 1987). Nor does i t  re lax  
preconstricted blood vessels or in h ib it  aldosterone secretion (Lewicki 
et a l . . 1988). In contrast, an increase in immunoreactive native ANP 
is observed when ring deleted ANP is injected into anaesthetized rats,  
with a corresponding increase in sodium excretion (Maack et a l . .
1987). These authors concluded that the majority of ANP receptors in 
the kidney are "b io log ica lly  s i le n t" ,  and postulated that these 
receptors act as clearance binding s ites ; the increase in plasma ANP 
in the in tact preparation being a d irec t consequence of these binding 
sites being occupied by ring-deleted ANP. These receptors have been 
termed C-ANP receptors, and wi l l  bind many truncated analogues of ANP 
with high a f f i n i t y .  The "b io log ica lly  active" binding sites are 
refered to as B-ANP receptors, and bind only ANPj^_28 with high 
a f f i n i t y  (Maack et a l . . 1987).
At a molecular l evel ,  the 60 to 70 kDa receptor species, as id en t if ie d  
by SDS-polyacrylamide electrophoresis under reducing conditions, 
appears to be the C-ANP receptor, since truncated and ring-deleted  
analogues of ANP bind to th is  species with high a f f i n i t y  (Takayanagi 
et a l . . 1987b; Lewicki et a l . . 1988). The 120-140 kDa receptor 
species, id e n t if ie d  under sim ilar conditions, and which is associated 
with guanylate cyclase a c t iv i ty ,  has a much lower a f f i n i t y  fo r  
truncated ANP analogues compared to ANPi_2g (Takayanagi et a l . .
1987b), and is l ik e ly  to be the B-ANP receptor (Lewicki et a l . . 1988).
2.6 Summarv
The evidence to date strongly suggests that most ce l l s  possess at 
least two types of ANP receptors. One receptor is in tim ate ly  
associated with the guanylate cyclase enzyme, has a M^  of 120 to 140
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kDa under reducing conditions and appears to be responsible for the 
vaso-relaxant properties of ANP. The second ANP receptor has a of 
60 to 70 kDa under reducing conditions, and i t  has been postulated 
tha t th is  receptor is responsible fo r  the clearance of ANP from the 
blood stream. No second messenger system has been id e n t if ie d  fo r th is  
receptor.
2.7 Reasons fo r  Experiments
ANP has been shown to increase in tra c e l lu la r  cGMP levels  in in tact ra t  
ven tr icu lar  myocytes (Aiton & Cramb, 1985). Because ANP is rap id ly  
degraded when incubated with ventricu lar myocytes (see chapter 9 ) ,  
fu r th e r  investigations into the mechanism of action o f ANP were 
performed in purif ied  ra t  cardiac sarcolemmal membranes isolated from 
ven tr icu la r  muscle. Guanylate cyclase a c t iv i ty  and [^^^I]-ANP binding 
sites  were measured in th is  preparation and the resu lts  compared with  
s im ila r  studies conducted on membranes isolated from bovine adrenal 
cortex.
[125 i ]„ANP binding s ites  have also been id en t if ie d  on in tact MDCK 
(Madin Darby canine kidney) cel ls (Aiton et a l . . 1987) and these were 
fu r th e r  investigated in membrane preparations.
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CHAPTER 3
3.1 Materials
ANP ( ra t  alpha ANPi_2g) was purchased from Sigma, Poole, Dorset. GTP 
and adenosine phophates were obtained from BCL, Lewes, Sussex. HPLC 
grade solvents and sa lts  were supplied by BDH, Poole, Dorset.
ANP ( ra t  alpha ANPi_28' specific  a c t iv i ty  2200 Ci/mmol) and [^^^I]-Na  
(sp ec if ic  a c t iv i ty  17 Ci/mg; pH 8-10) were obtained from Du Pont 
(U.K. )  Ltd. ,  Stevenage, Herts. JOKLIKS was purchased from Flow 
Laboratories, Rickmansworth, Herts. A ll other culture media were 
obtained from Gibco, Paisley, Renfrewshire. All other biochemicals 
were obtained from Sigma, Poole, Dorset. A ll general reagents were of 
ana ly t ica l grade supplied by BDH (Poole, Dorset).
The antibody to cGMP was a g i f t  from Dr. P Hamet (C l in ic a l  Research 
In s t i tu te ,  Montreal, Canada). SQ 20881 was a g i f t  from E.R. Squibb & 
Sons, Hounslow, Middlesex. Ramipril was a g i f t  from Hoechst U.K. Ltd. ,  
Pharmaceuticals D ivis ion, Hounslow, Middlesex.
Rats (Wistar) were obtained from the University of St.Andrews stocks. 
Animals were maintained under a 24 hr day/night cycle and allowed free  
access to food.
3.2 Membrane Preparation
3.2.1 Sarcolemmal Membranes
Sarcolemmal membranes were prepared as described by Cramb & Dow 
(1983). B r ie f ly ,  following decapitation, the hearts were removed from 
six , 8 to 12 week-old male Wistar rats (200 to 250g) and placed 
immediately into ice cold JOKLIKS medium (see appendix I ) .  The
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ventric les  were excised, washed in JOKLIKS and weighed. They were then 
placed in 50 ml IraM NaHCOg, pH 8.0 containing 1 mM PMSF and 0.5 mM 
DTT, minced with scissors, and homogenised using a Polytron (model PTA 
lOS, Kinematica, Switzerland) at setting 4 fo r  30 sec. The resulting  
homogenate was dilu ted  with 300ml of 1 mM NaHCOg, pH 8 . 0 ,  containing 
0.6  M KCl, 50 mM Na4P20y, 5 mM MgCl2 , 1 mM PMSF and 0 .5  mM DTT, and 
then s t ir red  fo r  45 min on ice. The homogenate was f i l t e r e d  though 8 
layers of muslin and centrifuged at 25,000 x g for 30min (Beckman J21, 
Type JA.20 fixed angle ro to r ) .  The p e l le t  was resuspended in 80 ml of 
1 mM NaHCOg, pH 8. 0,  containing 25 mM Na4P20y, 2.5 mM MgCl2 » 1 mM PMSF 
and 0 .5  mM DTT, and then recentrifuged at 25,000 x g fo r  30 min. The 
resu lt ing  p e l le t  was resuspended in 8 ml of 5 mM HEPES, pH 7.4,
containing 0.5 mM DTT and diluted to 20 ml with 67% (w t/v )  sucrose, 5
mM HEPES, 0.5 mM DTT to give a f in a l  concentration of 40 % sucrose.
Two discontinuous sucrose gradients were formed consisting of a 4 ml 
cushion of 60 % sucrose, followed by 10 ml of the membrane suspension, 
10 ml of 35 % sucrose, 10 ml of 30% sucrose and f i n a l l y  2 ml of 5 mM 
HEPES, pH 7.4,  0.5 mM DTT. A ll sucrose solutions contained 5 mM HEPES, 
0.5 mM DTT. The gradients were centrifuged at 100,000 x g fo r 2 hr 
(Beckman L2-65B, SW28 ro to r ) .  The bands formed at the 0/30% (Fraction  
A), and 30/35% (Fraction B) interfaces were collected, d iluted with 40 
ml of 5 mM HEPES, pH 7. 4,  containing 0.5 mM DTT, and centrifuged
25,000 X g fo r  40 min (Beckman J21, Type JA.20 fixed angle ro to r ) .  The
p e lle ts  were resuspended in 5 mM HEPES, pH 7.4,  250 mM sucrose, and 
0 .5  mM DTT, at a protein concentration of 0.5 to 1 mg/ml. The 
membranes were stored a t - 20^0 and were diluted to give a f in a l  
protein concentration of 5 to 20 jug/ml in a l l  assays.
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3. 2. 2  Bovine Adrenal Cortica l (BAC) Membranes
Bovine adrenal co rt ic a l  membranes were prepared by a modification of 
the methods described by Glossmann et a l . . (1974) and Meloche e t a l . . 
(1986a). B r ie f ly ,  adrenal glands were obtained within 20 min of death 
and sliced into ice-cold phosphate buffered saline (PBS) containing 1 
mM EDTA, 0.1 mM PMSF, and 1 juM aprotin in . The outer 1 to 2 mm of 
cortex were dissected, washed with fresh buffer and placed in 20 mM 
NaHCOg, containing 10 mM EDTA, 0.1 mM PMSF, 1 >iM aprotin in , 10>uM 
leupeptin and 1 juM pepstatin , at a concentration of 10 g of tissue  
(wet weight) to 5 ml of buffer. The tissue was roughly chopped in a 
blender and then homogenized, f i r s t  with a Polytron homogenizer at 
setting 4 fo r  10 to 20 sec, and then with 3 x 5  strokes of a motor 
driven g lass /te flon  homogenizer (300 rpm) with cooling between bursts. 
The resu lting  homogenate was f i l t e r e d  through a 250 jim  net and the 
f i l t r a t e  centrifuged at 1000 x g fo r  lOmin. The supernatant was 
recentrifuged at 25,000 x g fo r  45 min and the p e l le t  resuspended in 
250 mM sucrose, 10 mM Tris-HCl, pH 7.2,  1 mM EDTA. This suspension 
was layered on to the top of a discontinuous sucrose gradient, 
consisting of 31.5%, 38.5% , 42.5% and 60 % (w/w) sucrose layers, and 
centrifuged at 100,000 x g for 2 hr in a Beckmann SW28 ro to r .  The 
bands which formed at the interfaces were collected and d iluted with 
10 mM Tris-HCl, pH 7.2,  containing 1 wM EDTA, 0.1 >iM pepstatin, and 1 
yUM leupeptin, and recentrifuged at 25,000 x g for 45 min. The f in a l  
p e l le t  was resuspended in the same buffer containing 250 mM sucrose, 
and 5 mM MgCl2 and stored frozen at -20°C.
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3. 2 . 3  MDCK cel l  Membranes
MDCK cel l s (s tra ins  I and I I )  were grown in p las t ic  Roux flasks in 
Minimum Essential Medium with Earles' salts (MEME; see appendix I ) , 
supplemented with non-essential amino acids, 2 mM glutamine, 100/ig/ml 
kanamycin, 5% (v/v)  donor horse serum and 5% (v/v)  fe ta l  c a l f  serum in 
an 95% air/5% CO2 atmosphere. A fter 4 days growth, the cel l s  from 2 x 
175 ml flasks were washed with 3 x 100 ml of ice cold Krebs buffer, pH
7.4 (see appendix I fo r  composition). The ce ll were detached by 
scraping into 100 ml of the same solution and pelleted by 
centrifugation at 2000 x g fo r  10 min. The pelle ts  were resuspended in 
2 to 5 ml of 50 mM Tris  pH 7.4 at 4^C and homogenised using a polytron 
homogenizer at setting 4 fo r  30 sec. The homogenate was centrifuged at
25,000 X g for 15 min and the resulting p e lle t  washed once with the 
same buffer. The f in a l  p e l le t  was resuspended in 1ml of 50 mM Tris pH
7.4 (4°C) and stored at -20°C un ti l  used.
3.3 Measurement of Guanvlate Cvclase A c tiv ity
3.3.1 Guanvlate Cvclase Assay
Guanylate cyclase a c t iv i t y  was measured in ra t  cardiac sarcolemmal 
membranes and bovine adrenal cortica l membranes as fo llows. Membranes 
were usually incubated with 50 mM triethanolamine, pH 7.4,  1 mM GTP, 3 
mM MnCl2 i 2 mM IBMX, 10 mM theophylline, 0.1 mg/ml creatine  
phosphokinase, and 5 mM creatine phosphate for 20 min at 37°C in a 
f in a l  assay volume of 100j u l . Variations in th is  protocol such as the 
addition of ANP or i ts  truncated analogues, the replacement of Mn^* 
with Mg2* ,  or the inclusion of various adenosine phosphates are 
described in the appropriate f igure legends. The preparation of the
34
reagents and th e ir  storage are described in appendix I I .  Incubations 
were started by the addition e ither of membranes or GTP depending on 
the type of experiment. The f in a l  protein concentration was 5 to 20 
yug/ml fo r both membrane preparations. Incubations were terminated by 
the addition of 1 ml of 30 mM EDTA at lOO^C, and the solution was 
assayed fo r  cGMP by radioimmunoassay. Occasionally a p rec ip ita te  
formed upon the addition of EDTA. This was removed by centrifugation  
at 1,000 X g fo r  15 min in a refrigerated centrifuge (FissonsCoolspin) 
and did not a f fe c t  the subsequent assay for cGMP. To ensure that none 
of the reagents interfered with the subsequent measurement of cGMP, 
blanks were included in a l l  experiments. These tubes contained a l l  the 
reagents and membranes present in the assay tubes but were not 
incubated ( i . e .  zero time points).
3. 3. 2 Radioimmunoassay fo r  cGMP
cGMP was determined by radioimmunoassay as described by Richman et 
a l . . 1980. Duplicate 100yul of samples or unknown, standard, or buffer  
were placed in 3.5 ml polypropylene tubes (S te r i l in  RT30) followed by 
100>il of [125l]-ScGMP-TME (10,000 to 15,000 cpm) and 250>il . The 
[125 i ] -S cgmp- tme and the cGMP antibody were prepared in 50mM sodium 
acetate buffer, pH 4,75 containig 0.5% BSA (see appendix I I ) .  The 
reagents were allowed to eq u il ib ra te  by incubation overnight (15 to 24 
hr ) ,  at 4°C. The antibody was precipitated by the addition of 2 ml of 
95% ethanol. The tubes were mixed thoroughly and allowed to stand fo r  
30 min at room temperature. The precip ita te  was pelleted by 
centrifugation at 1,500 x g fo r  30 min at 4°C (Fissons Coolspin), and 
the supernatant removed by aspiration. The p e lle t  was counted for  
ra d io a c t iv ity  in a Prias gamma counter (Packard Instrument Company,
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I l l i n o i s ,  USA).
For each experiment, a standard curve was constructed in the range 30 
to 10,000 fmol cGMP. The nonspecific binding, defined as the 
ra d io a c t iv ity  bound in the presence of an excess of cGMP (20 nmol), 
was subtracted from a l l  values. The results were expressed as the 
counts bound in the absence of competing cGMP (Co) divided by the 
counts bound in the presence of cGMP (Cs).  A p lot of Co/Cs against the 
cGMP concentration was usually l inear over the concentration range 30 
to 1000 fmol ( f i g .  3 . 1 ) .  The exact range of l in e a r i ty  was defined as 
the range of the pairs of values yielding a corre lation  c o e ff ic ie n t  
(Pearson r )  greater than 0.900. The unknown values were treated in the 
same manner, and the amount of cGMP in each sample was calculated from 
the regression equation fo r the standard curve.
3 . 3 . 3  Preparation of [^^^I]-Tyrosine Methyl Ester Succinyl-cGMP
Succinyl-cyclic GMP tyrosine methyl ester (ScGMP-TME) was labelled  
with according to the method described by Richman et a l .
(1980). 20 jul of ScGMP-TME (2 jug) and 10 jjI of [^^^I]-Na (approx. 1 
mCi) were placed in a 1.5 ml microfuge tube, and the reaction  
in i t ia te d  by the addition of 20 jul chloramine-T (1 mg/ml in 50 mM 
potassium phosphate, pH 7. 4) .  A fter exactly 45 seconds the reaction  
was terminated by the addition of 50 jul of potassium metabisulphite (1 
mg/ml in 50 mM potassium phosphate, pH 7. 4) .  200 jul of 2.5 mM sodium 
iodide was then added to reduce the specific a c t iv i ty  of the unreacted 
[12^1] and to d i lu te  the ionic strenth to less than 250 mM.
The reaction mix was layered on to the top of the QAE-25 sephadex 
column which had been pre-equilibrated with 0.05 M ammonium formate pH
Figure 3.1
Measurement of cGMP by Radio-immunoassay
(a) A representative standard curve for the assay of cGMP. Each point is 
the mean ±  SEN of t r ip l ic a t e  determinations, (b) A p lo t of ra d io a c t iv ity  
bound against cGMP concentration.
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6.0 at 4°C ( fo r  de ta ils  of preparation see appendix I I ) .  The solution  
was allowed to run into the column and the top was then washed with 
approximately 300/ i l  of 250 mM ammonium formate, pH 6.0.  The [^ ^ ^ I] -  
Sc-cGMP was eluted with 250 mM ammonium formate pH 6.0,  at a flow rate  
of 1 ml/min at 4°C. 1 or 2 ml fractions were collected and from these 
5 / i l  aliquots were counted fo r ra d io a c t iv ity .  Fractions corresponding 
to peaks in ra d io a c t iv ity  were d ilu ted  to give 15,000cpm/10Qul and 
assayed fo r th e ir  binding to the cGMP antibody. The fractions  
containing the highest binding were combined and stored in lOOjul 
aliquots at -70°C.
The results of a typical preparation of [^^^I]-ScGMP-TME are shown in 
f ig u re  3.2.  Of the three main radioactive peaks eluted from the 
column, antibody binding was mainly associated with peak C (tab le  
3 , 1 ) .  Fractions from th is  were combined to provide [^^^I]-ScGMP-TME 
fo r  subsequent cGMP assays. Peak A, which showed no antibody binding 
and eluted close to the void volume of the column, is l ik e ly  to be 
f re e  [^^^ I].
3 . 4 .  [125i]_ANP Radioreceptor Assay
3. 4. 1  Cardiac Sarcolemmal Membranes.
Membranes were incubated fo r 40 min at 37®C with [^^^I]-ANP (40 to 
100 pM) in the presence of varying concentrations of unlabelled ANP 
and buffer containing 50 mM Tris-HCl, pH 7.4,  100 mM NaCl, 0.1 mM 
EDTA, 5 mM MgCl2 , 1 yUM leupeptin, 0.1 /iM pepstatin and 1 mg/ml BSA.
The f in a l  incubation volume was 200 jul. Incubations were terminated by 
the addition of 2 ml of ice cold wash buffer containing 50 mM T r is -  
HCl, pH 7.4,  and 100 mM NaCl. Bound [^^^I]-ANP was separated from free
Figure 3.2
P u rif ic a t io n  of [^^^IJ-ScGMP-TME
P r o f i le  of ra d io a c t iv i ty  eluted from a QAE-25 Sephadex column. The 
frac tio n s  marked by * were assayed fo r  cGMP antibody binding. The 
shaded area represents the fractions which were combined to give 
[125i]_scGMP-TME fo r  use in the cGMP assay. The percentage 
ra d io a c t iv i ty  recovered from each peak was 15.8, 6 . 7,  and 77.4,  fo r  
peaks A, B and C respective ly .
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Table 3.1
R adioactiv ity  Bound to cGMP Antibody
Aliquots were removed from the fractions indicated on f i g .  3.2 and 
d ilu ted  with 50 mM sodium acetate buffer (pH 4.75) ,  containing 0.5% 
BSA buffer to give approximately 12,000 cpm/ 100^1 . These were 
incubated with cGMP antibody in the absence (Co) and presence (C^gg) 
of 20 nmol cGMP overnight, at 4^C as described in section 3.3.2.
Sample
No.
Total
cpm
cpm
Co
cpm
^NSB
% cpm 
Bound
1 11743 269 632 -3.09
2 15589 799 638 1.03
3 12853 3728 356 26.2
4 12765 3850 339 27.5
5 12168 3749 782 24.4
6 10140 2880 356 24.9
7 13588 3879 753 23.0
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by rapid f i l t r a t i o n  through Whatman 6F/F f i l t e r s  followed by washing 
with 10ml of the same buffer. To reduce background binding the f i l t e r s  
were pre-soaked in 0.3% polyethyleneimine for 60 min prior to use 
(Brunks e t  a l . , 1983). The to ta l f i l t r a t i o n  time including washes was 
less than 30 sec.
3. 4 . 2  Bovine Adrenal Cortical (BAG) Membranes
The binding assay was carried out as decribed fo r sarcolemmal 
membranes. The f in a l  membrane concentration was 0.2 to 1.0 mg per ml
3. 4 . 3  MDCK Cell Membranes
The binding assay was carried out as decribed fo r  sarcolemmal 
membranes except that the incubations were performed at 20°C for 30 
min, in 50 mM Tris , pH 7.4 at 20^C, 5 mM MgCl2 , 1 yUM aprotin in , 500 
yuM PMSF, 1 mg/ml bacitracin and 1 mg/ml BSA. The f in a l  protein  
concentration was 30 to 300 ;ug/ml.
3.5.  Assessment of [^^^]-ANP Degradation by High Performance Liquid 
Chromatography (HPLC)
3.5.1 Sample Preparation
[125 i ]_^NP was incubated fo r  40 min at 37°C with ra t  cardiac 
sarcolemmal membranes in a f in a l  incubation yolume of 200>ul, as 
described previously. The incubation was terminated by the addition of 
2 ml of 50 mM Tr i s,  pH 7.4 at 4^C and the samples were p a r t ia l ly  
p u rif ied  p rio r to HPLC analysis by passage through preparative Cj^q CDS 
s i l i c a  columns (3 ml Tech Elut columns, cat. no. LSP 9515). B r ie f ly ,  
the columns were f i t t e d  to a Baker SPE 21 f i t r a t io n  manifold, and 
washed with 2 x 3 ml of 100% a c e to n it r i le  (ACN). The columns were
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conditioned with 1 x 3 ml of the sample buffer and samples were added 
before the column dried. The columns were washed with 3 ml of 15% ACN, 
containing 0.1% tr i f lu o ro a c e t ic  acid (TFA) and a ir -d r ie d  for 5 min.
The samples were eluted with 2 x 200/ i l  of 60% ACN, 0.1% TFA, and 
dried under nitrogen on a Technic sample concentrator at 37°C. The 
samples were resuspended in 150 >il of 15% ACN, 0.1% TFA and stored at  
-20°C u n t i l  analysed.
3 . 5 . 2  HPLC Analysis
Assessment of [^^^I]-ANP degradation was performed on a Gilson HPLC 
system equipped with Gilson Model 302 dual pumps with 5 ml pump heads, 
a Gilson model 802 manometer module and mixing chamber, a Rheodyne 
7125 in jec to r  valve with a 100 jul in jection  loop, and a Gilson ÜV 
holochrome detector f i t t e d  with an 11 ^1 flow cel l .  The system was 
f i t t e d  with a 150 x 4.6 i . d.  Cjg Spherisorb column (0DS2- SB5-401). 
Gradient control and peak analysis were carried out on an Apple l ie  
computer, linked to a Gilson Model 620 Data Master and a NEC PC8023BE- 
N p r in te r .
[^^^I]-ANP was eluted from the column with a l inear gradient of 15% to 
60% (ACN) in 0.1% (TFA), at a flow rate of 1 ml/min and a slope of 0.9  
%/min, followed by a gradient of 60 to 100% ACN, at a s im ilar flow  
ra te  with a slope of 4 %/min. 60 x 1 ml fractions were collected using 
a Gilson 205 fraction  co llector and measured for ra d io a c t iv ity .
3.6 Protein Assay.
Protein concentrations were determined using the Bio-Rad protein assay 
(Cat. No. 500-0002), which is based on the assay described by Bradford 
(1976). The princip le  of the assay is that the absorbance maximum for
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Coomassie B r i l l i a n t  Blue 6-200 sh if ts  from 465 nm to 595 nm when 
protein binding occurrs (Reisner et a l . . 1975). B r ie f ly ,  the protein  
standards, samples, or bu ffer, were d iluted to 800 jul with d is t i l le d  
H2O and to th is  was added 200 ul of undiluted Dye Reagent Concentrate 
( f i l t e r e d  before use). The reagents were mixed thoroughly, avoiding 
excess frothing and allowed to stand at room temperature fo r  5 min.
The absorbance was then measured at 595 nm in a P h il l ip s  P4 8620 
spectrophotometer. BSA was used as a standard and the assay was linear  
over the range 1 to 10 jug of protein ( f ig  3 .3 ) .  The sample protein  
concentration was determined from the regression l in e  fo r  the standard 
curve. Blanks, containing sample buffer only, were included in each 
assay, and were normally less than 5 % of the to ta l  absorbance.
Figure 3.3
Measurement of Protein Usina the Bio-Rad Protein Assay K it  
A typ ica l standard curve fo r  the Bio-Rad protein assay. Each point 
represents a single determination of absorbance measured at 595 nm. 
Bovine serum albumin was used as the standard.
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CHAPTER 4
4 Results of Guanvlate Cvclase Experiments
4 .1 .1  Preliminary Experiments in Rat Sarcolemmal Membranes
The e ffec ts  of incubation time and membrane concentration on guanylate 
cyclase a c t iv i ty  were investigated in purified  ra t  cardiac sarcolemmal 
membranes. Manganese-dependent guanylate cyclase a c t iv i t y  was measured 
in the presence and absence of ANP, over a range of membrane 
concentrations ( f i g .  4 .1 ) .  At protein concentrations up to 2 0 ^ug/ml, 
both basal and ANP-stimulated guanylate cyclase a c t iv i t y  increased 
l in e a r ly  with increasing protein. Above th is  concentration the rate  of 
cGMP production declined.
The re lationship  between incubation time and Mn^^-dependent guanylate 
cyclase a c t iv i ty  was also examined in these membranes. The ra te  of 
cGMP production was constant fo r  at least 20 min, both in the presence 
and absence of ANP ( f i g .  4 .2 ) ,  although the absolute ra te  varied  
between preparations (tab le  4 .1 ) .  Incubations longer then 20 min 
resulted in a decline in the rate of guanylate cyclase a c t iv i ty .
As a resu lt  of these experiments guanylate cyclase a c t iv i ty  in ra t  
cardiac sarcolemmal membranes was routinely  measured with protein  
concentrations of less than 2 0 / ig /m l, over a 20 min incubation period.
4 .1 .2  Comparison of Guanvlate Cvclase A c tiv ity  in Fractions A and B
The p u r if ic a t io n  of cardiac sarcolemmal membranes by sucrose gradient 
centrifugations resulted in two bands of m ateria l, both of which were 
enriched in plasma membrane markers (Cramb & Dow, 1983). Fraction A 
was recovered from the 0/30% sucrose in terface, and frac tio n  B from
Figure 4.1
The E ffect of Prote in  Concentration on Guanvlate Cvclase A c t iv i ty  in 
Rat Cardiac Sarcolemmal Membranes
Samples containing increasing concentrations of protein were incubated 
fo r  20 min at 37°C, in the absence ( a — A) and presence (□ — □) of 
10"^M ANP. Each point represents the mean + SEM fo r  3 determinations 
of guanylate cyclase a c t iv i ty ,  each of which was measured in duplicate  
fo r  cGMP.
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Figure 4.2
Time Course fo r  Guanvlate Cvclase A c tiv i ty  in Rat Cardiac Sarcolemmal 
Membranes
A representative time course fo r  guanylate cyclase a c t iv i ty  in the 
absence (a — a ) and presence ( □ — □) of 10"^ M ANP. Each point represents 
the mean + SEM fo r  duplicate determinations of guanylate cyclase 
a c t iv i t y ,  followed by duplicate determinations of cGMP.
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Table 4.1
Comparison of the I n i t i a l  Rates of Guanvlate Cvclase A c t iv i ty
Rate of cGMP production was measured over the f i r s t  20 min. The mean 
guanylate cyclase a c t iv i ty  was 112 + 20.5 and 204 + 38.7 pmol/min per 
mg protein for basal and ANP-stimulated a c t iv i t y  respective ly . The p 
values were calculated from the Pearson corre la t ion  c o e ff ic ie n t  (two- 
ta i le d  p ro b a b il i t ie s ) .
Prep. Condition GC.Act. 
pmols/ 
mg/min
Corr. 
Coeff.
No.
Obs.
P<
1 Basal 117 0.979 8 0.01
1 lO'G M ANP 250 0.973 8 0.01
2 Basal 129 0.984 9 0.01
2 10-6 M ANP 235 0.997 9 0.01
3 Basal 89 1.000 9 0.01
3 10-6 M ANP 127 0.995 9 0.01
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the 30/35% interface . Basal and ANP-stimulated guanylate cyclase 
a c t iv i t ie s  were measured in both fractions and the results compared. 
The rate  of cGMP production by fraction  A varied 3 -fo ld  fo r  both basal 
and ANP-stimulated guanylate cyclase a c t iv i ty ,  ranging from 68.4 to 
228 pmol/min per mg protein, and 101 to 359 pmol/min per mg protein  
respective ly . The v a r ia b i l i t y  between preparations was larger for  
fra c tio n  B, ranging from 32.5 to 325 pmol/min per mg protein , and
73.3 to 756 pmol/min per mg protein, fo r basal and ANP-stimulated 
guanylate cyclase a c t iv i ty  respective ly . ANP s ig n if ic a n t ly  increased 
the rate  of cGMP production in both fractions , with no d ifference  
being observed between the absolute levels of e ith e r  basal, or ANP- 
stimulated guanylate cyclase a c t iv i ty  fo r  the two fractions (tab le
4 .2 ) .  A s ign if ican t difference was observed in the percentage 
stimulation of basal a c t iv i t y ,  with IjnM ANP producing a 1 .80 -fo ld  
increase in a c t iv i ty  in f ra c tio n  B, w hilst the same concentration  
produced a s ig n if ic a n t ly  smaller increase (1 .4 5 -fo ld )  in f ra c tio n  A 
(tab le  4 .2 ) .  As ANP r e l ia b ly  produced a greater increase in guanylate 
cyclase a c t iv i ty  in frac tio n  B, only th is  frac tion  was used fo r  
subsequent experiments.
4 .1 .3  The Effect of Manganese and Magnesium
The e f fe c t  of manganese and magnesium on guanylate cyclase a c t iv i t y  
was examined in ra t  cardiac sarcolemmal membranes. Increasing  
concentrations of Mn^* resulted in a biphasic response fo r both basal 
and ANP-stimulated guanylate cyclase a c t iv i ty  ( f ig  4 .3 a ) .  In the 
presence of 1 mM GTP, the ra te  of cGMP production increased in a dose- 
dependent manner u n t i l  around 1 mM Mn^+, above which concentration no 
fu r th e r  increases in a c t iv i t y  were observed. At Mn^+ concentrations
Table 4.2
Comparison of Guanvlate Cvclase A c tiv i ty  in Fraction A and B Recovered 
from the Sucrose Gradient P u rif ica tio n  of Rat Cardiac Sarcolemmal 
Membranes
S ign ifican t differences between basal and ANP-stimulated leve ls  were 
tested for using a tw o-ta iled  t  tes t  (pa ired). *  p< 0.05, * * *  p<
0.001. S ign ifican t differences between manganese-dependent guanylate 
cyclase a c t iv i ty  in fractions A and B were tested fo r  using a two- 
ta i le d  t  tes t (unpaired). # = p< 0 . 001 .
Fraction  
(No.Obs.)
Guanylate Cyclase A c t iv i ty  
(pmol cGMP/min /mg protein)
Basal 10‘ 6m ANP ANP/Basal
A (9) MnZ+ 114 1  18 205 ±  29* 1.45 + 0.10
B (20) MnZ+ 129 1  17 241 ±  4 2 *** 1.80 + 0 .10*
B (9) MgZ+ 3.21+1.34 11.8+3.40* 3.68
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greater than 4 mM guanylate cyclase a c t iv i ty  declined. The Km was 
estimated fo r  values of manganese up to 4 mM, and found to be 50.8 + 
0 .7  and 22.8 ±  7 .9 juM, with H i l l  coeffic ien ts  of 5.41 + 0.02 and 6.35 
±  0 .50 , for basal and ANP-stimulated guanylate cyclase a c t iv i ty  
respective ly . In addition the stimulation of guanylate cyclase 
a c t iv i t y  by ANP was markedly reduced at concentrations of Mn^* above 
4mM.
The replacement of manganese with magnesium resulted in a substantial 
reduction of guanylate cyclase a c t iv i ty ,  with basal and ANP-stimulated 
a c t iv i t y  being 3 to 5% o f  that observed in the presence of Mn^* (tab le
4 .2 ) .  Dose response curves were constructed to examine the e f fe c t  of 
magnesium concentration on guanylate cyclase a c t iv i t y .  The amounts of 
cGMP produced in these experiments were very small and although the 
resu lts  were q u a li ta t iv e ly  s im ila r  to those observed with manganese, 
d eta iled  analysis was not possible ( f ig .  4.3b)
4 .1 .4  Effect of GTP on Guanvlate Cvclase A c tiv ity
The e f fe c t  of GTP concentration on Mn^^-dependent guanylate cyclase 
a c t iv i t y  was examined in the absence and presence of 1 juM ANP ( f ig  
4 .4 ) .  With Mn^* concentrations of 3 mM, the rate of cGMP production 
increased in a dose-dependent manner with increasing concentrations of 
GTP. Analysis of the data by 'E n z f i t te r '  (a l lo s te r ic  k inetics; see 
appendix I I I )  gave Km values of 43 + 16 and 130 + 60 juM for basal and 
ANP-stimulated guanylate cyclase a c t iv i ty  respective ly . The H i l l  
co e ff ic ien ts  were 1.79 + 0.12 and 2.27 + 0.15 fo r  the two conditions.
4 .1 .5  Dose Response Curves fo r  ANP, ANPg_2g, and ANP5.25
The effects  of ANP, ANPg_2g, and ANPg.^g, on guanylate cyclase
Figure 4.3
The Effect of Manganese and Magnesium on Guanvlate Cvclase A c t iv i ty  
Rat cardiac sarcolemmal membranes were incubated for 20 min, at 37°C with 
increasing concentrations on (a) MnCl2 , or (b) MgCl2 , in the absence 
(a — a ) and presence (□ — □) of 10"^ M ANP. Each point is the mean + SEM 
of 2 separate experiments in which guanylate cyclase a c t iv i t y  was 
measured in duplicate, followed by duplicate determinations of cGMP.
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Figure 4.4
Dose Response Curve fo r  GTP Stimulation of Guanvlate Cyclase A c t iv i ty  
Rat cardiac sarcolemmal membranes were incubated fo r  20 min at 37°C, with 
increasing concentrations of GTP, in the absence (A— A) and presence 
(o— □) of lO'G M ANP. Each point is the mean + SEM of duplicate  
determinations of guanylate cyclase a c t iv i ty ,  in which cGMP was measured 
in duplicate.
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O Ia c t iv i t y  in ra t  cardiac sarcolemmal membranes were examined. Mn'^  - 
dependent guanylate cyclase a c t iv i ty  was measured in the presence of 
increasing concentrations of the peptides ( f ig .  4 .5 )  and the dose 
response curves were analysed by E n z f it te r  (a l lo s te r ic  k in e t ic s ) .  ANP 
produced the largest stimulation of a c t iv i ty ,  with an estimated Km of 
1.87 -  0.43 nM and a H i l l  Coeffic ient of 0.468 -  0.073. ANPg.^g was of
s im ila r  potency to ANP^.^g, with a Km of 0.671 + 0.304 nM and a H i l l
c o e ff ic ie n t  of 0.766 + 0.229. The maximum response to th is  peptide was 
however only 50% of that produced by ANP. ANPg_25 the weakest 
peptide examined and only increased the rate of cGMP production at 
concentrations of above 100 nM.
4 .1 .6  E ffec t of Protease Inh ib itors  on Guanvlate cvclase A c tiv ity
The p o s s ib i l i ty  that ANP was degraded during the incubation was
examined by the measurement of Mn^^-dependent guanylate cyclase 
a c t iv i t y  in the presence and absence of various protease inh ib ito rs .  
Detailed dose response curves were constructed fo r  ANP-stimulated 
guanylate cyclase a c t iv i ty ,  in the presence and absence of 10 juM 
phosphoramidon, a specific  inh ib ito r  of endopeptidase 24.11 ( f ig  4 .6 ) .  
The Km values were 0.875 + 0.296 nM and 2.43 + 1.13 nM with H i l l  
co e ff ic ien ts  of 0.269 ±  0.057 and 0.300 + 0.074 fo r  the control and 
phosphoramidon curves respectively. There were no s ign ifican t  
differences between the Km values, the H i l l  co e ff ic ien ts , or the 
maximum stimulation fo r  ANP in the two conditions. A number of other 
in h ib ito rs  were also examined for th e ir  e ffec t  on basal and ANP 
stimulated guanylate cyclase a c t iv i ty  ( f ig  4 .7 ) .  None of the 
in h ib ito rs  tested had any e f fe c t  on basal rates of cGMP production.
The inclusion of 0 .5  mM PMSF in the incubation medium resulted in a
Figure 4.5
Dose Response Curves fo r  ANP, ANPq ,? * , and ANPq_9s Stimulation of 
Guanylate Cyclase A c t iv i ty
Rat cardiac sarcolemmal membranes were incubated fo r  20 min at 37°C, in 
the presence of 3 mM MnCl2 , and increasing concentrations of ANP ( □ — □ ),  
ANP5-28  , and ANPg_25 (O — O ). Each point represents the mean +
SEM fo r  6 (ANPi_28)'  ^ (ANp5_2g), and 1 (ANP5. 25) separate experiments in 
which guanylate cyclase a c t iv i ty  was measured in t r ip l ic a t e ,  followed by 
duplicate determinations of cGMP. The basal a c t iv i ty  was ranged from 32.5 
to 325 pmol cGMP/min per mg protein.
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Figure 4.6
Effect of Phosphoramidon on Guanvlate Cvclase A c t iv i ty  
Rat cardiac sarcolemmal membranes were incubated fo r  20 min at 37°C, with 
increasing concentrations of ANP, in the absence ( a — a ),  and presence 
(□ — □) of 10"5 M phosphoramidon. Each point represents the mean ±  SEM of 
2 separate experiments in which guanylate cyclase a c t iv i t y  was measured 
in t r ip l ic a te ,  followed by duplicate determinations of cGMP. The basal 
a c t iv i ty  was 40.6 and 103.6 pmol cGMP/min per mg protein fo r the two 
preparations.
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Figure 4.7
The E ffect of Various Peptides and Protease In h ib ito rs  on Guanvlate 
Cvclase A c t iv i ty
Rat cardiac sarcolemmal membranes were incubated fo r  20 min at 37°C, in 
the absence or presence of various protease in h ib ito rs  at the 
concentration indicated. Guanylate cyclase a c t iv i t i e s  were determined in 
the absence ( CD ) or presence of 10~^ M ( | | |  ) or 10“ M^ ANP ( ^  ) .  
Assays were carried out in duplicate followed by duplicate determinations 
of cGMP. S ig n if ican t differences from controls are indicated by * = p< 
0 .05 , and * *  = p< 0.01 as determined a tw o-ta iled  Student's t - te s t  
(unpaired so lu t ion ).
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decrease in guanylate cyclase a c t iv i ty  in the presence of both 1 nM 
and 100 nM ANP. Aprotinin also produced a small decrease in guanylate 
cyclase a c t iv i ty  in the presence of 100 nM ANP.
The e f fe c t  of glucagon and bradykinin, on manganese-dependent 
guanylate cyclase a c t iv i t y  was also examined. Neither of these 
peptides had any e f fe c t  on basal or ANP-stimulated cGMP production by 
ra t  cardiac sarcolemmal membranes ( f ig .  4 .7 ) .
4 .1 .7  E ffect of Adenosine Phosphates on Guanylate Cvclase A c tiv itv
The e f fe c t  of various adenosine phosphates on Mn^^-dependent guanylate 
cyclase a c t iv i t y  was examined. ADP and AMP, at m il l im o la r  
concentrations, had no e ffe c t  on e ith e r  basal or ANP-stimulated 
guanylate cyclase a c t iv i t y  ( f ig  4 .8 ) .  ATP and a non-hydrolysable 
analogue, AMP-PNP, attenuated cGMP production in both conditions. Dose 
response curves were constructed fo r  ATP in the presence and absence 
of 1 /iM ANP. The reduction of guanylate cyclase a c t iv i t y  was dose 
dependent, with h a lf  maximal inh ib it io n  occurring at 2 x 10"^ M fo r  
both basal and ANP-stimulated a c t iv i ty  ( f ig  4 .9 ) .
The e f fe c t  of 1 mM ATP on manganese-dependent guanylate cyclase 
a c t iv i t y  was examined over an extended time course ( f i g ,  4 .10 ) .  As 
observed in e a r l ie r  experiments, the rate  of cGMP production in the 
absence of ATP was l in e a r  for the f i r s t  20 min, fo r  both basal and 
ANP-stimulated guanylate cyclase a c t iv i ty ,  while longer incubations 
resulted in an attenuation of the a c t iv i ty .  When ATP was included in 
the incubation medium the i n i t i a l  rate  of cGMP production was s l ig h t ly  
reduced, but th is  lower a c t iv i ty  was maintained fo r  the duration of 
the time-course. Thus, in the presence of ATP, basal and ANP-
Figure 4 .8
Effect of Adenosine Phosphates on Mn ’^*’- Dependent Guanylate Cyclase 
A c t iv i ty
Rat cardiac sarcolemmal membranes were incubated fo r  20 min at 37°C, 
in the absence ( | | ) or presence ( ^  ) of 10"^ M ANP, and in the
presence of 1 mM adenosine phosphates as indicated. The results are 
the mean ±  SEM of at least 3 separate experiments in which guanylate 
cyclase was measured in t r ip l ic a te  followed by duplicate  
determinations of cGMP. Significant differences from controls are 
indicated by * = p< 0.05, * *  = p< 0.01  and * *  = p< 0.001  as determined 
by a tw o -ta iled  Student's t - te s t  (paired solution).
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Figure 4.9
Dose Response Curve fo r  the Effect of ATP on Mn^^-Dependent Guanylate 
Cyclase A c tiv ity
Rat cardiac sarcolemmal membranes were incubated fo r  20 min at 37^0, 
with increasing concentrations of ATP, in the absence (a — a ) or
presence of 10“  ^ M ANP ( □ ----- □ ) .  Mn^* was kept at a concentration 1 mM
in excess of the combined 6TP and ATP concentrations. The results are  
the mean ±  SEM of 3 separate experiments in which guanylate cyclase 
was measured in t r i p l i c a t e ,  followed by duplicate determinations of 
cGMP.
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Figure 4.10
The Effect of ATP on the Rate of cGMP Production
Rat cardiac sarcolemmal membranes were incubated fo r  20 min at 37°C, in 
the absence (A— A) and presence (□ — □) of 10“  ^ M ATP, (a) in the 
absence and (b)in  the presence of 10"^ M ANP. The Mn^* concentration was 
3x10’  ^ M. Each point represents the mean of duplicate determinations of 
guanylate cyclase a c t iv i t y ,  which had been assayed in duplicate fo r  cGMP.
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stimulated guanylate cyclase a c t iv i t ie s  were constant fo r at least 60 
minutes.
The e ffects  of various adenosine phosphates were also examined on 
magnesium-dependent guanylate cyclase a c t iv i ty .  ADP and AMP, both at 1 
mM, had no e f fe c t  on the ra te  of cGMP production in e ith er  the absence 
or presence of 1 juM ANP ( f ig  4 .11 ) ,  although both 1 mM ATP and 1 mM 
AMP-PNP produced s ign ifican t increases in basal and ANP-stimulated 
guanylate cyclase a c t iv i t ie s .  The dose response curves fo r the e ffe c t  
of ATP on Mg2+-dependent guanylate cyclase a c t iv i t y ,  both in the 
presence and absence of ANP, were biphasic ( f ig  4 .1 2 ) .  Concentrations 
of ATP up to ImM augmented both basal and ANP-stimulated guanylate 
cyclase a c t iv i ty  with fu r th e r  increases in ATP resu lting  in a decline  
in a c t iv i ty  under both conditions. A dose response curve was 
constructed fo r ANP stimulation of Mg^^-dependent guanylate cyclase 
a c t iv i t y  in the presence of ImM ATP ( f ig  4 .1 3 ) .  The Km fo r  ANP under 
these conditions was 2.31 + 0.36 nM with a H i l l  co e ff ic ie n t  of 1.22 ±  
0.28.
4 .1 .8  Guanvlate Cvclase A c t iv i tv  in BAG Membranes
Basal and ANP-stimulated, Mn^^-dependent, guanylate cyclase a c t iv i ty  
was measured in BAG membranes. In these membranes ANP produced a 2 .7 -  
fo ld  increase in guanylate cyclase from 267 + 39 fo r  basal a c t iv i t y  to 
728 + 54 pmol/min per mg protein fo r  ANP-stimulated a c t iv i t y .  The Km 
fo r  ANP was 0.691 ±  0.161 nM and the H i l l  c o e ff ic ie n t ,  of 0.754 +
0.026 ( f ig .  4 .1 4 ) .
Figure 4.11
E ffec t  of Adenosine Phosphates on Dependent Guanylate Cyclase
A c t iv i ty
Rat cardiac sarcolemmal membranes were incubated fo r  20 min at 37°C, 
in the absence ( ) or presence ( 0^0 ) of 10"^ M ANP, and in the
presence of 10"^ M adenosine phosphate as indicated. The values are 
the mean ±  SEM of at least 3 separate experiments in which guanylate 
cyclase was measured in t r ip l ic a t e  followed by duplicate  
determinations of cGMP. S ig n if ican t differences are indicated by 
*  = p< 0.05, * *  “ p< 0.01 and * *  = p< 0.001 as determined by a two- 
ta i le d  Student's t - te s t  (paired solution).
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Figure 4.12
Dose Response Curve fo r  the E ffec t of ATP on Mg2+-Dependent Guanylate 
Cyclase A c tiv ity
Rat cardiac sarcolemmal membranes were incubated fo r  20 min a t 37°C, 
with increasing concentrations of ATP, in the absence (a — A) or
presence of 10“  ^ M ANP (□------ □ ) .  was kept at a concentration
10"3 M in excess of the combined GTP and ATP concentrations. The 
results are the mean + SEM of 3 separate experiments in which 
guanylate cyclase was measured in t r ip l ic a te ,  followed by duplicate  
determinations of cGMP.
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Figure 4.13
Dose Response Curve fo r  ANP in the presence of ATP and Mg2+
Rat cardiac sarcolemmal membranes were incubated fo r  20 min at 37°C, in 
the presence of 2mM Mg2+, l  mM ATP, and increasing concentrations of ANP. 
Each point is the mean + SEM of t r ip l ic a te  determinations of guanylate 
cyclase a c t iv i ty  which were assayed in duplicate fo r  cGMP.
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Figure 4.14
Dose Response Curve fo r  ANP Stimulation of Guanylate C vclaseac t iv i t y  in 
BAG Membranes
A representive dose response curve fo r  ANP stimulation of guanylate 
cyclase a c t iv i ty  in BAG membranes, measured in the presence of 3x10“  ^ M 
Mn^^. The results are the means + SEM of t r ip l ic a te  determinations of 
guanylate cyclase a c t iv i t y  in which cGMP was measured in duplicate.
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4 .2  DISCUSSION
4 .2 .1  Guanvlate Cvclase A c t iv i ty  in Rat Cardiac Sarcolemmal Membranes
These resu lts  demonstrate basal and ANP-stimulated guanylate cyclase 
a c t iv i t y  in purif ied  sarcolemmal membranes isolated from ra t  
ven tr icu la r  muscle. The findings are in agreement with previous 
reports , which have demonstrated basal guanylate cyclase a c t iv i ty  in 
p a r t ic u la te  fractions isolated from the heart ventric les of several 
species, including ra t  (Kimura & Murad, 1974; Sulakhe et a l . , 1976a), 
ra b b it ,  hamster, guinea pig and mouse (Sulakhe et a l . . 1976a). The 
present results are also in agreement with previous studies 
demonstrating ANP-stimulated increases in in tra c e llu la r  cGMP levels in 
iso lated ra t  and rabbit ven tricu lar myocytes (Aiton & Cramb, 1985; 
Cramb e t  a l . . 1987).
In ra t  cardiac sarcolemmal membranes, Mn^* supported 20- to 40-fold  
higher levels of both basal and ANP-stimulated guanylate cyclase 
a c t iv i t y  than did Mg^*. Similar differences in the levels of basal 
guanylate cyclase a c t iv i t y  have been reported for ra t  l iv e r  plasma 
membranes (Kimura & Murad, 1975a), fo r  a part icu la te  frac tion  from 
rabb it  heart ventric les  (Sulakhe et a l . . 1976a), and fo r  basal and 
ANP-stimulated guanylate cyclase a c t iv i t y  in BAC membranes (Tremblay 
et a l . . 1986). The dose response curve fo r  GTP, in the presence of 
excess of Mn^+, indicated positive co -opera tiv ity  and/or multiple  
binding s ites , with the addition of ANP increasing the maximum 
v e lo c ity  of the enzyme but having l i t t l e  e ffe c t  on the K^ , or the slope 
of the dose response curve. Similar k inetics  have been described fo r  
basal p art ic u la te  guanylate cyclase a c t iv i t y  in the ra t  (Kimura & 
Murad, 1974) and rabb it (Sulakhe et a l . . 1976b) heart, and fo r basal
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and ANP-stimulated a c t iv i ty  in bovine adrenal cortex (Tremblay et a l . . 
1986). Likewise, the H i l l  coe ff ic ien t calculated from the stimulatory  
portion of the manganese dose response curves, both in the absence and 
presence of ANP, suggested that th is  cation was exerting positive co­
operative e f fe c ts .  In contrast, Mn^* concentrations in excess of 4 mM 
produced a marked reduction in guanylate cyclase a c t iv i t y .  These 
results  are in agreement with reports on the effects  of Mn^* ion 
concentration on basal guanylate cyclase a c t iv i ty  in ra t  (Kimura & 
Murad 1974) and rabbit (Sulakhe et a l . . 1976a) heart membranes.
Differences in ANP-stimulated guanylate cyclase a c t iv i t y  were observed 
between fra c t io n  A and frac tion  B. Both these fractions are enriched 
in membrane enzyme markers, but electron micrographs indicate that the 
membranes in frac tion  A have a tendency to 's tick  together ',  forming 
l iposom al-like  structures (Cramb & Dow 1983). I t  is possible that  
w hils t  these structures do not a ffec t basal guanylate cyclase 
a c t iv i t y ,  they do l im i t  the access of ANP to i ts  receptor, and hence 
reduce ANP-stimulated a c t iv i ty .
Half-maximal stimulation of guanylate cyclase a c t iv i ty  was produced by 
1 nM ANP. S im ilar concentrations of ANP have been reported to produce 
half-maximal stimulation of guanylate cyclase a c t iv i ty  in BAC 
membranes (Tremblay et a l . . 1986), and to produce half-maximal 
elevation of in tra c e l lu la r  cGMP levels in cort ica l co llecting  tubules 
(Narav-FeTes-Toth et a l . . 1988) and LLC-PKj cells  ( Inu i et a l . ,  1985). 
The dose response curve fo r  ANP stimulation of guanylate cyclase 
a c t iv i t y  was shallow in nature, with a H i l l  co e ff ic ien t  of less than 
1 , ind icating  negative co-opera tiv ity .
There have been a number of reports documenting the a b i l i t y  of various
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truncated analogues of ANP to relax preconstricted smooth muscle, and 
in a l l  cases ANPg_28 less potent that ANP (Thibault et a l . . 1984b;
Garcia et a l . . 1985; 01 ins et a l . . 1986). Physiological studies have 
shown that ANPg_28 e ffec tive  at producing natriuresis  and diuresis  
in ra t  but not in dog, indicating species variation  in the response to 
these two peptides (Wakitani et a l . . 1985). This is supported by the 
observation that while ANPg_2g is 10-fold less potent than ANP at 
producing a half-maximal increase in in tra c e l lu la r  cGMP in ra t  and 
human c e ll  l ines , i t  is 1000-fold less potent in bovine and canine 
cel ls  (Leitman & Murad, 1986). In the present experiments, the 
concentrations of ANP and ANPg_2g required to produce half-maximal 
stimulation of guanylate cyclase a c t iv i ty  in ra t  cardiac sarcolemmal 
membranes were not s ig n if ican tly  d if fe re n t .  There was however a 
s ig n if ican t  difference between the maximum responses e l ic i te d  by these 
two peptides, with ANPg_2g producing less than 50% of the response 
produced by ANP.
In agreement with a previous report on the e f fe c t  of 
ANP5„25 guanylate cyclase a c t iv i ty ,  th is  peptide was more than 
1000-fold weaker than ANP in stimulating guanylate cyclase a c t iv i ty  in 
ra t  cardiac sarcolemmal membranes (Leitman & Murad 1986).
4 . 2 . 2  Degradation of ANP
Endopeptidase 24.11 has been implicated in the breakdown of ANP by pig 
kidney membranes (Stephenson & Kenny, 1987a). Phosphoramidon, a 
specific  in h ib ito r  of th is  peptidase, had no e f fe c t  on the k inetics of 
the ANP dose response curves.
Of the other protease inhib itors tested, only the serine protease
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in h ib ito rs ,  PMSF and aprotin in , had any e f fe c t  on guanylate cyclase 
a c t iv i t y .  Both these compounds produced a small decrease in ANP- 
stimulated a c t iv i ty .  I t  has previously been shown that treatment of 
ra t  l iv e r  plasma membranes with various proteases, including several 
serine proteases, results in an increase of guanylate cyclase a c t iv i ty  
(Lancombe & Hanoune, 1979). This increase in a c t iv i t y  appears to be 
due to the d irec t  action of the protease on guanylate cyclase, as 
stimulation occurs even a f te r  so lub iliza tion  of the enzyme. The 
decrease in a c t iv i t y  observed in the presence of PMSF and aprotinin in 
ra t  cardiac sarcolemmal membranes ( f ig .  4 .7 ) raises the p o s s ib il i ty  
that proteolysis is involved in the regulation of ANP-stimulated 
guanylate cyclase a c t iv i ty  in th is  preparation.
4 .2 .3  E ffect of Adenosine Phosphates
ATP has previously been shown to decrease Mn^^-dependent guanylate 
cyclase a c t iv i t y  in ra t  and rabbit heart membranes (Kimura & Murad 
1974; Sulakhe e t a l . . 1976b). The results reported here support these 
f indings and show that s im ilar decreases in guanylate cyclase 
a c t iv i t y  are observed in purif ied  ra t  cardiac sarcolemmal membranes, 
both in the presence and absence of ANP. The e f fe c t  of ATP on Mg^*- 
dependent guanylate cyclase a c t iv i ty  is more complicated, producing 
biphasic dose response curves. ImM ATP, a concentration s im ilar to 
tha t found inside the c e l l ,  produces a marked stimulation of guanylate 
cyclase a c t iv i t y .  Similar observations have been reported fo r  basal 
and ANP-stimulated guanylate cyclase a c t iv i t ie s  in ra t  l iv e r  membranes 
(Kurose et a l . ,  1987). I t  is l ik e ly  that the attenuation of guanylate 
cyclase a c t iv i t y  observed at high concentrations of ATP is a resu lt  of 
the d irec t  competition between ATP and GTP, whereas the augmentation
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of Mg2+-dependent guanylate cyclase, observed with lower ATP levels ,  
suggests a possible a l lo s te r ic  ro le  fo r  nucleotide. This is supported 
by the observation that 1 mM AMP-PNP, a non-hydrolysable analogue of 
ATP, also increases Mg^^-dependent guanylate cyclase. In te re s tin g ly ,  
the dose response curve fo r  ANP measured in the presence of magnesium 
and ATP displays normal Michael is Menten k ine t ics , with a H i l l  
co e ff ic ien t  of 1. I t  is not known i f  th is  is a re s u lt  of magnesium, 
ATP, or a combination of the two, since ANP dose response curves fo r  
Mg2+-dependent guanylate cyclase in the absence of ATP have not been 
determined.
Further evidence in support of an a l lo s te r ic  ro le  fo r ATP comes from 
the measurement of Mn^^-dependent guanylate cyclase a c t iv i ty  over an 
extended time-course. Although 1 mM ATP produces a small decrease 
Mn^^-dependent guanylate cyclase a c t iv i ty ,  the ra te  of cGMP 
production is maintained fo r at least 60 min, whereas in the absence 
of ATP, the cGMP production decreases a f te r  about 30 min. This e f fe c t  
is observed both in the presence and absence of ANP, suggesting that  
modulation of cGMP production by ATP is occurring through the 
guanylate cyclase e n t i ty ,  rather than through the ANP receptor.
4 .2 .4  Guanvlate Cvclase A c tiv itv  in BAC Membranes
Guanylate cyclase a c t iv i ty  was measured in p u r if ied  membranes from 
bovine adrenal cortex (BAC) and compared to that in the cardiac 
sarcolemmal membrane preparation. The concentration of ANP required to 
produce half-maximal stimulation in BAC membranes was the same as fo r  
heart membranes, and s im ilar to that previously reported fo r  BAC 
membranes (Tremblay et a l . . 1986). The dose response curves fo r  ANP 
were s ig n if ic a n t ly  steeper than those observed with ra t  cardiac
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sarcolemmal membranes, suggesting that the k inetics  of cGMP production 
by BAC membranes are closer to normal Michaelis-Menten k inetics than 
are those observed with the cardiac preparation. BAC membranes were 
stored in buffer containing 5 mM Mg^+, whereas the cardiac membranes 
were stored in the absence any divalent cation. Although a fte r  
d ilu t io n  the concentration of Mg^+ in the guanylate cyclase assay was 
less than O.lmM, th is  may have been high enough to modulate guanylate 
cyclase a c t iv i ty .
4 .3  Summary
These results are consistent with e a r l ie r  reports indicating basal 
guanylate cyclase a c t iv i t y  in ra t  cardiac sarcolemmal membranes, and 
provide evidence of ANP-stimulated guanylate cyclase a c t iv i ty  in the 
same preparation. In addition, these results support the hypothesis 
that ATP modulates both basal and ANP-stimulated guanylate cyclase 
a c t iv i t y .
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CHAPTER 5
5 Results of Receptor-Binding Experiments
5 .1 . Binding to Rat Cardiac Sarcolemmal Membranes
Incubation of [^^^I]-ANP with ra t  cardiac sarcolemmal membranes at  
37°C resulted in a time-dependent increase in ra d io a c t iv ity  ( f ig  5 .1 ) .  
Specific  binding, defined as that binding not displaced by 10’*®M ANP, 
reached a steady state within 40 min, with a t ^/2  10 min. The
displacement of [^^^I]-ANP by unlabelled ANP was measured in a number 
of separate preparations ( f ig  5.2 ) ,  and the concentrations of ANP 
required to produce a 50% inh ib it ion  of binding (ICgg ) were 
determined by ind irect H i l l  plots. The potency of ANP displacement of 
[125i]^ANP varied 130-fo ld , ranging from 1.65 x 10“^^ M to 2.17 x 10“® 
M, with a mean of 5.16 ±  3.38 x 10”^M. The H i l l  coe ff ic ien ts  ranged 
from -0.130 to -0.504 (tab le  5 .1 ) ,  indicating the presence of complex 
binding phenomena or technical a r t i fa c ts .  The [^^®I]-ANP displaced was 
expressed as a percentage of the to ta l  [^^®I]-ANP present in the 
incubation and the results  of the individual experiments combined ( f ig  
5 .3a ) .  Scatchard analysis of these data resulted in a biphasic p lo t ,  
which could be resolved into two stra ight lines ( f i g .  5 .3b). The 
estimates of the IC5Q fo r  ANP were 1.41 x 10"^^ M and 9.25 x 10"^ M, 
fo r  the high and low a f f i n i t y  binding sites respective ly . Since 
analysis of the data by H i l l  plots and Scatchard plots suggested the 
presence of two ANP binding sites in the cardiac sarcolemmal membrane 
preparation, the resu lts  of the individual dose response curves were 
analysed using E nzfit  (ligand-binding two-s ite  so lution; see appendix 
I I I ) .  IC5Q values fo r  the low a f f in i t y  s i te  were in good agreement 
with those obtained by H i l l  and Scatchard p lots, ranging from 1.14 x
Figure 5.1
Time Course for the Binding of [^^^Ij-ANP to Rat Cardiac Sarcolemmal 
Membranes
[125ij_ANP (lOOpM) was incubated with ra t  cardiac sarcolemmal membranes
(11.3yug protein /m l) at 37°C, in the absence A A^ (T o ta l)  and presence
□ — □ (NSB) of 10"^M ANP. At the times indicated, ZOQwl aliquots were 
removed and f i l t e r e d  through Whatman GF/F f i l t e r s  as described in the 
materials and methods. The specific  binding — * )  was calculated by 
subtracting the NSB from the to ta l  binding. Each point represents 
duplicate determinations from a single preparation.
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Figure 5.2
In h ib it io n  of [^^^I]-ANP binding in Rat Cardiac Sarcolemmal Membranes by
M P
Dose response curves fo r ANP displacement of [^^^I]-ANP binding to ra t  
cardiac sarcolemmal membranes (2 to 15 pg p ro te in /m l) .  The results  shown 
are for individual experiments performed on separate membrane 
preparations, in the presence of [^^^I]-ANP a t  (a) 81.6 pM, (b) 8 8 .6  pM, 
(c )  60.6 pM, (d) 90.0 pM, (e) 70.9 pM, and ( f )  43.3 pM. Each point is the 
mean of at least 2 determinations which varied by less than 10%
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Table 5.1
Results of H i l l  Plots of the ANP Displacement Curves
Expt.
No.
Slope Corr. 
Coeff.
IC50
(pM)
|-125i]
(pM)
1 -0.130 -0.971 165 43.29
2 -0.287 -0.962 21700 60.6
3 -0.367 -0.967 5047 70.93
4 -0.416 -0.986 1752 81.6
5* -0.420 -0.990 1648 88.6
6 -0.504 -0.996 628 90.9
*  Membranes were prepared in the absence of OTT.
Figure 5.3
Mean Dose Response Curve fo r  ANP Displacement of [^^^I]-ANP from Rat 
Cardiac Sarcolemmal Membranes
(a) The results of experiments shown in f ig .  5.2 were corrected fo r  NSB, 
and expressed as the percentage inh ib it io n  of [^^^I]-ANP binding. Each 
point represents the mean + S.E.M. (b) A Scatchard p lo t of the data from 
( a ) .
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10-10 M to 1.61 X  10-8 M with a mean of 3.93 + 2.50 xlO"® M. High
a f f i n i t y  binding s ites could not be detected in two of the dose 
response curves, and in the rest the estimates fo r  these sites varied  
280-fo ld , ranging from 5.96 x 10"^^ M to 1.67 x 10“ ^^  M, with a mean 
of 6.11 + 3.90 X 10-12 M (tab le  5 .2 ) .  The mean of these results was of 
a s im ilar  magnitude to that determined by Scatchard analysis.
The fa i lu re  to detect high a f f i n i t y  binding sites in two of the 
experiments may have been re lated  to the concentration of [125i]_ANP 
present in the incubation. A p lo t of to ta l [125i]_ANp concentration 
against the amount of [125i]_AWp displaced by 1 pM ANP yields a 
s tra ig h t l in e ,  ind icative  of a negative re lationship  between the two 
variables ( f ig  5 .4 ) .  The only exception to th is  general finding were 
data obtained from sarcolemmal membranes which had been prepared in 
the absence of d i th io th e r i to l  (DTT). Extrapolation of the line  
i l lu s t ra te d  in f ig .  5.4 indicates that at a concentration of 30 pM 
[125i]_ANP, 50% of the ra d io a c t iv ity  can be displaced by IpM ANP. This 
re s u lt  is not consistent with ANP and [125i]-ANP possessing the same 
a f f i n i t y  for the binding s ite .
To assess the a f f i n i t y  and to ta l  number of [125i]-ANP binding s ites  in 
p u r if ie d  ra t  sarcolemmal membranes a saturation binding curve was 
constructed ( f ig .  5 .5a ) .  Although the maximum concentration of [125j]_  
ANP (700 pM) was not enough to saturate a l l  the binding s ites , a 
Scatchard plot of the data indicated the presence of two or more 
a f f i n i t y  states/binding sites in th is  preparation ( f ig  5 .5b). The Kq ' s 
were estimated as 5.59 pM and 0.98 nM, and the values were 10.55 
and 980 fmol/mg protein, fo r  the high and low a f f i n i t y  sites  
respective ly . Analysis of the data by E n z fit ,  (ligand binding two-site
Table 5.2
Results of Enzfit  Analysis of ANP Displacement Curves
The Kq for ANP were determined using the Cheng Prusoff equation. The 
dissociation constants fo r  [^^^I]-ANP were 10.9 pM and 1.23 nM fo r  the 
high and low a f f in i t y  sites respectively.
Expt. Site I (pM) Site II(nM) 12Si]_ANP
No. IC50 Ko IC50 Ko (pM)
1 0.060 0.012 0.114 0.110 43.3
2 0.410 0.063 2.630 2.51 60.6
3 16.7 2.130 16.10 15.2 70.9
4 7.27 0.857 0.904 0.848 81.6
5* - - 3.730 3.48 8 8 .6
6 - - 0.131 0.122 90.9
Mean 6.11 0.765 3.930 3.66
±  S.E.M ±  3.9 1  0.494 1  2.500 i  2.40
* Membranes were prepared in the absence of DTT
Figure 5.4
Relationship Between Radioactiv ity  Displaced and Concentration of 
[125i]_ANp
A comparison of the percentage ra d io a c t iv ity  displaced by 10"^^ M ANP, 
and the to ta l  concentration of [^^^I]-ANP. The data are the individual 
values from f ig .  5 .3 . Membranes were prepared in the presence ( □  ) or 
absence ( * ) of DTT.
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Figure 5.5
Saturation Curve fo r  [^^^I]-ANP Binding to Rat Cardiac Sarcolemmal 
Membranes
(a) Rat cardiac sarcolemmal membranes were incubated for 40 min at 37^C, 
with increasing concentrations of [^^^I]-ANP in the absence A — A (to ta l  
binding) and presence[]— □(NSB) of lO'^M ANP. Specific  b in d in g , * — * ,  
is the to ta l binding minus the NSB. The results are the mean ±  S.E.M. for  
t r ip l ic a t e  determinations from a single membrane preparation, (b) 
Scatchard plot of the data shown in (a)
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solution) gave s im ilar  results , with a Kq of 10.9 pM and a 8^^% 15.3 
fmols/mg protein fo r  the high a f f in i t y  s i te ,  and a Kq of 1.23 nM and 
B^ax 944 fmols/mg protein for the low a f f i n i t y  s i te .  These results  
are very close to the IC5Q values obtained from ANP displacement 
curves.
The p o s s ib i l i ty  that degradation of [^^^I]-ANP was responsible fo r  the 
complex binding curves was examined. Endopeptidase 24.11 has been 
shown to degrade [^^^I]-ANP in pig kidney membranes (Stephenson & 
Kenny 1987a). Therefore ANP displacement curves were constructed in 
the presence and absence of 10 /iM phosphoramidon, a specific  in h ib ito r  
of th is  enzyme. Phosphoramidon had no e f fe c t  on the displacement of 
[125i]_ANP by unlabelled ANP ( f ig .  5 .6 ) .
To exclude the p o s s ib i l i ty  that degradation by unspecified peptidases 
was occurring, and to confirm the results of the previous experiment, 
HPLC analysis was performed on the samples. Membranes were incubated 
with [^^^I]-ANP fo r  40 min at 37®C, in the presence and absence of 
unlabelled ANP (1 >iM) and phosphoramidon (10 /iM). A fter 40 min the 
samples were extracted on Sep-Pak C^g cartridges and analysed by 
reverse phase HPLC. The pro files  of the recovered ra d io a c t iv ity  were 
compared with those obtained from [^^^I]~ANP standards which had 
e ith e r  been extracted or applied d ire c t ly  to the HPLC column. The 
d is tr ib u tio n  of ra d io a c t iv ity  in the standards was the same whether or 
not they had been extracted, with more than 90% of the ra d io a c t iv ity  
elu ting  in a single peak at 51.23% ACN ( f ig s .  5.7a and 5 .7b).
Following incubation of the radioligand with sarcolemmal membranes in 
the absence of unlabelled ANP, the amount of ra d io a c t iv ity  recovered 
was reduced to 75%, with two small peaks of ra d io a c t iv ity  e lu ting  at
Figure 5.6
The e f fe c t  of Phosphoramidon on [^^^I]~ANP Binding to Rat Cardiac 
Sarcolemmal Membranes
|-125ij_ANP was incubated with ra t  cardiac sarcolemmal membranes fo r  40 
min at 37°C, in the presence of ANP at the concentration indicated. The 
resu lts  are expressed as the percentage of [^^^I]-ANP bound in the 
presence o f 10"^ M phosphoramidon compared with that bound in i ts  
absence. Values are the means + the S.E.M. from 3 separate membrane 
preparations.
% of Control120 -
10.000
ANP (pM)
Figure 5.7
HPLC Analysis of [^^^I]~ANP
P r o f i le  of the d is tr ib u tio n  of rad io a c t iv ity  following reverse phase 
HPLC analysis of [^^^I]-ANP. (a) standard; (b) extracted standard. 
|-125ij_anp incubated with cardiac sarcolemmal membranes fo r  40 min at  
37°C, (c) in the absence, and (d) in the presence of lO"^ M ANP, or 
(e) 10"5 M phosphoramidon, or ( f )  10"^ M ANP and 10"^ M 
phosphoramidon. Arrows indicate, (1) the position of native  
[1 2 5 i] .a n p ,  and (2) and (3 ) ,  the positions of radio labelled breakdown 
products.
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48.9% and 34.4% ACN ( f ig .  5 .7 c ) .  The addition of 1 /iM ANP increased 
the ra d io a c t iv ity  in the major peak to 85% of the to ta l  counts, with a 
corresponding reduction in the two smaller peaks ( f ig .  5 .7d ).  The 
inclusion of phosphoramidon in the incubation had no e f fe c t  on the 
amount or d is tr ibu tio n  of the rad io ac tiv ity  recovered ( f ig s .  5.7e and 
5 .7 f  and table 5 .3 ) .
5 .1 .2 .  [125i]_ANP Binding to Membranes Isolated from Bovine Adrenal 
Cortex
The incubation of [^^^I]-ANP with membranes isolated from bovine 
adrenal cortex resulted in a time-dependent increase in ra d io a c t iv ity  
with a t i /2  specific  binding of 5.3 min at 20°C ( f ig .  5 .8 ) .  The 
e f fe c t  of increasing concentrations of [^^^I]-ANP was examined in 
these membranes ( f ig .  5 .9 a ) .  As with binding to cardiac sarcolemmal 
membranes, the highest concentration of [^^^I]-ANP ava ilab le  was not 
enough to f u l l y  saturate the binding s ites . Nonetheless, a Scatchard 
p lot of the data indicated the presence of two binding sites ( f ig .  
5 .9b ), with Kq of 11.3 pM and 0.972 nM, and 8^^ % of 8.59 fmol/mg 
protein and 2.32 pmol/mg protein, for the high and low a f f i n i t y  sites  
respective ly . The data were also analysed by E n z f i t te r  (ligand  
binding, tw o-site  so lu tion ).  The Kq ' s were estimated as 26.1 pM and 
1.78 nM, with B^^x of 25.1 fmol/mg protein and 3.56 pmol/mg protein  
fo r  the high and low a f f i n i t y  sites respectively.
5 .1 .3  [^^^I]-ANP Binding to Membranes Isolated from MOCK c e lls
Experiments were carried out on crude membranes isolated from two 
strains of MDCK ce lls  (Madin Darby canine kidney c e l ls ) .  The
Table 5.3
D istribution  of Radioactiv ity  Following the Incubation of [^^^I]-ANP 
with Cardiac Sarcolemmal Membranes
The d is tribu tion  of ra d io a c t iv ity  following the incubation of [^^^I]- 
ANP with purified  ra t  cardiac sarcolemmal membranes. The resu lts  are 
expressed as a percentage of the to ta l ra d io a c t iv ity  recovered from 
the HPLC. See tex t  for d e ta i ls  of extracted (Ex.) and non-extracted  
(Non-Ex.) standards.
Control Phosphoramidon
Buffer ANP Buffer ANP Standards
% ACN 10“ M^ 10“^M Ex. Non-Ex.
34.3 5.30 1.57 4.40 1.20 0.48 0.34
48.8 4.40 2.39 4.34 2.16 1.36 0.96
51.2 75.4 85.7 77.3 85.5 89.4 89.3
Total 85.1 89.7 86 .0 88.9 91.26 89.3
Figure 5.8
Time Course fo r  the Binding of [^^^I]-ANP to BAC Membranes
[125 i ]_anp (lOOpM) was incubated with BAC membranes ( 118 >ug prote in /m l)
at 37°C, in the absence A — A (Tota l)  and presence □  □(NSB) of 10"^M
ANP. The specific  binding ( * ------ * )  was calculated by subtracting the
NSB from the to ta l  binding. Each point represents duplicate  
determinations from a single preparation.
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Figure 5.9
Saturation Curve fo r [^^^I]~ANP Binding to BAC Membranes
(a) BAC membranes were incubated for 40 min at 37°C, with increasing  
concentrations of [^^^I]-ANP in the absence a — A ( to ta l  binding) and 
presenceD— o(NSB) of 10"^M ANP. Specific binding, * — *  , is the to ta l  
binding minus the NSB. The results are the mean + S.E.M. for t r i p l ic a t e  
determinations from a single membrane preparation.
(b) Scatchard p lot of the data shown in (a )
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association of [^^^I]-ANP to crude membranes prepared from MDCK ce lls  
(s t ra in  I )  was time-dependent, with a t ^ j 2 of 14.58 + 2.75 min at 20°C 
min ( f i g .  5 .10 ).  A saturation curve fo r  [^^^I]-ANP binding to these 
membranes was constructed, and Scatchard analysis of th is  curve 
indicated a single population of high a f f in i t y  binding sites ( f ig  
5 .1 1 ) .  Further analysis of the data using E n zfit ,  ( ligand binding one- 
s ite  solution) gave a Kq of 41.3 pM and a of 339 fmol/mg protein.  
Dose response curves were constructed fo r the displacement of 
ANP by unlabelled ANP ( f ig .  5 .12 ) .  The [^^^I]-ANP displaced was 
expressed a percentage of the to ta l  [^^^I]-ANP present in the 
incubation and the results of the individual experiments combined 
( f i g .  5 . 1 3 ) .  Scatchard analysis of the results again indicated a 
single class of binding sites with an ICgQ of 30.5 pM ( f ig .  5.13b).  
Analysis the data from the individual dose response curves by 
E n z f i t te r  (ligand binding one-site solution) yielded an ICgQ 15.5 +
1.8 pM. When the IC5Q was corrected fo r  the amount of [^^^I]-ANP 
present in the incubation (Cheng & Prusoff, 1973; see appendix I I I ) ,  
a Kq of 8.18 pM was obtained fo r  ANP. However, H i l l  plots ( in d ire c t )  
of the same data had slopes ranging from -0.397 to -1 .302, suggesting 
the presence of more complex Interactions in these experiments ( tab le  
5 . 4 ) .
S im ilar  displacement experiments were performed on membranes prepared 
from s tra in  I I  MDCK c e l ls .  No spec if ic  binding of [^^^-I]-ANP could be 
demonstrated with these membranes ( f i g .  5 .14).
Figure 5.10
Time Course for the Binding of [^^^I]~ANP to MDCK (s tra in  I )  Membranes 
(30 pM) was incubated with MDCK (s tra in  1) membranes ( 34 |ig
pro te in /m l)  at 37^C, in the absences A (T o ta l)  and presenceo— •□(NSB)
of 1 jjM ANP. The specific  binding ( *  —  * )  was calculated by subtracting  
the NSB from the to ta l  binding. Each point represents duplicate  
determinations from a single preparation.
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Figure 5.11
Saturation Curve for [^^^I]-ANP Binding to MDCK (Strain I )  Membranes 
MDCK (s tra in  I )  membranes were incubated fo r  30 min at 20^C, with 
increasing concentrations of [^^^I]-ANP in the absenceA— A ( to ta l
binding) and presenceo— ü(NSB) of 10“  ^ M ANP. Specific b in d in g , *  * .
was calculated by subtracting the NSB from the to ta l binding. The resu lts  
are the mean ±  S.E.M. for t r ip l ic a te  determinations from a single  
membrane preparation.
( i"l)-ANP Bound 
(fm ol/m g protein)
800 1
700-
600 -
500-
400 -
300-
200 - 6 %
100 -
0 100 200 300 400 600 700600
Free (pM)
Bound/Free7
6
6
4
3
2
0
0 50 100 150 200 250 300 360
Bound (fm ol/m g protein)
Figure 5.12
ANP Displacement of [^^^I]-ANP Binding to MDCK (S tra in  I )  Membranes 
[125i]_ANP (37pM) was incubated with MOCK (Stra in  I )  membranes(10 to 40 
jug protein /m l) fo r  30 min at 20^0, in the presence of increasing 
concentrations of unlabelled ANP. The results shown are for 4 separate 
experiments performed on separate membrane preparations. Each point is 
the mean of at least 2 determinations, which varied by less than 10%.
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Figure 5.13
Mean Dose Response Curve for ANP Displacement of [^^^I]-ANP from MDCK 
(S tra in  I )  Membranes
(a )  The results of experiments shown in f ig .  34 were corrected fo r  NSB, 
and expressed as the percentage inh ib it io n  of [^^^I]-ANP binding. Each 
point represents the mean + S.E.M. (b) A Scatchard p lot of the data shown 
in (a ) .
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Table 5.4
Expt. No. Slope Corr. IC50 [lZSl]-ANP
Coeff. (pM) (pM)
1 -0.525 -0,994 17.8 37
2 -0.397 -0.900 24.6 37
3 -1.302 -0.976 10.8 37
4 -0,902 -0.992 12.7 37
Mean 16.5
±  S.E.M. ± 3 . 1 -
Figure 5.14
ANP Displacement of [^^^I]-ANP binding to MDCK (S tra in  I I )  Membranes 
[125ij„ANP (37pM) was incubated with MDCK (S tra in  I I )  membranes (10 to 40 
pg protein /m l) fo r  30 min at 20°C, in the presence of increasing  
concentrations of unlabelled ANP. The results shown are fo r  2 separate 
experiments performed on separate membrane preparations. Each point is 
the mean of duplicate determinations, which varied by less than 10%.
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5.2 Discussion of [^^^I]-ANP binding experiments
5 .2 .1  Analysis of Data From Ligand Binding Experiments
There are two general approaches which can be taken to analyse ligand 
binding data: ( i )  the transformation of the data to a l inear  form, and 
( i i )  the s ta t is t ic a l  f i t t i n g  of raw data to a mathematical model.
The most commonly used transformations are Scatchard plots (Scatchard, 
1949) and H i l l  plots ( H i l l ,  1913; Adair, 1925; see appendix I I I ) .  The 
premise behind both these transformations is that the ligand interacts  
with a single population of binding sites via a simple reversib le  
bimolecular reaction which obeys the Law of Mass Action (Limbird,
1986). When th is  is the case then Scatchard plots of the data are 
s tra ig h t l ines , with a slope equal to - 1/Kq, and the x intercept 
equal to the maximum number of binding sites in the preparation. 
S im ila r ly ,  a H i l l  p lot of the same data w i l l  also be a s tra igh t l in e ,  
with a slope ( H i l l  c o e ff ic ie n t)  of 1 and an x intercept equal to the 
Kq . C urv il inear Scatchard plots and H i l l  coe ff ic ien ts  of greater or 
less than 1 indicate complex binding phenomena or technical a r t i fa c ts .  
For example, a H i l l  co e ff ic ien t  of less than 1 suggests e ith er  
negative co -opera tiv ity  ( i e .  the a f f in i t y  of the receptor decreases 
with increasing occupancy), multiple receptor populations, or multiple  
a f f i n i t y  states of a single receptor. In contrast, a H i l l  coe ff ic ien t  
of greater than 1 suggests e ither positive co -opera tiv ity  ( i . e .  the 
a f f i n i t y  of the receptor increases with increasing occupancy; Limbird,
1986), or the p o s s ib i l i ty  that the reaction has not reached 
equilibrium  (Motulsky & Mahan, 1984).
Curved Scatchard plots can arise fo r  s im ilar reasons, with upward
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concave plots indicating negative co-opera tiv ity , m ultip le  binding 
sites  or m ultip le  a f f in i t i e s  of the same binding s i te .  In situations  
where evidence exists to suggest the presence of two binding s ites , i t  
is possible to resolve the Scatchard plots into two stra ig h t lines,  
from which can be estimated the a f f in i t ie s  and re la t iv e  proportions of 
the two binding sites (Barnett et a l . . 1978; Rugg et a l . . 1978). This 
analysis is based on the assumption that the ligand interacts  
independently with the two binding sites via a simple bimolecular 
reaction . When the a f f in i t i e s  of the two binding s ites d i f f e r  by 100- 
fo ld  or more, such that the high a f f in i t y  s i te  is almost saturated 
before binding to the low a f f i n i t y  s ite  is detectable, then the 
resolution of Scatchard plots into two stra ight lines w i l l  provide an 
accurate estimation of the IC5Q or Kq of the ligand (Nahorski, 1981). 
This however, is predicated on one of the following assumptions being 
va lid :  i )  the radioligand must not distinguish between the two binding 
sites  i . e .  i t  must have the same a f f in i t y  fo r  both s ite s ,  or i i )  i f  
the radioligand does have d if fe re n t  a f f in i t i e s  fo r  the two s ite s ,  
these a f f in i t i e s  must be the same as those fo r  the displacing ligand.
C u rv e -f i t t in g  routines provide a more f le x ib le  approach to the 
assessment of ligand binding data. The models of receptor binding on 
which the computer programmes are based are analogous to those of the 
Scatchard and H i l l  analyses described above. For example, ' A l l f i t '  is 
based on the H i l l  equation (De Lean et a l . . 1978), w h ils t  'Ligand' is 
derived from the 'sum of hyperbolas' model of complex receptor binding 
(Feldman, 1972; Munson & Robard, 1980). These computer-assisted forms 
of analysis provide a more objective approach than l i n e - f i t t in g  by eye 
when m ultip le binding s ites or complex interactions are present.
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With any form of analysis i t  is important to ensure that the model to 
which the data is being f i t t e d  correctly  describes the system under 
investigation. For th is  reason, i t  is useful to analyse ligand binding 
data by a number of d if fe re n t  methods. The more agreement there is 
between the d if fe re n t  methods, the more re l ia b le  are the conclusions 
tha t  can be drawn concerning the data. This approach has been applied 
to the ligand binding experiments described in th is  chapter, with the 
data being f i r s t  assessed by Scatchard and H i l l  p lo ts , and 
subsequently by curve f i t t i n g  of the data to a one- or tw o-s ite  model 
fo r  receptor binding, using E n z f i t te r  (see appendix I I I ) .
5 .2 .2 .  Binding Experiments in Rat Cardiac Sarcolemmal Membranes and 
BAC Membranes
H i l l  plots ( in d ire c t )  of the data from ANP displacement experimemts 
with ra t  cardiac sarcolemmal membranes and BAC membranes had low H i l l  
co e ff ic ien ts .  Scatchard plots of the same data were upwardly concave. 
Although these results  suggest multiple ANP binding sites and/or 
a f f i n i t y  states in these preparations, sim ilar plots would re s u lt  from 
technical a r t i fa c ts  in the experiments. Potential causes of upwardly 
concave Scatchard plots include i )  inappropriate d e f in it io n  of non­
specific  binding, i i )  the aggregation of ligand at higher 
concentrations to form a dimer or multimer possessing a lower a f f in i t y  
fo r  the receptor, and i i i )  a d ifference in a f f i n i t y  of the ligand and 
radioligand fo r  the receptor (Limbird, 1986).
Non-specific binding (NSB) is an estimation of binding not associated 
with physiological binding s ites  (receptors). This binding results  
from the adsorption of radiolabel to the f i l t e r ,  the in teraction  of 
label with non-receptor sites in the membrane (such as p a r t i t io n
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between the l ip id  b ilayer and the incubation medium) and the presence 
of radiolabel which has merely become trapped, possibly in vesicles in 
the membranes. Since binding due to these processes would not be 
expected to saturate, NBS should increase l in e a r ly  as a function of 
rad io labelled  ligand. In the present experiments the amount of [^ ^ ^ I] -  
ANP displacement by 1 /iM ANP was d ire c t ly  proportional to the 
concentration of radioligand ( f ig s .  5.5, 5 .9, 5 .11 ) .  In addition, no 
fu r th e r  displacement of ra d io a c t iv ity  was observed when 10juM ANP was 
included in the incubation. These results suggest that the counts 
bound in the presence of 1 juM ANP are a reasonable assessment of NSB. 
Therefore i t  is un like ly  that innaccurate measurement of NSB 
contributes to the curv il inear Scatchard plots.
A dimeric form of ANP (beta-hANP), which consists of two a n t ip a ra l le l  
ANP molecules linked by intermolecular disulphide bridges, has been 
id e n t if ie d  in human a t r ia  (Kangawa & Matsuo, 1984; Oikawa et a l . . 
1984). In addition i t  has been reported that a free  th io l  group in BSA
can part ic ipa te  in the opening and rejo in ing of alpha-hANP to form a
BSA-ANP conjugate (Miyata et a l . . 1987). Reactions of th is  kind have 
not been reported fo r ra t  ANP, although there is no obvious reason why 
they should not occur. I t  is possible that the 5-10% of ra d io a c t iv ity  
which was not recovered following HPLC analysis of [^^^I]-ANP was in 
fa c t  high molecular weight complexes of the peptide. Since such 
complexes, i f  they are present, would only account fo r  a small
proportion of the to ta l  ra d io a c t iv ity ,  i t  is u n like ly  that th is  is the
cause of the non-linear Scatchard plots and low H i l l  co e ff ic ien ts .
M is in terpreta tion  of binding data, because of d i f fe r in g  a f f in i t i e s  
between the labelled and unlabelled ligand, would only arise i f  the
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calculation  of the results  were based on the combined concentration of 
these two species (Taylor 1975). In the experiments described here no 
p r io r  assumptions were made as to the re la t iv e  a f f in i t i e s  of ANP and 
[125 i ]_anP fo r  binding sites in any of the membranes investigated.
Other a r t ifac tu a l reasons for non-linear Scatchard p lots , and H i l l  
co e ff ic ien ts  d if fe r in g  from 1 , include the measurement of binding 
p r io r  to reaching equilibrium, and degradation of the ligand to a less 
active  form during the incubation (Limbird, 1986). Both these 
a r t i f a c ts  would give r is e  to downward concave curves and H i l l  
coe ff ic ien ts  greater than 1 , and therefore can be excluded as 
contributing to the e ffects  seen in sarcolemmal and BAC membranes. I t  
is therefore l ik e ly  that the curved Scatchard plots and the low H i l l  
co e ff ic ien ts  resulting from the ligand binding experiments carried out 
in these membranes r e f le c t  the nature of the ANP receptor(s) in these 
preparations, rather than technical d i f f ic u l t ie s  with the assays.
The presence of two ANP receptors has been well documented in several 
tissues (Meloche et a l . ,1986a; Napier et a l . ,1984: Hamada et a l . .
1987), and therefore the results were analysed assuming th is  to be the 
case in cardiac sarcolemmal and BAC membranes. ICgQ values calculated  
fo r  ANP binding to high and low a f f i n i t y  sites in these preparations 
are s im ila r  to those previously reported for BAC membranes (Meloche e t  
a l . . 1986a), ra t  and rabb it kidney cortex membranes (Napier et a l . . 
1984), and purified  ra t  glomerular membranes (Hamada et a l . . 1987). 
There was considerable varia tion  in the a f f in i t y  of ANP for these 
binding sites between d if fe re n t  preparations of ra t  cardiac 
sarcolemmal membranes (tables 5.1 and 5 .2 ) ,  and in two preparations 
only a single s ite  could be detected. Some of the varia t ion  may be
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accounted fo r by the differences in the amount of radiolabel present 
in the experiments, and th is  may explain the fa i lu r e  to detect high 
a f f i n i t y  binding sites in two of the preparations. As less than 5% of 
the binding sites in the sarcolemmal membranes are of high
a f f i n i t y ,  these sites can only be measured when the radiolabel is at a 
concentration such that i t  does not bind to the low a f f i n i t y  s ite s .
The concentrations of [^^^I]-ANP present in the two experiments where 
only single binding sites could be measured were 88.6  and 90.9 pM. I t  
is l ik e ly  that at these concentrations s ign ifican t amounts of 
rad io label binds to the low a f f in i t y ,  high capacity s ites  and results  
in a masking of the presence of the high a f f in i t y ,  low capacity  
binding s ites .
The concentration of radiolabel must also be taken into account when 
estimating the Kq ' s fo r  ANP fo r  the ICgg values determined from 
displacement experimemts. This is normally achieved by application of 
the Cheng Prusoff equation (Cheng & Prusoff,1973; see appendix I I I ) .  
This correction fac tor is based on the assumption tha t the 
rad io labelled  ligand interacts with both populations of binding s ites  
with a single a f f in i t y  (Cheng & Prusoff, 1973; Limbird, 1986). 
Scatchard analysis of saturation binding data indicates that [^ ^ ^ I] -  
ANP has d if fe re n t  a f f in i t i e s  fo r  the two binding s ite s ,  and in 
addition i t  is l ik e ly  that these a f f in i té s  d i f f e r  from those fo r  ANP 
( f i g .  5 .4 ) .
Although the assumptions of the Cheng Prusoff equation are v io la ted ,  
i t  is possible to assess the e f fe c t  of the radioligand concentration 
on apparent a f f in i t y  of ANP fo r  i ts  binding sites by the use of the Kg 
values calculated from the [^^^I]-ANP saturation binding experiment.
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Assuming the Kq of [^^^I]-ANP to be 10.9 pM and 1.23 nM fo r  the high 
and low a f f i n i t y  sites respective ly , the Kq of ANP fo r  the two sites  
can be calculated (tab le  5 .2 ) .  The concentration of [^^^I]-ANP was 
less then 100 pM in a l l  the displacement experiments, and therefore i t  
had l i t t l e  e f fe c t  on the apparent a f f i n i t y  of ANP fo r  the low a f f i n i t y  
s i te .  In contrast, these concentrations of radiolabel have a marked 
e f fe c t  on the estimation of the a f f i n i t y  of ANP fo r  the high a f f i n i t y  
s ites , with the calculated Kq values being 5- to 9- fo ld  lower than the 
ICgQ values.
I t  is not possible from any of these experiments to determine whether 
the two binding s ites are actua lly  due to d is t in c t  receptors, or i f  
they are a resu lt  of the same receptor with two d is t in c t  a f f in i t y  
states. In addition, i t  is possible th a t  the complex binding curves 
described here and elsewhere are a re s u lt  of negative co -opera tiv ity .  
K inetic  studies on the dissociation ra te  of rad io label, in the 
presence and absence of an excess of unlabelled ligand, are required 
before th is  p o s s ib i l i ty  can be excluded (De Meyts et a l . ,  1976).
5 .2 .3  [^^^I]-ANP Binding to Membranes Isolated from MDCK ce lls
The resu lts  of the experiments carried out with MDCK ce ll  (s tra in  I )  
membranes indicate the presence of a single population of binding 
s ite s ,  which possess an a f f i n i t y  fo r  ANP s im ilar to that observed fo r  
the high a f f i n i t y  s i te  in ra t  cardiac sarcolemmal and BAC membranes. 
Sim ilar studies with MDCK (s tra in  I I )  c e l l  membranes fa i le d  to detect 
any spec if ic  ANP binding s i te .  These resu lts  confirm e a r l ie r  studies 
from th is  laboratory, which have id e n t if ie d  [^^^I]-ANP binding sites  
in in ta c t  MDCK (S tra in  I )  ce lls  but not in stra in  I I  ce lls  (Aiton et 
a l . ,  1987).
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MDCK ce lls  are established ce ll  lines which display many features  
c h a ra c te r is t ic  of renal ep ith e l ia  (M is fe ld t et a l . , 1976; Cereijido et  
a l . . 1978). Two strains of these ce lls  have been described which 
d i f f e r  in morphological, biochemical, and physiological 
c h arac te r is t ics . Strain I ce lls  form monolayers with characteristics  
s im ila r  to co llecting  duct c e l ls .  They have a high e le c tr ic a l  
resistance, and a low basal short c i r c u i t  current, which can be 
stimulated by adrenaline, prostaglandin E^, and arginine vasopressin. 
In contrast, s tra in  I I  ce lls  form low resistance monolayers, with a 
short c i r c u i t  current which is insensitive to any of these hormones. 
Strain I I  ce lls  possess the proximal tubule enzyme markers a lka line  
phosphatase and gamma-glutamyl transpeptidase, whereas stra in  I ce lls  
do not. In addition, the specific  a c t iv i t y  of (Na* + K^J-ATPase is 
two-fold higher in s tra in  I I  than s tra in  I ce lls  (Richardson et a l . . 
1981). Other differences between the two strains include the existence 
of beta adrenergic receptors and VIP receptors on stra in  I ,  which are 
absent from stra in  I I  (Rugg & Simmons, 1984; Rugg & Simmons 1986).
A recent report by Leitman et a l . (1988) fa i le d  to detect ANP binding 
s ites  in in tac t MDCK c e l ls ,  and i t  is therefore l ik e ly  that the ce lls  
used in tha t study were equivalent to the s tra in  I I  c e lls  described 
here. ANP receptors have been id e n t if ie d  on ra t  inner medullary 
co llec t in g  ducts (Koseki et a l . . 1986ab), and thus the present results  
are consistent with the observation that s tra in  I ce lls  have 
character is t ics  s im ilar to these c e l ls .  Furthermore the lack of 
binding s ites  on s tra in  I I  ce lls  supports the evidence that these 
c e l ls  are of proximal o r ig in .
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5.2.4 Summary
The results  of [^^^I]-ANP binding studies carried out in p urif ied  ra t  
cardiac sarcolemmal and BAC membranes are consistent with the 
existence of high and low a f f i n i t y  ANP receptors and/or a f f in i t y  
states. In contrast, s im ilar  studies with MDCK (s tra in  I )  ce ll  
membranes indicate the presence of a single receptor in th is  
preparation, with an a f f i n i t y  s im ilar  to the high a f f i n i t y  s ite  
observed in cardiac and adrenal preparations.
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CHAPTER 6
6 General Discussion of Guanvlate Cvclase and Ligand Binding 
Experiments
ANP stimulates guanylate cyclase a c t iv i ty  in ra t  cardiac sarcolemmal 
membranes with a potency s im ilar to or s l ig h t ly  higher than that  
described fo r other preparations, including ra t  kidney membranes 
(Waldman et a l . . 1984) and bovine adrenal cortex membranes (Tremblay 
et a l . , 1986), The results of [^^^I]-ANP binding experiments in the 
sarcolemmal membranes are consistent with the presence of two binding 
s ite s ,  with a f f in i t i e s  fo r  ANP of around 10 pM and 1 nM 
respective ly .
S im ilar high and low a f f in i t y  binding sites have been described fo r  
other preparations (De Lean et a l . . 1984b; Hamada et a l . . 1987; Resink 
et a l . . 1988)). Maack et a l .  (1987) have id e n t if ie d  two ANP receptors 
in the ra t  kidney, one of which possesses b io logical a c t iv i ty  (B-ANP 
receptors), while the other is apparently devoid of b iological 
a c t iv i t y  (C-ANP receptors). Likewise, several biochemical studies have 
id e n t if ie d  two d i f fe re n t  ANP receptors, one of which is coupled to 
guanylate cyclase (see section 2 .4 ) .  The ANP receptor coupled to 
guanylate cyclase (M  ^ - 130 kDa) has been termed the ANP-1 receptor 
and the uncoupled s ite  (My. - 66 kDa) the ANP-2 receptor (Murad et a l . .
1988). Based on i )  the corre lation  between the incidence of C-ANP 
receptors and ANF-2 receptors, and i i )  the fa c t  that B-ANP receptors 
mediate increases in in tra c e l lu la r  cGMP, whereas C-ANP receptors do 
not, i t  has been proposed that the B-ANP receptor is the 130 kDa s ite  
and the C-ANP receptor is the 66 kDa s ite  (Lewicki et a l . . 1988). This 
awaits confirmation. More than 95% of the ANP binding sites in most
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c e lls  and tissues appear to be of the C-ANF (or ANP-2) receptor type 
(Maack et a l . . 1987; Leitman & Murad, 1987), and th is  may explain the 
l inear  Scatchard plots obtained with many preparations.
A comparison of the ANP dose response curves fo r  the stimulation of 
guanylate cyclase a c t iv i ty  and the displacement of [^^^I]-ANP in ra t  
cardiac sarcolemmal membranes ( f ig s .  4.5 and 5 .3 ) makes i t  tempting to 
speculate that the high a f f in i t y  sites in th is  preparation are the C- 
ANP (ANF-1) receptors, and the low a f f in i t y  s ites are the B-ANP (ANF- 
2) receptors. I f  th is  is the case then the m ajority  of binding sites  
in th is  preparation are of the b io lo g ica lly  active  type. Evidence 
against th is  hypothesis comes from ligand binding studies on purif ied  
ANF-1 and ANF-2 receptors from bovine adrenal cortex, which indicate  
that the two types of receptor have equal a f f i n i t i e s  fo r  ANP (Kq = 54 
to 69 pM; Takayanagi et a l . . 1987b). I t  should be noted, however, that  
Takayanagi et a l . found that a f te r  co -purif ica tion  of guanylate 
cyclase with ANP binding s ites , the enzyme could no longer be 
stimulated by ANP. A sim ilar loss in ANP-stimulated guanylate cyclase 
a c t iv i t y  has been observed a f te r  the p u r if ica t io n  of guanylate cyclase 
a c t iv i t y  from ra t  lung ( Kuno et a l . . 1986). I t  is therefore possible 
that a f f in i t i e s  of ANP for its  receptors may be d i f fe r e n t  in p urif ied  
preparations, compared to membrane preparations. Investigation  of the 
subunit composition of the ANP receptors in ra t  cardiac sarcolemmal 
membranes is required before f irm  conclusions can be drawn. In 
addition , studies w ith  the ring-deleted analogue of ANP, C-ANP^^gs may 
also help to id e n t i fy  the predominant ANP receptor in ra t  cardiac 
sarcolemmal membranes. I f  the low a f f in i t y  sites are the b io lo g ic a lly  
active  ANP receptors, then C-ANP^_23 should not displace [^^^I]-ANP 
from these sites (see section 2 . 5 ) .
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Ligand binding experiments with MDCK (s tra in  I )  c e l ls  indicated the 
presence of a single population of binding s ites w ith an a f f i n i t y  fo r  
ANP s im ila r  to that of the high a f f i n i t y  binding s ite s  in ra t  cardiac  
sarcolemmal membranes. No guanylate cyclase a c t iv i t y  could be detected 
in th is  preparation. These results are consistent w ith the hypothesis 
that the high a f f i n i t y  binding sites are devoid of b io logical  
a c t iv i t y ,  and i t  is predicted that C-ANP4_23 w i l l  displace [^^^I]-ANP 
from a l l  the s ites in th is  preparation.
As noted previously, Leitman et a l . , (1988) fa i le d  to  id e n t ify  any 
[125i]_ANP binding s ites  on MDCK ce lls  from th e ir  laboratory, although 
ANP did increase in t ra c e l lu la r  cGMP in these c e l ls .  I f  the ce l ls  used 
in th e ir  experiments are the same as MDCK (s tra in  I I )  c e l ls ,  i t  is 
possible that s tra in  I I  ce lls  possess a small number of B-ANP 
receptors and ANP should stimulate guanylate cyclase a c t iv i ty  in these 
c e l ls .
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CHAPTER 7
7 Degradation of [^^^I]-ANP
7.1 Introduction
The m ajority of investigations into the mechanism of action of ANP 
have been concerned with the synthesis and release of th is  peptide, 
i t s  receptor binding, and i ts  a b i l i t y  to stimulate guanylate cyclase 
a c t iv i t y .  L i t t l e  a tten tion  has been paid to i ts  inactiva tion  however, 
although ANP has a h a l f - l i f e  in the blood of only 1 to 3 minutes ( 
Luft e t  a l . . 1986; Yandle et a l . . 1986; Murthv et a l . , 1986ab).
A number of peptide hormones, such as angiotensin, glucagon, and LHRH 
are believed to be inactivated at the brush border of the renal 
proximal tubule, which is rich in membrane bound peptidases (Carone et  
a l . . 1982; Kenny & Maroux, 1982). In the lung, angiotensin I 
converting enzyme is responsible fo r  the both the ac tiva tion  and 
inactiva tion  of peptides. This enzyme both hydrolyses angiotensin I to 
form the potent vasoconstrictor angiotensin I I ,  and degrades the 
hypotensive agent, bradykinin (Linehan et a l . . 1986; Ferre ira  et a l . . 
1967).
ANP may be degraded by mechanisms s im ilar to those described above. 
Moreover, the ra te  of i t s  degradation may be as important as i ts  rate  
of synthesis in the regulation of plasma levels of th is  hormone. This 
chapter reviews the possible mechanisms by which the degradation of 
ANP may occur.
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7.2 C lass if ica tio n  of Proteases and Peptidases 
7 .2 .1 .  Introduction
On the basis of th e ir  mechanisms of action, mammalian proteases can be 
divided into two main groups, the endopeptidases (or proteinases) and 
the exopeptidases. Endopeptidases attack bonds within protein or 
peptide chains, and are generally e ith er  c lass if ied  according to the 
reactive  groups at th e ir  c a ta ly t ic  s ite  (the serine, cysteine, or 
aspartic proteinases) or in terms of metal co-factor requirements (the 
m etalloproteases). Exopeptidases cleave peptide bonds at the ends of 
the peptide/prote in  molecule and can be c lass if ied  according to th e ir  
s i te  (terminus) of attack, preferred substrate and/or s ize of fragment 
l ibera ted  ( f i g .  7 .1 ) .  These groups are fu rther subdivided according to  
the actions of various inh ib ito rs  and th e ir  pH s p e c if ic i ty .  
Comprehensive reviews of proteinase a c t iv i ty  and in h ib ito rs  include 
monographs by Barrett & McDonald (1980), McDondald & B arre tt  (1986) 
and Barre tt & Salvesen (1986). A summary of protease a c t iv i t y  and 
protease inh ib ito rs  re levant to th is  thesis is given below.
7 .2 .2  Serine Proteinases
Serine proteinases are the largest group of pro teo ly tic  enzymes, and 
can be subdivided into chymotrypsin-1ike proteinases and s u b t i l is in -  
l ik e  proteinases. Whilst the s u b t i l is in - l ik e  proteinases are found 
only in bacteria , the chymotrypsin-1ike proteinases are ubiquitous to 
the plant and animal kingdom. The wide var ie ty  of serine proteinases 
found in mammals include enzymes involved in blood coagulation, 
complement ac t iva t io n , digestion, hormone generation or degradation, 
f ib r in o ly s is ,  phagocytosis, and protein turnover.
Figure 7.1
C la s s if ic a t io n  of Proteases
The subdivision of proteases according to th e ir  s ite  of action
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Serine proteinases contain, a t  th e ir  active s i te ,  serine and h is tid ine  
residues, and many specific  inh ib itors of th is  class of enzyme act by 
in teraction  with these amino acids.
Phenylmethylsulphonyl f lu o rid e  (PMSF) is a member of a group of such 
inh ib ito rs  which acts by the formation of a sulphonyl enzyme 
derivative  which is res is tan t to hydrolysis. PMSF has a broad 
s p e c if ic i ty  and inactivates a number of enzymes including tryptases, 
elastases, and blood coagulation proteinases.
Aprotinin is another broad spectrum serine proteinase in h ib ito r ,  which 
was f i r s t  id e n t if ie d  in bovine lymph nodes and found to inactivate  
k a l l ik r e in .  I t  has subsequently been id en tif ie d  in several other 
bovine tissues and found to in h ib it  a number of other enzymes, 
including trypsin , chymotrypsin, and plasmin. Aprotinin acts by the 
formation of a stable complex with the active s i te  of the proteinase 
(Huber & Bode, 1978; Blow et a l . . 1972). Since aprotinin is a large 
molecule (Mol. Wt 5200) i ts  a b i l i t y  to form th is  complex is d ire c t ly  
re la ted  to the 'goodness of f i t '  between the in h ib ito r  and the active  
s ite  of the enzyme. For instance, aprotinin has a high a f f i n i t y  for  
trypsin with only minimal conformational changes of the two structures 
being required to form a stable complex (Huber & Bode, 1978). In 
contrast, the r e la t iv e ly  low a f f in i t y  of th is  in h ib ito r  fo r  
chymotrypsin is caused by the 'poor f i t '  of the enzyme with the active  
s ite  in aprotinin (Blow et a l . . 1972).
Leupeptin is a peptide aldehyde of microbial o r ig in ,  and is a potent 
in h ib ito r  of serine proteinases which possess ' t r y p s in - l ik e '  a c t iv i ty  
(Umezawa, 1976). Thus i t  is a potent in h ib ito r  of trypsin, plasmin, 
and k a l l ik r e in ,  but only poorly inh ib its  chymotrypsin and thrombin
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(Aoyagi et a l . , 1969). Leupeptin is also a potent in h ib ito r  of some 
cysteine proteinases as discussed below.
7 .2 .3  Cvsteine proteinases
Cysteine proteinases have at th e ir  ca ta ly t ic  s ite  cysteine and 
h is t id in e  imidazole residues. This group of proteinases contain 
enzymes such as papain, many of the cathepsins and the fam ily of 
calcium dependent proteinases, known as the calpains.
Many inh ib itors of these enzymes act by alkylation of the cysteine  
sulphydryl group, and one such group of compounds are the 
epoxysuccinyl peptides. Epoxysuccinyl-leucyl-agmatine (E -64), which 
was the f i r s t  member of th is  fam ily  to be discovered, rap id ly  
inactivates papain, cathepsin B, cathepsin L, f ic in ,  and calpain. I t  
is not a universal in h ib ito r  of cysteine proteinases, having l i t t l e  
e f fe c t  on proteolysis by streptoccal cysteine proteinase, and no 
e f fe c t  on c los tr ipa in  a c t iv i ty .  E-64 does not in h ib it  any of the 
serine or aspartic proteinases, or any metalloproteases yet tested  
(B arre tt  et a l . . 1982).
A var ie ty  of other reagents such as N-ethylmaleimide, iodo- and 
bromoacetates and p-chloromercuric benzoate (PCMB) in h ib it  cysteine 
proteinase a c t iv i t y  by a mechanism sim ilar to E-64 (Means & Feeney, 
1971). These reagents are not as specific  as the epoxysuccinyl 
peptides and w i l l  also react with low molecular weight th io l  compounds 
and cysteine proteinases.
Leupeptin in h ib its  several cysteine proteinases, including papain, 
cathespin B (Umezawa, 1982), and calpains I and I I  (Sasaki, et a l . , 
1984). I t  is a member of a class of enzyme inh ib itors  referred  to as
73
t ra n s it io n -s ta te  analogue inh ib ito rs , which act by mimicking the 
geometry of the tra n s it io n  state fo r  the enzyme catalysed reaction  
(see Rich, 1986).
7 .2 .4  Aspartic proteinases
Pepsin and cathepsin D are the two major members of th is  class of 
proteinases. The mechanism by which they act is not f u l l y  understood, 
but i t  is known to involve two aspartate residues at the active s i te  
(Tang et a l . . 1973). Pepstatins are a group of potent inh ib ito rs  of 
th is  class of proteinases and studies using X-ray crystallography  
indicate that these inh ib itors  act by binding to the active s i te  of 
these enzymes (Bott et a l . . 1982; James et a l . ,  1982).
7 .2 .5  Metalloproteases
This is a diverse group of proteases, whose c a ta ly t ic  a c t iv i ty  is 
dependent on the presence of a metal ion, usually z inc, at the active  
s i te .  Included in th is  group of proteases are thermolysin, mammalian 
collagenase, almost a l l  of the membrane-bound endopeptidases and the 
m ajority  of the exopeptidases. Inh ib itors  of th is  class of protease 
usually act by chelating the metal ion associated with the enzyme.
Metal ion chelators such as 1,10-phenanthroline and EDTA 
(ethylenediam ine-tetraacetic acid) are both good inh ib itors  of 
metalloprotease a c t iv i t y .  However, whilst 1,10-phenanthroline is 
spec if ic  fo r  th is  class of proteases, EDTA w i l l  also in h ib it  calcium- 
dependent serine proteases.
Phosphoramidon is a member of a phosphorus containing group of 
inh ib ito rs  specific  fo r  neutral metalloendopeptidases, in p a r t ic u la r
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the bacterial protease thermolysin. The only mammalian protease known 
to be inhibited by phosphoramidon is endopeptidase 24.11.
Amastatin is a peptide in h ib ito r  derived from a species of 
streptomyces and is an in h ib ito r  of some of the metallo-exopeptidases. 
I t  is  specific fo r  amino peptidases, inh ib it ing  the actions of 
aminopeptidase A, leucine aminopeptidase, tyrosine aminopeptidase, 
t r ip e p t id y l - ,  and tetrapeptidyl-aminopeptidases. I t  has no e f fe c t  on 
the a c t iv i ty  of aminopeptidase B, trypsin, chymotrypsin, elastase, 
papain, pepsin or thermolysin.
7 .2 .6  Unclassified Proteinase Inh ib ito rs
Bacitracin is the name given to a number of polypeptide an tib io t ics  
produced by certain strains of Bacillus subtil is and Baci1 lus 
1icheniformis. Of th is  group of antimicrobial agents the most common 
is Bacitracin A, which contains four D-aminoacids, including 
o rn ith in e , which is not normally present in proteins. Bacitracin A 
exerts its  a n t ib io t ic  action by inh ib it in g  the dephosphorylation of 
l ip id  pyrophosphate to l ip id  phosphate and so impairing ce ll  wall 
synthesis (Bowman and Rand, 1980). The mechanism by which i t  in h ib its  
proteolysis is unknown but, as i t  is a polypeptide, i t  may well 
involve binding to the c a ta ly t ic  s i te .  I t  is a potent in h ib ito r  of 
glucagon degradation (Desbuquois e t a l . . 1974).
7 .3 .1  The Removal of ANP from the C irculation
There are two d i f fe re n t  mechanisms by which peptide and protein  
hormones may be removed from the c ircu la tio n , namely receptor-mediated 
endocytosis and degradation. Receptor-mediated endocytosis involves 
the binding of the hormone to i ts  receptor followed by the
75
in te rn a lisa tion  of the hormone-receptor complex, resu lting  in the 
'down regulation' of the receptor. This process has been demonstrated 
to occur following ANP binding to cultured vascular smooth muscle 
c e l ls  fHirata et a l . , 1985; Napier e t  a l . , 1986), and there is 
increasing evidence to suggest that th is  process is important in the 
regulation of ANP levels . As described e a r l ie r ,  there are at least two 
types of ANP receptor, one coupled to guanylate cyclase, the other not 
(section 2 .4 ) .  I t  has been postulated that the receptor which is not 
associated with guanylate cyclase a c t iv i t y  acts as a 'clearance' 
receptor, thereby modulating ANP levels in the blood (Maack et a l . .
1987). This view is supported by the observation that th is  receptor 
type appears to be more susceptable to down regulation than the
guanylate cyclase coupled form (H ira ta  et a l . ,  1987b).
Degradation of ANP by the action of various non-specific endogenous 
t issue proteases may also account fo r  the loss of th is  peptide from 
the c ircu la tio n . I t  is not known to what exent degradation contributes  
to the regulation of plasma ANP leve ls , but there have been several 
reports suggesting an inherent in s ta b i l i t y  of ANP when incubated with  
various biological preparations.
In the remainder of th is  chapter I shall outline the major findings  
concerning the degradation of ANP.
7 .3 .2  Degradation of ANP in the Blood
The importance of the blood in the inactivation of ANP was f i r s t
investigated by Veress e t a l . . (1985), who reported that the pre­
incubation of ANP with whole blood or plasma resulted in the 
attenuation of the renal response in the bioassay r a t .  Although no
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id e n t if ic a t io n  was made of the protease(s) responsible, plasma 
k a l l ik r e in  was precluded by the observation that the e f fe c t  was 
abolished when the p la te le ts  and leucocytes were removed from the 
plasma. [Plasma k a l l ik re in  is located in the plasma per se (K lu ft ,
1978).]  A subsequent investigation has shown that incubation of ANP 
with plasma results in the conversion of the 28 amino acid ANP^.^g to  
the 24 amino acid ANPg_2g (Murthy e t a l . . 1986b). In both of these 
reports degradation is r e la t iv e ly  slow ( t 2/ 2 * 60min) and un like ly  to 
account fo r  the rapid disappearance of both radio labelled ANP and 
immunoreactive ANP from the bloodstream (Murthv et a l . , 1986ab), I t  is
therefore un like ly  that blood components play a major ro le  in the
degradation of ANP in the body.
7. 3 . 3 .  Degradation of ANP in the Kidney
Incubation of ANP with ra t  kidney cortex membranes results  in rapid 
degradation of the peptide. The i n i t i a l  cleavage s ite  has been 
id e n t if ie d  as occurring at the Cys^-Phe® bond (Koehn et a l . . 1987). 
Degradation could be inh ib ited  by the inclusion of EDTA and 1,10-  
phenanthroline in the incubation, thus suggesting that a 
metalloendoprotease may be responsible. Stephenson & Kenny (1987a) 
carried out s im ilar experiments using pig kidney m ic ro v il l i  membranes 
and also iden tif ied  th is  bond as a potentia l cleavage s i te .  They 
obtained s im ilar degradation p ro files  when ANP was incubated with  
endopeptidase-24.11, and suggested that th is  enzyme was prim arily  
responsible for the breakdown of ANP by kidney membranes. The 
importance of endopeptidase-24.11 in the degradation of ANP is 
discussed in more d e ta il  in section 7. 4. 3.
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7. 3. 4  Degradation of ANP in the Lung
The lung is important fo r  the degradation of several peptides, 
including angiotensin I and bradykinin (Bakhle, 1968; Yang et a l . . 
1971). Since the m ajority of ANP released from the heart f i r s t  passes
through the pulmonary c ircu la tio n , any degradation by the lung wi l l  be
of primary importance to the f in a l  levels of peptide c ircu la ting  in 
the systemic system. Hydrolysis of ANP has been shown to occur during 
the perfusion of the ra t  lung in v i t ro  (Numan et a l . . 1986). Using in 
situ  perfused rabbit lungs, Turrin & Gil l i s  (1986) showed that 67% of
rad io labe lled  ANP was removed from the c ircu la tio n  during a single
passage through the lung. The ra d io a c t iv ity  could be recovered from 
the preparation by perfusion with unlabelled ANP, suggesting that the 
radio label was binding to a specific  receptor. Since no analysis was 
made of the recovered ra d io a c t iv ity  i t  is not known i f  degradation of 
rad io labe lled  ANP had occurred.
7 . 3 . 5 .  Degradation of ANP in the Mesenteric Artery
Studies of the fa te  of [^^^I]-ANP in the isolated perfused mesenteric 
arte ry  have shown that less than 40% of the ligand is in tact a f te r  15
min at 37°C (Murthy et a l . ,  1986b). The degradation p ro f i le  of this
peptide, as assessed by reverse phase HPLC, is s im ilar  to that  
obtained from in vivo studies and thus suggests a s im ila r  mechanism of
breakdown. I t  is not known i f  degradation involves receptor binding or
i f  i t  is caused by the action of a protease(s).
7. 3 . 6 .  Summarv
The incubation of ANP with kidney, lung, mesenteric a r te ry  and plasma 
in v i t ro  resu lts  in degradation of the peptide. The extent to which
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these tissues are responsible fo r  degradation in vivo is not known, 
but i t  is u n like ly  that plasma is a major contributor because of i ts  
slow action. I t  is also unclear whether the enzymes responsible for  
degradation are of in tra c e l lu la r  or ex tra c e llu la r  o r ig in .
7.4 Degradation of ANP bv Purif ied  Proteases
7.4. 1 Tissue K a ll ik re in
The name tissue k a l l ik re in  refers to a group of very closely related  
serine proteases found in the pancreas and sa livary  glands, and 
excreted in the urine. These enzymes are highly active in the 
hydrolsis of the peptide bond on the carboxyl side of the sequence 
Phe-( or Leu)-Arg-X, and are capable of cleaving prorenin to renin 
(Sealev et a l . . 1978) and proinsulin to insulin  (Ole-Moi Yoi e t  a l . .
1979).
Incubation of ANP (synthetic and p a r t ia l ly  p u r if ied )  with pancreatic 
k a l l ik r e in  results  in a marked reduction in the n a tr iu re t ic  and 
d iu re t ic  responses to these peptides (Thibault et a l . , 1984c; Briggs 
et a l . , 1984). Furthermore, the simultaneous infusion of aprotin in , a 
serine protease in h ib ito r ,  with ANP results in the potentiation of the 
renal responses in the ra t .  Since the kidney is a major source of 
k a l l ik r e in  a c t iv i t y ,  i t  is possible that renal k a l l ik re in  is , at least 
in part responsible fo r  the inactivation of ANP in v ivo .
7 . 4 . 2  Other Serine Proteases
Other serine proteases, namely trypsin , chymotrypsin, and elastase  
have been shown to reduce the d iu re t ic  and n a tr iu re t ic  a c t iv i ty  of ANP
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(Briggs et a l . . 1984). I t  is un like ly  that trypsin and chymotrypsin 
are present in s u f f ic ie n t  quantities in tissues which come in contact 
with ANP to cause degradation in vivo. Elastase (tissue) is present in 
mammalian aorta and is secreted by cultures of rabbit aort ic  smooth 
muscle ce lls  (B arre tt  and McDonald, 1980). I t  therefore may be 
responsible fo r  some of the degradation observed in v ivo .
7 . 4 . 3  EndoDeptidase-24.il
Endopeptidase-24.11, a membrane bound ectoenzyme, was f i r s t  purif ied  
from rabbit kidney (Kerr and Kenny 1974), and shown to be most 
abundant in the brush border of the proximal tubules ( Booth & Kenny, 
1974). I t  has since been found in the kidneys of other species, 
including the pig (Kerr & Kenny 1974), ra t ,  mouse (Kennv et a l . .
1981), and man (Abbs & Kenny 1983). I t  has also been id en tif ie d  in a 
v a r ie ty  of other organs and tissues including pig in testine , lymph 
nodes, chondrocytes, p i tu i ta r y  and brain synaptic membranes ( Matas et  
a l . . 1983; Gee e t  a l . . 1985). An enzyme with s im ilar  characteristics  
has been found in bovine p i tu ita ry  (Almenoff e t  a l . . 1981; Orlowski & 
Wilks,  1981).
Endopeptidase-24.11 cleaves bonds on the amino side of hydrophobic 
amino acid residues (Kerr & Kenny 1974). The e ff ic ien cy  of th is  
hydrolysis is g rea t ly  influenced by the nature of the residues on the 
amino side of the cleaved bond, preferring arginine or small neutral 
amino acids fo r  the two residues adjacent to the cleavage position  
(Orlowski & Wilks 1981; Almenoff & Orlowski 1983; Matsas et a l . .
1984). This enzyme is the only mammalian representive of a class of 
Zn^^-containing metalloendopeptidases fo r  which phosphoramidon is a 
potent specif ic  in h ib ito r  (Suda et a l . . 1973; Kenny, 1977). The
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contribution of th is  enzyme to ANP degradation in preparations 
containing other peptidases can be assessed by measuring a c t iv i ty  in 
the presence and absence of th is  in h ib ito r .  Endopeptidase-24.11 has 
been shown to contribute to the hydrolysis of substance P, bradykinin, 
oxytocin and angiotensins I ,  I I  and I I I  by pig kidney m ic ro v il la r  
membranes (Stephenson and Kenny 1987b), and to the degradation of 
[Leu]enkephalin and substance P by caudate synaptic membranes (Matsas 
et a l . , 1983). Endopeptidase-24.11 is identical to the enzyme 
enkephalinase (Almenoff et a l . . 1981; Fulcher et a l . . 1982; Matsas et  
a l . . 1983).
Incubation of ANP with purified  endopeptidase 24.11 or pig kidney 
m ic ro v il la r  membranes results in the rapid hydrolysis of the peptide 
w ithin  the disulphide linked ring, and a slower hydrolysis of Ser^S- 
Phe^G bond, y ie ld in g  the C-terminal fragment Phe-Arg-Tyr (Stephenson 
and Kenny 1987a). Cleavage occurs at three points w ithin the loop 
(Cys^-Phe^, Arg^^-Ile^^ and Gly^G-Ala^^), although the i n i t i a l  point 
of attack has not been id en t if ie d .  Other studies using ra t  and rabbit  
kidney brush border membranes have identif ied  the Cys^-Phe® bond as 
the primary s i te  of ANP hydrolysis in these preparations (Koehn ^  
a l . . 1987; 01 ins e t a l . . 1987). These membranes are known to contain a 
large number of peptidases but, as phosphoramidon was not used to 
assess the contribution of endopeptidase-24.11 to th is  hydrolysis, i t  
remains to be established i f  th is  enzyme is responsible.
The widespread d is tr ib u t io n  of endopeptidase-24.11, and i ts  apparent 
s p e c if ic i ty  fo r  the Cys^-Phe® bond of ANP, strongly suggest an 
important ro le  in the metabolism of ANP. Approximately 30% of ANP 
isolated from human coronary sinus plasma was found to be in the
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'ring-open' form (Cys^-Phe® cleaved ANP; Yandle et a i . , 1987), and i t  
is possible that endopeptidase 24.11 or a s im ilar enzyme is 
responsible fo r  th is  hydrolysis. I t  is known that the in te g r ity  of the 
disulphide bond is essential for the biological a c t iv i t y  of ANP 
(C hartie r  et a l . . 1984, Misono et a l . , 1984b), from which may be 
surmised that hydrolysis at any point within the ring  would also cause 
in ac t iva tio n . This however has not been demonstrated and the 
p o s s ib i l i ty  that 'r in g  open-ANP' possesses a c t iv i ty  cannot be 
excluded. The slower hydrolysis of ANP at Ser^G-Phe^G iden tif ied  by 
Stephenson & Kenny (1987a) may also be of b iological importance, as 
removal of the t r ip e p tid e  Phe^G-Arg^^-Tyr^B from the C-terminal 
resu lts  in a 70- to 150-fold reduction in vaso-relaxant and d iu re tic  
potency (Suqivama et a l . . 1984; Garcia et a l . . 1985).
7 .5  Reasons fo r  Experiments
Receptors fo r  [125i]_ANp have been id en tif ie d  in p u r if ied  sarcolemmal 
membranes prepared from ra t  ventricular muscle, and ANP has been shown 
to stimulate guanylate cyclase a c t iv i ty  in th is  preparation.
Incubation of ANP with intact ra t  and rabbit ven tr icu lar  myocytes, in 
the presence of a phosphodiesterase in h ib ito r ,  results  in an increase 
in in tra c e l lu la r  cyc lic  6MP (Aiton & Cramb, 1985; Cramb et a l . . 1987), 
but attempts to measure specific binding of rad io labelled  ANP in these 
in ta c t  preparations were unsuccessful. As described e a r l ie r ,  rapid 
degradation of ANP has been demonstrated in many preparations, both in 
vivo and in v i t r o , and th is  could explain the fa i lu r e  to measure 
[■125j]_amp binding to these ce l ls .
In the following chapter I wi l l  present evidence to show that
ANP is rap id ly  degraded when incubated with ra t  and rabb it  ven tricu lar
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myocytes and that part of th is  degradative a c t iv i ty  is associated with 
a soluble extract isolated from ce ll  homogenates. I w i l l  also present 
results  which show that sim ilar degradative a c t iv i t y  can be isolated  
from a soluble frac tio n  prepared from ra t  kidney and lung.
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CHAPTER 8
8.1 Materials
Collagenase (Type I )  was obtained from Lome laboratories , Reading, 
Berks. Heparin (5000 units/m l) was supplied by The Boots Company, 
Nottingham, Notts. A ll other reagents were supplied as described in 
section 3.1 .
Rats (Wistar) and rabbits (New Zealand White) were obtained from the 
University of St. Andrews stocks. Animals were kept under a 24 hr 
day/night cycle and allowed free access to food.
8 .2  Methods
8 . 2 . 1 . i Iso la tion  of Rat Ventricular Mvocvtes
Rat ven tr icu lar myocytes were prepared from 8-12 week- old male Wistar 
rats  (200-250g) by a modification of the method described by Powell e t  
a l . . (1980). The rats were injected with heparin (2500 lU, ip . )  30 min 
before s a c r if ic e .  Following decapitation, the heart was rapid ly  
removed, with the minimum amount of handling, and washed with ice cold 
KRBG (Ca2+ f re e ) .  The aorta was cannulated, secured with cotton thread 
( f ig .  8 .1 ) ,  and perfused retrogradely (Langendorff technique) at 37°C 
with KRBG (Ca^* fre e )  at a rate of approximately Iml/min. The f i r s t  15 
to 25 ml of perfusate, which removed most of the blood c e l ls ,  was 
discarded and the eluate then was recirculated for a fu r th e r  1 to 2 
minutes and the to ta l  perfusate volume adjusted to 100ml. Calcium was 
then added to the perfusate to a f in a l  concentration of 20/iM, and 
perfusion continued fo r  a further 3 to 5 minutes. I f ,  during th is  
i n i t i a l  perfusion period, the flow rate declined or the heart
Figure 8 .1  
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developed white patches, ind icative  of ischaemia and necrosis, the 
preparation was discarded. F in a lly ,  collagenase was dissolved in 10 
mis of perfusate and added to the reservoir. The perfusion was 
continued fo r  a fu rther  20 to 30 minutes during which time the pH was 
maintained in the range of 7 .1 -7 .8  by regulating the ra te  of gassing 
with 95% 02/ 5% CO2 . During th is  time the flow rate  was monitored and 
in a typical preparation i t  would gradually slow and then begin to 
increase, at which point the heart was removed from the perfusion 
apparatus. The exact time tha t th is  occurred varied from preparation 
to preparation. The a t r ia  were discarded and the ven tr ic les  were 
chopped into small pieces. These were placed together with ISOmg BSA 
Fraction V (essen tia lly  f a t t y  acid fre e )  in a te flon  beaker containing 
50ml of perfusate. Digestion was continued at 37°C fo r  a fu rther  10 to 
20 minutes. During th is  period the dispersion of the myocytes was 
aided by gentle t r i tu r a t io n  with a wide bore p ipette . The appearance 
of single ce lls  was monitored by l ig h t  microscopy. Trypsin and DNAse 
were added at a f in a l  concentration of 0.1%, fo r  the f in a l  5 min of 
digestion, as th is  prevented the ce lls  aggregating during subsequent 
p u r if ic a t io n  and incubations.
The digest was f i l t e r e d  through a 118/im nylon net to remove 
undigested tissue, and the f i l t r a t e  centrifuged at 60 x g fo r  1 min at 
room temperature in a bench top centrifuge (MSE). The p e l le t  was 
resuspended in 10 to 15 ml of KRBG (20 juM Ca^*, 0.1% BSA), 5 to 8 ml 
were layered onto the top of 4% BSA in KRBG (20 jjM Ca^^) and 
centrifuged at 60 x g fo r  1 min. The resu lting  pe lle ts  were 
resupended in 5m1 of the same buffer and the previous step repeated. 
The f in a l  p e l le t  was resuspened in 5 to 10 ml of KRHG (20juM Ca^*, 1% 
BSA). An aliquot of the c e l l  suspension was d ilu ted  with isoton and
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c e ll  number estimated on a Coulter Counter (Model ZM) attached to a 
Coulter Channelizer (Model 250). (See appendix IV ) .
The percentage rods ( in ta c t  c e l ls )  to rounds (damaged c e l ls )  was 
estimated using a haemocytometer. The ce l l  number was normally 
adjusted to between 10^ and 10^ cells /m l with KRHG, 20 uM Ca^^, 1% BSA 
and the ce lls  were gassed with 100% O2 and kept at 37°C u n t i l  
required.
8 . 2 . 1 . i i  Iso lation  of Rabbit Ventricular Mvocvtes
Ventricu lar myocytes were isolated from 6- to 10-week old New Zealand 
White rabbits (1 .5 -2 .5  kg) as described in the preceding section, 
except for the following modifications. The rabbits were given 5000 lU 
of heparin intravenously, 30 min prior to death. The f in a l  perfusion 
volume was 200 ml and the f in a l  digestion of the ven tr ic les , in the 
te f lo n  beaker, was performed in 75ml of perfusate. The amounts of 
collagenase and BSA were adjusted as appropriate to keep the 
concentrations at the same levels as described fo r  the ra t .
8 . 2 . 1 . i i i  Results and Discussion
The ra t  hearts produced an average of 3.44 x 10^ ce l ls  per 
preparation, w hils t the rabb it  hearts, which were approximately four 
times larger by weight, averaged approximately twice as many ce lls  
(7.55 X 10^). Examination of these ce l l  suspensions by l ig h t  
microscopy revealed that they were composed of 'rod* and 'round' 
shaped c e l ls .  The rods were in tact myocytes and the rounds were 
damaged c e l ls ,  formed because th e ir  ce ll  membranes were ' leaky ' to 
Ca2+, causing them to contract (Powell et a l . . 1978). The average
y ie ld  of rods ( in ta c t  c e l ls )  was 70 % and 30% fo r  ra t  and rab b it
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respective ly . The average c e l l  volume d iffered  between the two 
species, being 20774 jum^  and 17464 ^m^ for ra t  and rabbit  
respective ly . These results are summarised in table 8 .1 .  I t  is not 
c lear i f  the d ifference in size between the ra t  and rabbit myocytes 
represents a true difference or merely re f lec ts  the d if fe re n t  
proportion of rods and rounds in the preparations. The rounds must by 
necessity have a smaller volume than the rods, since a change in shape 
from a cylinder to a sphere, in the absence of a change in surface 
area, results in a smaller volume. In addition, as Coulter counter 
estimates of c e l l  volume are based on the assumption that the ce lls  
are spheroid, th is  w i l l  lead to an under-estimation of ce ll  volume 
when rods are present (Nash e t  a l . . 1979). A correlation of c e l l  
volume with % rods sugggests a l inear relationship between these two 
variables (Fig . 8 .2 ) .  Additional values are needed, especially  fo r  
preparations of ra t  myocytes containing a low proportion of rods, and 
rabb it  myocytes containing a high proportion of rods, before a 
d e f in ite  conclusion concerning the difference in size between the two 
species can be drawn.
8 .2 .2  Preparation of Homoqenate and Soluble Fraction from Ventricu lar  
Mvocvtes
Myocytes were prepared as described in the previous section and 
d ilu ted  in KRHG, 20 /im Ca^*, 1% BSA to the concentration required in 
the assay. The ce l ls  were homogenised with a Polytron PTIO homogeniser 
at setting 4 fo r  30 seconds. This homogenate was e ith e r  used d ire c t ly  
or the soluble frac tion  was prepared from i t  by centrifugation  at 
100,000 X g fo r  60 min in a Beckman SW 65 ro tor.  The f in a l  supernatant 
was stored in 1ml aliquots at -20°C u n ti l  use.
Table 8.1
Summary of Rabbit and Rat Ventricu lar Hvocvte Preparations
Yield Volume
Cells X 10® % Rods
Rabbit 7.54+1.44 (11) 17464+563 (12) 30.7+4.7 (8 )
Rat 3.44+0.80 (8) 20774+1119 (7) 70.2+ .5 (11)
Figure 8.2
Comparison of the Volume of Rat and Rabbit Mvocvtes with the Number of 
Rods Present in the Preparation
Values from individual preparations of ra t  ( □  ) ,  and rabbit ( a  ) 
ven tr icu lar  myocytes. The corre lation  coe ff ic ien t fo r  the regression  
equation was 0.697.
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8 .2 .3  Preparation of Soluble Fraction from Rat Luna and Kidney.
The lungs and kidneys were rapid ly  removed from fresh ly  k i l le d  8-12 
week old male Wistar rats (approx. 250g). The kidneys were dissected 
into two fractions , the cortex and medulla. The tissues were •
homogenised in 5-10 vol. 10 mM tr is -H C l,  pH 7.4, at 4°C with a
Polytron PTIO Homogeniser at setting 4 for 3 x 20 sec bursts. The 
homogenate was centrifuged at 2000 x g for 15min in a Fisons Coolspin 
and the resulting supernatant was centrifuged at 100,000 x g fo r  60min 
using a Beckman SW 65 ro tor. The f in a l  supernatant was stored in 1ml 
aliquots at -20°C u n t i l  use.
8 .2 .4  Measurement of [^^^I]ANP Degradation
8 . 2 . 4 . i Principle of Assay
Proteins and large peptides form insoluble precip ita tes when mixed 
with certain acids such as tr ich loroacetic  acid (TCA) and perchlororic  
acid (PCA). This property has been widely used to deproteinize  
bio logical f lu id s  and ce l l  extracts prior to analysis for low 
molecular weight, acid stable molecules such as glucose and amino 
acids. I t  has also been used to determine the extent of degradation of 
insu lin  and glucagon following incubation with proteases (Bohley e t  
a l . ,  1971). [^^^I]-ANP can be completely precipitated by 5% TCA and 
th is  has been used to estimate peptide degradation
8 . 2 . 4 . i i  Protocol
[125ij-Af(|p degradation was measured as the percentage of radiolabel 
not precip ita ted by 5% TCA. In a typ ical experiment with ven tr icu lar  
myocytes, 50 jul of c e l l  suspension (1 to 5 x 10^ c e l ls /m l) ,  or soluble
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f ra c t io n  isolated from these c e l ls ,  were incubated fo r  15 min at 37°C 
with 25 >il [125i]_ANP (100 or 200 pM), 25 ; il  buffer (50 mM Tris-HCl, 
pH 7 .4 ) ,  and peptide or protease in h ib ito r  when indicated.
Incubations were terminated by the addition of 100/ i l  of ice cold 10% 
bovine serum albumin followed by rapid sampling of 50 >il aliquots into  
250 jul 6% TCA. A fter standing on ice fo r  15 min, p rec ip itab le  
ra d io a c t iv ity  was separated from the non-precipitable by centrifuging  
fo r  2 min in a Beckman microfuge. The t ip  of the microfuge tube 
containing the p e l le t  was removed and the ra d io a c t iv ity  in both the 
p e l le t  and supernatant were determined in a Packard Gamma Counter.
The percentage [^^^I]-ANP degraded was defined as:
cpm in supernatant
Total cpm
100   Background
The background was defined as the percentage ra d io a c t iv ity  not 
prec ip ita ted  by 5% TCA when [^^^I-]-ANP was incubated in the absence 
of c e l ls  or ce l l  ex trac t .  This ranged from 7 to 13% of the to ta l  
ra d io a c t iv i ty  and did not vary with incubation time or temperature. 
These values of non-precipitable rad io a c t iv ity  are consistent with the 
HPLC analysis of [^^^I]-ANP which indicated that approximately 10% of 
the ra d io a c t iv ity  was not associated with the peptide (section 5 .1 ) .
The protocol fo r the measurement of the degradation of [^^^I]-ANP by 
the soluble fractions from isolated kidney and lung was as described 
above, except that the incubation tubes contained 10 to 100 }xg of 
protein from the appropiate frac tion .
8 .2 .5  Degradation of ANP by ra t  ventricu lar mvocvtes
ANP was incubated with the soluble frac tion  prepared from ra t
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ven tr icu la r  myocytes at 37°C as described fo r  degradation of 
ANP above. At various times lOOjul aliquots were removed and mixed with
33.3 jul of 0.4% TFA and 60% ACN. An assessment of ANP degradation was 
made by reverse phase HPLC using the system described in section 
3 .5 .2 .  B r ie f ly ,  100 jul of incubation mixture were injected onto a C^g 
Spherisorb column (0DS2, Capital HPLC Specialists) and ANP and i ts  
degradation products were eluted with a linear gradient of 15% to 60% 
a c e to n it r i le  (ACN) in 0.1% t r i f lu o ro a c e t ic  acid (TFA), at a flow rate  
of Iml/min and a slope of 0.9%/min. The elution was monitored at 220nm 
with a Gilson Holochrome UV monitor attached to a Rikadenki chart 
recorder. The concentration of ANP was linear with respect to peak 
area over the range 0.4 to 1.6 nmols ( f ig .  8 .3 ) .
Figure 8 .3
A Standard Curve fo r the determination of ANP Concentration by HPLC 
Known amounts of ANP, in the range 0.4 to 1.6 nmol, were analyzed by 
HPLC. ( □ ) ,  ( X ) and ( *  ) indicate determinations carried out on 
d i f fe re n t  days.
Peak Area x 10*32000-]
1600-
1000 -
600-
1.6 20 0.6
ANP (nmol)
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CHAPTER 9 
9 Results of Degradation Studies
9.1 Preliminary Experiments with Rabbit Ventricu lar Mvocvtes
Incubation of rabbit ventricu lar myocytes with [^^^I]-ANP resulted in 
the rapid degradation of the peptide, as measured by loss of acid 
prec ip itab le  ra d io a c t iv ity .  Degradation was temperature sensitive,  
with s ig n if ic a n t  breakdown occurring even at 4°C ( f ig .  9 .1 ) .  The 
i n i t i a l  ra te  of degradation was variable between preparations, with 
the mean ra te  being 3.38 + 1.37 fmol/min per 10® ce lls  (tab le  9 .1 ) .
One possible source of th is  varia tion  was the length of time the 
myocytes were preincubated prior to the measurement of degradative 
a c t iv i t y .  To assess the e f fe c t  of preincubation time on the rate  of 
degradation, ce lls  were preincubated fo r  0 .5 ,  10 and 30 min at 37°C, 
followed by the measurement of degradative a c t iv i t y  in the whole 
preparation and in the 6,500g supernatant ( f i g  9 .2 ) .  Approximately 50% 
of the degradative a c t iv i ty  was located in the supernatant immediately 
fo llowing the resuspension of c e l ls .  This rose to nearly 70% of the 
to ta l  a c t iv i t y  a f te r  30 min. During th is  time the to ta l  degradative 
a c t iv i t y  also slowly increased, suggesting that the fa c to r (s )  
responsible fo r  the degradation were leaching from the ce lls  into the 
incubation medium. To assess the potential la ten t a c t iv i t y  in the 
c e l ls ,  myocytes were homogenised and degradation ra te  compared with 
that of the in tac t  preparation ( f ig .  9 .3 ) .  Homogenisation resulted in 
a 1.65- fo ld  increase in degradation rate  in th is  preparation. 
Preincubation of the homogenate for 15 minutes at 60°C resulted in 
almost to ta l  loss of degradative a c t iv i ty  ( f i g .  9 .4 ) .
Figure 9.1
Degradation of [^^^Ij-ANP by Rabbit Ventricular Myocytes 
A representative experiment showing the degradation of [^^^I]-ANP by 
rabb it  ven tr icu lar  myocytes, at 4®C (A— A) and 20°C ( □ — □ ).  Each point 
is the mean SEM of t r ip l ic a te  determinations.
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Table 9.1
[125 i j _ANP Degradation by Rabbit Ventricular Myocytes
Prep. Temp
[125i]_ANP Degraded 
fmol/min per 10® Cells
No. °C Cells/ml Cells Homogenates
1 4 5x10® 0.567 -
1 20 SxloS 6.033 -
2 20 5x10^ 1,377 2.376
3 20 5x10® 2.650 -
4 20 1.25xl05 - 21.04
5 20 l.SxlO® - 3.566
Figure 9.2
E ffec t  of Preincubation Time on [^^^I]-ANP Degradation by Rabbit 
Ventricu lar Myocytes
Rabbit ven tr icu lar myocytes were preincubated at 37°C fo r  the times 
indicated. [^^^I]-ANP degradation associated with the c e l l  suspension was 
subsequently measured over 30 min in the to ta l c e l l  suspension (A— A ),  
or the 6,000 x g supernatant (□ — □ ) at 20°C. Each value represents the 
mean + SEM fo r  3 determinations.
( ^^®1]-ANP Degraded 
(fm o l/m ln  per 10* cells)
2.51
0.5-
3520 255 16 300 10
Prelncubotlon Time (m in)
Figure 9.3
The E ffect of Homogenization on the Degradation of [^^^I]-ANP by Rabbit 
Ventricu lar Myocytes
The degradation of [^^^I]-ANP by intact ce lls  (a — a ) ,  or homogenates 
{□— □) of rabbit ven tr icu lar  myocytes at 20^C. Each value represents the 
mean + SEM of t r ip l ic a t e  determinations.
( *2*1)-ANP Degraded 
Ômol /  10* cells)
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Figure 9.4
The E ffect of Heat Treatment on [^^^I]-ANP Degradation by Rabbit 
Ventricu lar Myocytes
Rabbit ven tricu lar myocytes were preincubated fo r  15 min at 20°C (A— A) 
or 60°C (□ — □) p r io r  to the measurement of [^^^I]-ANP degradation at 
20°C. Each point represents the mean ±  SEM fo r  t r i p l ic a t e  determinations
( ^2®1)-ANP Degraded  
(fmol /  10* cells)
600 1
600 -
400 -
3 0 0 -
200 -
100 -
60 70604030200
Time (m in)
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9.2 Experiments with ra t  ventricu lar mvocvtes
Sim ilar degradation was observed during the incubation of [^^^I]-ANP 
with ra t  ventricular myocytes ( f ig .  9 .5 ) .  The i n i t i a l  degradation 
ra te ,  at 20°C, was 6.70 + 1.12 fmol/min per 10^ c e l ls .  This increased 
to 40.13 + 10.49 fmol/min per 10^ ce lls  on homogenization ( f ig .  9 .6 ) .  
Experiments performed with intact rabbit ventricu lar myocytes 
suggested that at least some of th is  a c t iv i ty  was soluble ( f ig .  9 .3 ) .  
To investigate i f  th is  was the case with ra t  ven tr icu lar myocytes, a 
soluble (cytosolic ) frac tion  was prepared from an homogenate of these 
c e l ls .  The average degradative a c t iv i ty  of the to ta l  homogenate, at 
37°C, was 68.08 + 4.99 fmol/min per 10^ c e l ls .  Of th is  approximately 
60% of the degradative a c t iv i ty  could be recovered from the 
supernatant ( f ig .  9 .6 ) .
9.3 Degradation of [^^^-I]-ANP by the Soluble Fraction from Rat 
Ventricu lar Myocytes
The results  of the Investigations described above suggested that a 
substantial proportion of degradative a c t iv i ty  was located in the 
soluble fraction  isolated from ra t  ven tr icu lar myocytes. To further  
investigate the nature of th is  breakdown, several protease and 
peptidase inhib itors were tested fo r  th e ir  e ffects on degradation 
( f ig .  9 .7 ) .  Incubation of soluble frac tio n  with the general serine 
protease inhib itors phenylmethylsulphonyl f luo ride  (PMSF) and 
apro tin in , had no e f fe c t  on a c t iv i ty .  Amastatin, an in h ib ito r  of a 
number of aminopeptidases also fa i le d  to in h ib it  degradation. SQ 
20881, a peptidyl dipeptidase A in h ib ito r ,  produced a small reduction 
in degradative a c t iv i ty  w hils t bradykinin potentiating factor C 
(BPFC), an in h ib ito r  of the same enzyme, and phosphoramidon, a
Figure 9.5
The Effect of Homogenization on the Degradation of [^^^I]-ANP by Rat 
Ventricu lar Myocytes
The degradation of [^^^I]-ANP by in tact ce l ls  ( a — a ) ,  or homogenates 
(□ — □) of ra t  ventricu lar myocytes, measured a t 20°C. Each value 
represents the mean ±  SEM of t r ip l ic a te  determinations.
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Figure 9.6
The Degradation of [^^^I]>ANP by Rat Ventricular Myocytes
The degradation of [^^^I]-ANP was measured in the preparations indicated.
Each values is the mean + SEM for the number of experiments indicated.
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Figure 9.7
The E ffec t  of Various Protease Inh ib itors  and Peptides on [^^^I]-ANP 
Degradation by a Soluble Fraction from Rat Ventricular Myocytes
Degradation was measured over a 15 min incubation period at 37®C in the
presence of various protease inh ib ito rs . The soluble frac tio n  was 
preincubated with EDTA and PCMB at 37°C fo r  45 min, p rio r to the 
measurement of degradation ( ^ ) .  The results are the mean ±  SEM.
S ig n if ican t differences from 100% are indicated by * = p< 0.05, * *  = p<
0.01 and * * *  = p< 0.001 as determined using a tw o-ta iled  Student's t - t e s t  
(unpaired so lution).
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specific  in h ib ito r  of endopeptidase 24.11, were without e f fe c t .  The 
general metallo-proteinase inh ib itors , 1 ,10-phenanthroline and EDTA, 
produced an almost to ta l inh ib it io n  of degradation, as did the 
cysteine protease in h ib ito r ,  PCMB. EDTA and PCMB were only e f fe c t iv e  
a f te r  a 45 min preincubation at 37°C. Epoxysuccinyl-leucyl-agmatine 
(E -64), an irrev e rs ib le  in h ib ito r  of some cysteine proteinases also 
fa i le d  to reduce degradation. The most e ffe c tive  protease in h ib ito r  
tested was the bacteria l a n t ib io t ic  bacitracin , which t o t a l l y  
inhib ited degradation.
ANP, glucagon, and bradykinin were found to in h ib it  [^^^I]-ANP 
degradation and the e f fe c t  of these peptides was examined in more 
d e ta i l .  ANP inhib ited  the degradation of [^^^I]-ANP in a dose- 
dependent manner ( f ig .  9 .8 ) ,  with half-maximal inh ib it io n  occurring at 
3.31 + 0.68 X 10” M^ (see tab le  9 .2 ) .  Similar dose response curves were 
obtained fo r  the inh ib ito ry  actions of glucagon and bradykinin ( f ig .
9 .8 ) ,  although these peptides were less potent than ANP, with h a lf -  
maximal inh ib it io n  occurring at 6.95 + 1,88 x 10”^M and 3.12 + 0.36 x |
10“ M^ respective ly .
The e f fe c t  of pH on degradative a c t iv i ty  of the soluble fra c tio n  
isolated from ra t  ven tr icu lar  myocytes was also examined. The 
degradative a c t iv i t y  was optimum at a lka line  pH's, with a 30-fo ld  
stimulation of a c t iv i ty  occurring as the pH was increased from 6.5 to
8 .5  ( f ig .  9 .9 a ) .  In order to assess whether changes in pH in the 
physiological range could increase degradative a c t iv i t y ,  i ] - aNP
was incubated with the soluble fraction at pH 6.1 fo r  15 min. The pH 
was then increased to 7.5 and incubation continued fo r  a fu r th e r  15 
min. This small a lte ra t io n  in pH resulted in almost a doubling of the
Figure 9.8
Dose Response Curves fo r the Inh ib it ion  of [^^^I]-ANP Degradation by ANP, 
Glucagon, and Bradykinin
Degradation of [^^^I]-ANP by a soluble frac tion  isolated from ra t  
ven tr icu lar  myocytes was measured over a 15 min incubation period at 37°C 
in the presence of increasing concentrations of ANP (□— □ ),  glucagon 
(A— A), or bradykinin ( 0 — <>). The results are the mean + SEM from at 
least 3 separate experiments.
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Figure 9.9
The E ffect of pH on [^^^I]-ANP Degradation by a Soluble Fraction Isolated  
from Rat Ventr icu lar Myocytes
(a )  [125i]_ANP was incubated fo r  15 min at 37^C with soluble frac tion  at 
the pH indicated. Each value is the mean + SEM fo r  2 separate experiments 
in which degadation ra te  was determined in t r i p l i c a t e ,  (b) Time course of 
[125i]_ANP degradation at pH 6.1 and 7.5; degradative a c t iv i t y  was 
monitored e ith er  a t  pH 6.1 fo r a l l  time points (a — A ),  or i n i t i a l l y  at 
pH 6.1 and then, a f te r  adjustment at pH 7.5 (□ — □ ) ,  as indicated by the 
arrow.
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Table 9.2
Concentrations of ANP. Glucaoon. and Bradvkinin Required to Produce 
50% In h ib it io n  of Binding
The mean concentrations of ANP required to produce h a lf  maximal 
inhib iton of [^^^I]-ANP degradation by the soluble f ra c t io n  from lung, 
kidney cortex, kidney medulla, and ventricular myocytes, were compared 
using a tw o-ta iled  f - te s t  (unpaired). * (p<0.05), and * *  (p<0.01) 
indicates values which were s ign fican tly  d iffe ren t  from those obtained 
from the kidney cortex preparation. Similar comparisons were made for  
glucagon. # (p< 0 .05 ) ,  and ## (p<0.01) indicates values which were 
s ig n i f ic a n t ly  d if fe re n t  from those obtained from the lung eparation.
ANP Glucagon Bradykinin
Lung 0.557+0.072*(3 ) 1.99+0.64 (4) 13.6+3.1 (3)
Kidney Cortex 1.04+0.13 (3 ) 6.74+1.73* (3) 20.3+5.4 (3)
Kidney Medulla 0 .463+0 .075*(3 ) 9.89+1.52**(4 ) 26.6+9.5 (3)
Vent.Myocytes 0.331+0.068**(3 ) 6.95+1.88 (3) 31.2+3.6 (3)
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degradation ra te , from 16,1 fmol/min per 10^ ce lls  to 29.7 fmol/min 
per 10^ ce lls  ( f ig .  9 .9b).
9.4 HPLC Analysis of ANP Degradation bv Soluble Fraction from Rat 
Ventricu lar Mvocvtes
Reverse phase HPLC was used to examine the degradation of unlabelled  
ANP by the soluble fraction  isolated from ra t  ven tr icu lar  myocytes. 
Degradation of ANP was both rapid and complex, with several products 
being formed ( f ig .  9 .10 ) .  A fte r  only 2 min incubation at 37°C, 
approximately 50% of the ANP was degraded, and by 20 min ANP was 
undetectable ( f ig .  9 .11 ) .  There was a corresponding appearance of two 
products, which eluted at 19.42% ACN (peak 1) and 22.77% ACN (peak 2 ) .  
Peak 1 increased stead ily  with increasing incubation time w h ils t  peak 
2, a f te r  an i n i t i a l  decline, reached a steady state at a level 
s l ig h t ly  higher than i ts  i n i t i a l  value. A fter 5 min incubation a th ird  
product eluted with 34.97% ACN (peak 3 ).  This increased slowly to 
reach a steady state a f te r  40min ( f ig .  9 .12a).
During the course of the incubation two other major products appeared, 
e lu ting  at 43.52% ACN (peak 4) and 44.99% ACN (peak 5) respective ly .  
These products showed a steady increase over the f i r s t  15 to 20min, 
followed by a slow decline to almost undetectable levels ( f i g .  12b).
9.5 Degradation of [^^^-I]-ANP by Soluble frac tion  Prepared from Rat 
Lung and Kidney
To investigate the tissue s p e c if ic i ty  of the p ro teo ly tic  fa c to r (s )  
responsible fo r degrading [^^^I]-ANP, s im ilar experiments were 
performed with the soluble f ra c tio n  isolated from ra t  kidney cortex, 
kidney medulla and lung.
Figure 9.10
P r o f i le  of ANP Degradation Products
The absorbance p r o f i le  of the products eluted by HPLC from a C;g reverse- 
phase column, fo llowing incubation of ANP with the soluble f ra c t io n  from 
r a t  ventricu lar myocytes at 37^C fo r  (a) 0 min, (b) 5 min, and (c )  40 
min. Absorbance was measured at 220 nm.
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Figure 9.11
The Degradation of ANP following Incubation with Soluble Fraction from 
Rat Ventricular Mvocvtes
ANP was incubated with soluble f ra c tio n  at 37°C fo r  the times indicated  
ANP levels were monitored by absorbance at 220 nm.
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Figure 9.12
Time Course fo r  the Degradation Products of ANP
(a) Peaks 1 (□— □), 2 (x x), and 3 (a — a ) ,  (b) Peaks 4 (0— 0),
and 5 {♦— * )  as indicated in f ig .  9 .10 . A Peak Area of 100,000 is 
equivalent to 0.01 AU.min.
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Although [^^^-I]-ANP was degraded by a l l  preparations, the ra te  of 
degradation was s ig n if ic a n t ly  lower in the soluble fraction  from the 
lung than from the kidney (tab le  9 .3 ) .  There was no difference in the 
degadation rates of the two kidney preparations (tab le  9 .3 ) .  The 
e ffe c ts  of various protease inh ib itors  on [^^^I]-ANP degradation rate  
were examined. The incubation of [^^^I]-ANP with soluble frac tion  
prepared from ra t  kidney cortex, kidney medulla and lung, in the 
presence of phosphoramidon, E-64, amastatin, and aprotin in , had l i t t l e  
or no e f fe c t  on the ra te  of degradation by any of the preparations 
( f ig s .  9 .13, 9.14 and 9 .1 5 ) .  Similar incubations in the presence of 
1,10-phenanthroline and bacitracin  reduced degradation by 70 to 80% in 
a l l  preparations. PCMB only produced a s ign ifican t inh ib it ion  of 
degradative a c t iv i ty  in the kidney medulla soluble fra c tio n . Likewise, 
EDTA only inhib ited a c t iv i t y  in the kidney cortex soluble f ra c tio n .  
There was, however, a tendency fo r these compounds to decrease 
degradative a c t iv i ty  in a l l  preparations by a small amount.
ANP, glucagon, and bradykinin were a l l  e f fec tive  at reducing 
degradation (tab le  9 .3 ) ,  and the dose response curves to these 
compounds were examined in more d e ta il  ( f ig s .  9.16, 9.17, and 9 .18 ) .  
ANP Inh ib ited  degradation in a dose-dependent manner, with h a lf -  
maximal in h ib it io n  occurring at s im ila r  concentrations in the kidney 
medulla and lung preparations, although ANP was s l ig h t ly  less potent 
at in h ib it in g  degradation in the kidney cortex (tab le  9 .2 ) .  Glucagon 
was equipotent at in h ib it in g  degradation by both kidney preparations, 
and was s ig n if ic a n t ly  more potent at inh ib it ing  degradation by the 
lung than the kidney. Bradykinin was also most e ffe c t iv e  at in h ib it in g  
degradation by the lung. The order of potency fo r inh ib it io n  of 
degradation by these three peptides was ANP > glucagon > bradykinin in
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a l l  preparations.
Table 9.3
Summary of the Degradation of [^^^I]-ANP by a Soluble Fraction 
Prepared from Rat Heart, Lung, and Kidney
Mean basal degradative a c t iv i t ie s  of the soluble fractions isolated  
from lung, kidney cortex, and kidney medulla were compared using two 
t a i l e d  t - te s t  (unpaired). The basal a c t iv i t ie s  of both kidney 
f ra c t io n s  were s ig n if ic a n t ly  higher than that obtained from lung. * * *  
p< 0.001
(^” l]-A N P  D egraded
fmol /  mln per mg protein fm ol/m ln  10 cells
Lung Kidney
Cortex
Kidney
Medulla
Myocytes
Basal 4.50
±0.68
(17) 11.10 (19 )***  
±1.16
14.48 (17 )***
±2.16
41.94 (26) 
±288
ANP
(lcr*M )
0.41 
±0.1 1
(4) 2.06 (4)
±0.43
1.23 (4) 
±0.34
6.13 (3) 
±2.07
Glucagon
OxICT^M)
1.25
±0.37
(6) & 3 0 (5 )
±0.23
4.68 (6) 
±078
6.20 (4) 
±1.19
Bradykinin L50
±0.55
(4) 4.83 (4) 
±0.61
3J7 (4)
±1.04
21.00 (4) 
±2.64
Figure 9.13
The E ffec t of Various Protease Inh ib itors  on [^^^I]-ANP Degradation by 
a Soluble Fraction from Rat Lung
Degradation was measured over a 15 min incubation period, at 37®C. The 
soluble frac tion  was preincubated with EDTA and PCMB at 37®C, for 45 
min, p r io r  to the measurement of degradation ( ^  )• The results are 
the mean + SEM for the number of experiments indicated (see appendix 
V). S ign ifican t differences from 100% are indicated by * *  = p< 0.01 as 
determined using a tw o -ta iled  Student's t - te s t  (unpaired so lu tion ).
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Figure 9.14
The E ffec t of Various Protease Inh ib itors  on [^^^I]-ANP Degradation by 
a Soluble Fraction from Rat Kidney Cortex
Degradation was measured over a 15 min incubation period, at 37°C. The 
soluble frac tion  was preincubated with EDTA and PCMB at 37°C, for 45 
min, p r io r  to the measurement of degradation ( ^  )• The results are
the mean ±  SEM fo r  the number of experiments indicated (see appendix 
V ). S ign ifican t differences from 100% are indicated by * = p< 0.05, * *  
= p< 0.01 and p< 0.001 as determined using a tw o-ta iled  Student's t -  
te s t  (unpaired so lu tion ).
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Figure 9.15
The E ffec t of Various Protease Inh ib itors  on [^^^I]-ANP Degradation by 
a Soluble Fraction from Rat Kidney Medulla
Degradation was measured over a 15 min incubation period at 37°C. The 
soluble fraction  was preincubated with EDTA and PCMB at 37°C fo r 45 
min, p r io r  to the measurement of degradation The results are
the mean + SEM for the number of experiments indicated (see appendix 
V). S ignificant differences from 100% are indicated by * = p< 0 .0 5 ,* *  
= p< 0.01 and p< 0.001 as determined using a tw o-ta iled  Student's t -  
te s t  (unpaired so lution).
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Figure 9.16
Dose Response Curves for the In h ib it io n  of [^^^I]-ANP Degradation by ANP, 
Glucagon, and Bradykinin
Degradation of [^^^I]-ANP by a soluble fra c t io n  isolated from ra t  lung 
was measured over a 15 min incubation period a t  37^C in the presence of 
increasing concentrations of ANP (□— □ ),  glucagon (A— a ) ,  bradykinin 
( 0 — <>)• The resu lts  are the mean +. SEM fo r  a t  least 3 separate 
experiments.
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Figure 9.17
Dose Response Curves for the Inh ib it ion  of [^^^I]-ANP Degradation by ANP, 
Glucagon, and Bradykinin
Degradation of [^^^I]-ANP by a soluble frac tio n  isolated from ra t  kidney 
cortex was measured over a 15 min incubation period at 37®C in the 
presence of increasing concentrations of ANP (□— □), glucagon (A— A), 
and bradykinin ( 0 — <». The results are the mean ±  SEM for at least 3 
separate experiments.
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Figure 9.18
Dose Response Curves for the In h ib it io n  of [^^^I]-ANP Degradation by ANP, 
Glucagon, and Bradykinin
Degradation of [^^^I]-ANP by a soluble frac tion  isolated from ra t  kidney 
medulla was measured over a 15 min incubation period at 37^C in the 
presence of increasing concentrations of ANP (□— •□), glucagon (A— A ),  
or bradykinin ( 0 — 0 ) .  The results are the mean + SEM for at least 3 
separate experiments.
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CHAPTER 10
10 Discussion of Degradation Experiments
10.1 Introduction
Following interaction with a membrane receptor, many peptide hormones 
are degraded by one of two mechanisms. The major pathway is 
in te rn a liza t io n  through receptor- mediated endocytosis, followed by 
degradation in the lysosome (King & Cautrecasas, 1981; Anderson & 
Kaplan, 1983). Examples of th is  process are the degradation of insulin  
by adipocytes (Marshall, 1985ab), and the degradation of epidermal 
growth factor by human f ibrob las ts  (Wilev et al . 1985). A lte rn a t ive ly ,  
some peptides have been shown to be degraded by membrane-bound 
proteinases, and th is  is the case with the hydroylisis of 
bradykinin,and angiotensins I ,  I I ,  and I I I  by pig kidney membranes 
(Stephenson & Kenny, 1987b). Elucidation of the processes by which ANP 
is degraded is of primary importance to an understanding of the 
regulation of the levels of th is  peptide in the body, and u lt im ate ly  
to an understanding of i ts  physiological actions.
There have been several reports on the degradation of ANP during 
incubation of th is  peptide with kidney membranes (Napier et a l . . 1984; 
Koehn et a l . . 1987; Stephenson & Kenny, 1987a). Pro teo ly tic  a c t iv i ty  
in these preparations is most l ik e ly  due to the action of the 
metalloproteinase, endopeptidase-24.11 (Stephenson & Kenny, 1987a). In 
addition , the conversion of ANPg_2;  to ANPg_25 by enzymes isolated  
from bovine a t r ia  (H arr is  & Wilson 1985) and human a t r ia  (Sakharov et  
a l . . 1988) have also been described. These enzymes appear to be 
isozymes of pulmonary peptidyl dipeptidase A (EC 3 .4 .1 5 .1 ) .
97
10.2 Experiments with In ta c t  and Homoaenates of Rat and Rabbit 
Ventricu lar Mvocvtes
These experiments were performed to assess the extent of the 
degradation which occurs when [^^^I]-ANP is incubated with isolated  
ven tr icu lar myocytes, and to determine the c e l lu la r  loca liza tion  of 
th is  degradative a c t iv i t y .  The results c lea r ly  show that incubation of 
[125 i ]„ANP with ra t  and rabb it  ven tr icu lar myocytes resu lts  in the 
rapid degradation of the radio labelled peptide. Degradative a c t iv i ty  
was increased when the c e l ls  were homogenised, suggesting that at 
least part of the a c t iv i t y  was of in tra c e llu la r  o r ig in .  Degradative 
a c t iv i t y  was also temperature sensitive, increasing in rate  with 
increasing incubation temperature up to 37°C. However, a c t iv i ty  was 
almost t o ta l ly  abolished by a 15 min pre-incubation a t 60°C. These 
results  strongly suggest that the fac to r(s )  responsible fo r the 
degradation of rad io labelled  ANP is proteinaceous in nature.
A fte r  incubating the myocytes fo r  a short period, a s ig n if ican t amount 
of degradative a c t iv i t y  was located in the incubation medium, th is  
suggesting that the fa c to r (s )  responsible fo r  degradation was leaching 
from the ce lls  into the medium. Since homogenisation increased 
degradative a c t iv i ty ,  i t  is l ik e ly  that the number of damaged ce lls  in 
the preparation, in combination with the length of time the ce lls  are 
incubated prior to the assay of [^^^I]-ANP degradation, w i l l  e f fe c t  
the to ta l  measurable a c t iv i t y .  These variables may account fo r some of 
the varia t ion  observed in the proteo ly tic  a c t iv i ty  of in tact myocyte 
suspensions. Further experiments on the c e l lu la r  d is tr ib u t io n  of the 
degradative a c t iv i ty  in homogenates of ra t  ven tr icu lar myocytes, 
localised more than 60% of th is  a c t iv i ty  to the 100,000 x g
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supernatant (cytosolic f ra c t io n ) .
I t  is therefore concluded that degradative a c t iv i ty ,  observed when ^
;[125i]_^f^p ^5 incubated with ventricu lar myocytes, is due to the 
action of unspecified protease(s) in the preparation. I t  is further  
concluded that at least part of th is  a c t iv i ty  is of in t ra c e l lu la r  
o rig in ,  and soluble in nature. 5
10.3 Experiments with a Soluble Fraction Isolated from Rat Ventricular  
Mvocvtes
At least 50% of the p ro teo ly tic  a c t iv i ty  found in homogenates of ra t  I
ven tr icu lar  myocytes was located in the soluble or cytosolic f rac tio n ,  
and is therefore un like ly  to be a resu lt  of the membrane-bound 
proteases described in section 10.1. In order to elucidate the nature 
of th is  soluble a c t iv i ty ,  fu rthe r  experiments were carried out. An 
i n i t i a l  c la s s if ic a t io n  of protease a c t iv i ty  can be made on the basis 
of the re la t iv e  action of a number of protease inh ib itors  on the 
preparation (Knight, 1986). This approach was used to assess the 
protease a c t iv i ty  present in the soluble fraction  isolated from rat  
ven tr icu la r  myocytes. Since 1% BSA was present throughout the 
incubations, and casein was without e f fe c t  on the degradative 
a c t iv i t y ,  i t  is un like ly  tha t degradation in th is  preparation occurs 
by the action of non-specific proteases.
Incubation of [^^^I]-ANP with the soluble fraction  isolated from ra t  
ven tr icu la r  myocytes in the presence of EDTA or 1,10 phenanthroline 
resulted in at least an 80% reduction of degradative a c t iv i t y .  Both -I
EDTA and 1,10 phenanthroline are general metalloproteinase inh ib ito rs ,  
which act by chelation of the metal ion at the active s i te  enzyme. The
J
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general serine proteinase inh ib ito rs , phenylmethylsulphonyl f luo ride  
(PMSF) and aprotin in , were without e f fe c t .  This p ro f i le  of in h ib it io n ,  
that is , a suppression of a c t iv i ty  by EDTA and 1,10 phenatholine, in 
the absence of an e f fe c t  with serine proteinase inh ib ito rs , is a good 
indication of the presence of a metalloproteinase (Powers & Harper 
1986). The general cysteine proteinase in h ib ito r ,  p-chloromercuric 
benzoate (PCMB), also inh ib ited  degradation, indicating a requirement 
of free  sulphydryl groups fo r  proteolytic  a c t iv i ty  (Camargo et a l . . 
1973; Rich, 1986). Both ETDA and PCMB required preincubation with the 
ven tr icu lar c e l l  suspension in order to in h ib it  a c t iv i ty .  This suggest 
these compounds act as 'slow-binding in h ib ito rs ' ,  possibly interacting  
with the protease with normal Michael is Menten k inetics , but followed 
by a slow re-arrangement of the enzyme-inhibitor complex (Knight,
1986)
The lack of inh ib it io n  by epoxyl succinyl-leucyl-agmatine (E -64), a 
specific  in h ib ito r  of a number of cysteine proteinases, precludes the 
presence of papain and cathepsin B, H, and L a c t iv i ty  in th is  
preparation (B arre tt  et a l . . 1982). Other specific  protease inhib itors  
were tested fo r  th e ir  e f fe c t  on degradative a c t iv i ty .  Amastatin, an 
in h ib ito r  of a number of metallo-exopeptidases, including leucine 
amino peptidase, tyrosine aminopeptidase, and t r ip e p t id y l -  and 
tetrapeptidyl-aminopeptidases (Powers & Harper, 1986), was also 
without e f fe c t .  The contribution of these enzymes to degradation can 
therefore be discounted. Phosphoramidon, a specific  in h ib ito r  of 
endopeptidase 24.11 (Suda, e t  a l . . 1973; Kenny, 1977) also fa i le d  to 
reduce pro teo ly tic  a c t iv i t y .
ANP, glucagon and bradykinin were a l l  e f fe c tive  inh ib itors  of
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degradative a c t iv i t y .  Comparison of the amino acid composition of ANP 
and bradykinin reveals the presence of the dipeptide sequences 
phenylalanine-arginine at the carbox^ftermini of both peptides ( f ig .  
10 .1 ) .  These amino acids are known to be cleaved by peptidyl 
dipeptidase A in bradykinin, and are a potential s ite  of hydrolysis in 
ANP or related peptides (Harris & Wilson, 1985). Removal of these 
residues from bradykinin is potently inhibited by bradykinin 
potentiating fac to r  C (BPFC) and SQ 20881 (Erdos 1976). BPFC had no 
e f fe c t  on degradation ra te ,  although a small reduction in a c t iv i t y  was 
observed in the presence of SQ 20881. I t  is possible that peptidyl 
dipeptidase A, or a s im ilar  enzyme, may be responsible fo r  some of the 
degradation observed, but is un like ly  to account fo r  a l l  of the 
a c t iv i ty .  A s im ilar comparison of the amino acid sequences fo r  
glucagon and ANP reveals no obvious sequence homology between the two 
peptides ( f ig .  10 .1 ) .  Bacitracin , a potent inh ib ito r  of glucagon 
degradation in the l iv e r ,  also suppresses proteolytic  a c t iv i t y  in the 
present experiments. This may indicate a common mechanism of 
inactiva tion .
Degradation of rad io labelled  ANP by ventricular soluble fra c t io n  is 
optimum at pH 9.0 , and small changes in pH from 6.1 to 7.5 produce a 
marked e f fe c t  on degradative a c t iv i ty .  These results ra ise the 
p o s s ib i l i ty  that changes in pH in the physiological range may regulate  
pro teo ly tic  a c t iv i ty .
A group of enzymes with s im ila r  inh ib ition p ro files  have been 
described and termed metal-dependent cysteine proteinases. These 
enymes include cytosol insulin-glucagon proteinase, calcium-dependent 
cysteine proteinase I and I I ,  collagenase-like peptidase, and lens
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neutral proteinase and brain neutral endopeptidases (B arre tt  and 
McDonald, 1980). Calcium-dependent proteinase I u t i l is e s  casein and 
albumin as a substrate, and calcium-dependent proteinase I I  is la b i le  
above pH 8 .0 . I t  is therefore u n lik e ly  that these enzymes are 
responsible fo r the degradative a c t iv i t y  observed in th is  preparation. 
Lens neutral proteinase is also u n lik e ly  to account fo r  degradation as 
th is  enzyme is only poorly inhib ited by 1,10 phenanthroline. Cytosol 
insulin-glucagon proteinase, in addition to having a s im ilar  
in h ib it io n  p ro f i le  to the a c t iv i ty  in ventricu lar soluble frac tion ,  
also possesses a s im ilar  a f f in i t y  fo r  glucagon . The K,^  fo r  
degradation of glucagon by th is  enzyme is 3 x 10"^M (Duckworth, 1976; 
B arre tt  and McDonald, 1980). This value which is very close to that  
observed fo r  glucagon inh ib it ion  of [^^^I]-ANP degradation by 
ven tr icu la r  soluble fraction
Two brain neutral endopeptidases have also been described which have 
s im ila r  characteris tics  to the preparation described here. These 
enzymes, endopeptidase A and B, have been p urif ied  from a soluble 
f ra c t io n  of rabbit brain and appear to play a ro le  in the central 
nervous system in the hydrolysis of small peptides such as bradykinin, 
angiotensin I and I I  and LH-RH (Camargo et a l . ,  1979). The pH optimum 
fo r  endopeptidase B hydrolysis of bradykinin is 8 .5  (O liv e ira  et a l . . 
1976), close to that observed fo r degradation of [^^^I]-ANP by 
ven tr icu la r  soluble fra c tio n . This enzyme has however only been shown 
to hydrolyse Pro-Phe bonds and these are not present in ANP.
Before discussing the results of the HPLC investigation , i t  is worth 
considering several points concerning the nature of reversed-phase 
HPLC (RP-HPLC) separation, and the in terpre ta tion  of data obtained by
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th is  method. RP-HPLC columns are packed with m icro-particulate  s i l ic a ,  
which has been chemically modified to give a surface coating of 
hydrophobic hydrocarbon chains. The p r inc ip le  of separation is based 
on the re la t iv e  a f f in i t i e s  of the substances under investigation fo r  
the hydrophobic solid phase and the polar, usually aqueous mobile 
phase. The a lte ra tio n  of the p o la r ity  and hydrophobicity of the mobile 
phase makes th is  an extremely useful technique for the analysis of 
substances of mixed hydrophobic-hydrophillic character, as is the case 
with peptides. Substances are eluted from RP columns in order of 
increasing hydrophobicity. Because larger peptides usually possess 
more hydrophobic groups, peptides w i l l  be eluted with increasing size.  
Some small peptides, however, possess a disproportionate number of 
hydrophobic residues, and therefore may be retained on the column fo r  
much longer than would be predicted by th e ir  s ize. To id en tify  the 
composition of a peak, i t  is therefore necessary e ith e r  to carry out 
amino acid analysis of that peak or to show that i t  elutes in the same 
position as a sample of known composition. An example of the 
s e n s it iv i ty  of th is  technique is given by fac t  that ANP and 'r in g -  
open' ANP can be separated by RP HPLC (Koehn et a l . . 1987). These 
peptides have identical amino acid compositions but d i f f e r  in th e ir  
secondary stucture, in that the amino acid chain of the 'ring-open' 
form has been cleaved at the Cys^-Phe® bond.
The id e n t if ic a t io n  of several peaks resu lt ing  from the incubation of 
ANP with ventr icu lar soluble frac tion  indicated that the degradation 
was complex. Since amino acid analysis was not carried out, and the 
only peptide of known composition was ANP i t s e l f ,  i t  is not possible 
to id e n t i fy  the points at which hydrolysis occurs. I t  is however 
possible to draw some conclusions from th is  investigation. The i n i t i a l
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rate  of disappearance of ANP from the incubation medium was 280 
pmol/min per 10^ c e l ls .  The rate  of degradation measured by acid 
prec ip ita t io n  of [^^^I]-ANP was 380 pmol/min per 10^ ce lls  under 
s im ilar  conditions. These values are in good agreement and indicate  
that acid prec ip ita tion  is a reasonable measure of ANP degradation.
The i n i t i a l  products of degradation were ra p id i ly  eluted from the 
column, and are character is t ic  of the e lution  p ro f i le  fo r  small 
peptides or, possibly, single amino acids. This suggests that i n i t i a l  
cleavage occurs at one or both of the term in i. HPLC analysis of 
I]-ANP degradation by the isolated ra t  mesenteric artery ( in v i t r o ) 
and during c ircu la tion  ( in v ivo) resulted in the rapid appearance of a 
breakdown product in a s im ila r  position to that seen in th is  
preparation (Murthv et a l . 1986b). These authors concluded that th is  
peak was the carboxyl-terminal of ANP.
As discussed above, 'ring-open' ANP formed by the cleavage of the 
Cys^- Phe& bond results in a peptide which elutes just prior to in tact  
ANP. Hydrolysis of th is  bond has been shown to be the i n i t i a l  cleavage 
point in kidney cortex membranes (Koehn et a l . . 1987), possibly via 
the action of endopeptidase 24.11. (Stephenson & Kenny, 1987a). I t  is 
possible tha t the product e lu ting  in peak 3 may be 'ring-open' ANP. 
Given the number of products formed during the incubation, and the 
fa c t  that two of these appear simultaneously during the f i r s t  two 
minutes, i t  is l ik e ly  that more than one protease is responsible fo r  
the p ro teo ly tic  a c t iv i ty  observed in th is  preparation. Further 
experiments in the presence and absence of a combination of protease 
in h ib ito rs ,  followed by amino acid analysis of the products, are 
needed to draw firm  conclusions as to the nature of degradation in 
th is  preparation.
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10.4 Degradation of ANP bv Soluble Fractions Prepared from Rat Kidney 
Cortex. Kidney Medulla and Lung
Studies of the d is tribu tion  of p ro teo lytic  a c t iv i ty  in the kidney 
indicate that the majority of th is  a c t iv i ty  is associated with the 
proximal convoluted tubule (Colder et a l . , 1970; Maack et a l . . 1971), 
the brush border membranes being p a r t ic u la r ly  rich in peptidases 
(Kenny & Maroux, 1982). In the lung, there are high levels of peptidyl 
dipeptidase a c t iv i t y ,  which is responsible fo r  the conversion of 
angiotensin I to angiotensin I I .  The majority of information ava ilab le  
concerning p ro teo ly tic  a c t iv i ty  in these two tissues is on the action  
of membrane bound enzymes.
Experiments were performed to assess the degradation of [1^5 i ] - anP by 
the soluble fractions isolated from ra t  kidney cortex, kidney medulla, 
and lung, and to compare th is  with that observed in the soluble 
f ra c t io n  prepared from ventricu lar myocytes. A ll preparations 
possessed p ro teo ly t ic  a c t iv i ty ,  although the a c t iv i ty  isolated from 
the lung was approximately 3 -fo ld  less than from the kidney. Unlike 
the d is tr ib u t io n  of membrane-bound enzymes, the degradative a c t iv i ty  
was approximately the same in soluble fractions isolated from kidney 
cortex and kidney medulla.
ANP, glucagon and bradykinin inhib ited the ra te  of degradation in a l l  
preparations. They showed s im ilar potencies to those observed fo r  
in h ib it io n  of degradative a c t iv i ty  in ventricu lar soluble f ra c tio n ,  
with the exception of ANP which was s ig n if ic a n t ly  weaker at in h ib it in g  
pro teo ly t ic  a c t iv i t y  in the kidney cortex soluble fra c t io n .
Comparison of the effects  of several proteinase inh ib itors  on the
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degradative a c t iv i ty  in the various preparations indicate that there  
are tissue differences. None of the inh ib itors  examined was as 
e f fe c t iv e  at reducing proteolytic  a c t iv i ty  in these preparations as 
they were at reducing a c t iv i ty  in the soluble frac tion  from ra t  
ven tr icu la r  myocytes. In addition, some of the inh ib itors  showed 
s e le c t iv i ty  between the preparations, suggesting the enzymes 
responsible fo r  degradative a c t iv i ty  were d i f fe re n t .  In p a rt ic u la r ,  a 
small (10%), but s ign ifican t inh ib it io n  of the a c t iv i ty  of kidney 
cortex soluble frac tion  was observed in the presence of PMSF. These 
resu lts  suggest the presence of serine proteinase a c t iv i ty  in th is  
preparation.
As is the case fo r  ventricular soluble fra c tio n , further studies, 
using a combination of inhib itors and the analysis of the degradation 
products, are required before any conclusions can be drawn about the 
nature of proteolysis in these preparations.
10.5 Summary
These results show that a soluble protease or proteases, which degrade 
[125%]_ANP, is present in the high speed supernatant fraction  isolated  
from the heart, kidney and lung of the ra t .  In h ib it io n  of p ro teo lytic  
a c t iv i t y  by ANP, glucagon and bradykinin is s im ila r  in a l l  cases, 
whereas d i f fe re n t  inh ib it ion  p ro f iles  are obtained when various 
protease inh ib ito rs  are included in the incubation. The degradation of 
rad io labelled  ANP by the soluble frac tion  prepared from heart appears 
to be p rim arily  caused by the action of a metal-dependent cysteine 
proteinase, although the p o s s ib i l i ty  of other proteases being present 
can not be excluded. The proteolytic  degradation observed in the 
preparations isolated from lung and kidney are almost cera in ly due to
106
the actions of more than one enzyme.
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CHAPTER 11 
11 The Role of ANP in Cardiac Muscle
Experiments described in th is  thesis demonstrate the presence of 
[^^^I]-ANP receptors in purified  ra t  cardiac sarcolemmal membranes, 
and ANP stimulation of guanylate cyclase a c t iv i ty  in the same 
prepartion. These results  extend e a r l ie r  studies from th is  laboratory  
which demonstrated ANP-stimulation of in tra c e llu la r  cGMP levels in 
isolated ra t  and rab b it  ventricular myocytes (Aiton & Cramb, 1985; 
Cramb et a l . . 1987). The concentration of ANP required to produce 
half-maximal stimulation of guanylate cyclase a c t iv i t y  in the p urif ied  
membrane preparation, is approximately 10-fold less than that required  
fo r  half-maximal elevation of in tra c e llu la r  cGMP in the in tact  
preparation. This discrepancy is most l ik e ly  a re s u lt  of the rapid  
degradation of ANP which occurrs when the peptide is incubated with 
ven tr icu lar myocytes. Despite th is  degradation, ANP is able to produce 
a 5 -fo ld  increase in in tra c e lla r  cGMP in these ce l ls  and produce 
levels of the cyc lic  nucleotide which are approximately 50% higher 
than those observed in the presence of carbachol, and nearly 40% of 
the response to sodium nitroprusside (Cramb et a l . , 1987).
The ro le  of cGMP as a second messenger fo r  ANP has been questioned 
because of the discepancy between the levels of the peptide 
c ircu la ting  in the blood stream and the concentrations of ANP required  
to increase cGMP (see section 2 .3 ) .  However, the concentration of ANP 
in the heart, as assessed by sampling blood from the coronary sinus 
(Yandle et a l . . 1987), is more than su ff ic ien t  to increase ven tr icu lar  
cGMP. This strongly suggest that the heart ventric les are a target  
tissue fo r  ANP.
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Increases in in tra c e l lu la r  cGMP have been correlated with a reduction 
in the force of contraction of ventricular muscle (George et a l . ,
1970; George et a l . . 1973; Endoh , 1979; Lincoln & Keely, 1980), and 
dibutyl cGMP has been shown to antagonize the positive inotropic  
e f fe c t  of isoprenaline (Watanabe & Besch, 1975). I t  appears that cGMP 
antagonizes agonist-induced positive inotropic e f fe c ts ,  with l i t t l e  or 
no e f fe c t  on resting tension (Endoh, 1979; Watanabe & Besch, 1975). 
These results are s im ila r  to those observed fo r  ANP-induced relaxation  
of preconstricted smooth muscle (see section 1 .6 .1 ) .  I t  is therefore  
possible that ANP stimulation of in tra c e llu la r  cGMP may also resu lt  in 
a negative inotropic e f fe c t  on ventricu lar muscle. This being the case 
then at least part of the decrease in cardiac output observed in vivo 
(see section 1 .6 .1 )  may be a result of a decrease in stroke volume 
brought about by the d ire c t  action of ANP.
An a lte rn a t ive  ro le  fo r  ANP receptors sited on ven tr icu la r  muscle is 
that they are part of a feedback mechanism. The existence of ANP and 
ANP transcrip ts  in ven tr icu lar  muscle raises the p o s s ib i l i ty  that ANP 
released from the a t r ia  may modulate the expression of the ANP gene in 
the ven tr ic les .
In conclusion, the resu lts  presented in th is  thesis provide 
biochemical evidence fo r  the d irect action of ANP on ven tr icu lar  
muscle. In addition, they provide evidence of proteases in heart, 
lung, and kidney which rap id ly  degrade ANP. Further studies are 
required to determine the physiological ro le  of ANP in the heart, and 
the contribution of p ro teo ly tic  degradation to the nature and time- 
course of i ts  a c t iv i ty .
'■•f.
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APPENDICES
Appendix I
1 2 5
I .1 Composition of Culture Media 
Ingredients
MEME
m g/litre
JOKLIKS
m g /l i t re
L-Arginine HCl
L-Cystine disodium s a lt
L-Glutamine
L-H istid ine  HCl H2O
L-Isoleucine
L-Leucine
L-Lysine HCl
L-Methionine
L-Phenylalanine
L-Threonine
L-Tryptophan
L-Tyrosine disodium s a lt  
L-Valine
D-Ca pantothenate
Choline chloride
Folic  acid
i - In o s i to l
Nicotinamide
Pyridoxyl HCl
Riboflavin
Thiamin HCl
CaClp
KCl
MgSOa./HpO
NaCl
NaHCOo
NaHpPO^ . ZHpO 
D-GTucose
Phenol red sodium sa lt  
Sodium succinate 6H20 
Succinic acid 
Choline b i ta r t ra te  
D i hydrostreptomyc i n 
Sulphate
Sodium p e n ic i l l in  G
126.4
28.4
41.90
52.50
52.50 
73.06
14.90
33.02 
47.64 
10.20
45.02 
46.9
1.00
1.00
2.00
1.00
1.00
0.10
1.00
264.90
400.00
200.00 
6800.00
158.30
1000.00
17.00 
110.0
75.00 
1.80
105.00
29.60
294.00
41.90
52.00
52.00
72.50
15.00
32.00
48.00
10.00
46.98
46.00 
1.00 
1.00 
1.00 
2.00 
1.00 
1.00 
0.10 
1.00
400.00
242.40
6500.00
2000.00
1500.00
2000.00
10.00
50,00
75000.00 lU
126
(mM) (mM) (mM) (mM)
137.0 118.5 118.5 150.0
5.40 2.58 2.58 “
2.80 - 1.00 -
1.20 1.19 1.19 -
0.30 - - 1.87
- - - 12.63
0.30 1.19 1.19 -
14.00 - -
- 14.50 - -
- - 25.0 -
12.0 11.1 11.1 -
- 2.00 - -
1.2 Composition of Buffers
1 .KREBS 2.KRB6 3.KRHG 4 . PBS
Salt
NaCl 
KCl 
CaC 12 
MgSOa.
NaHprOa.
NapHPOa 
KH2PO4.
Tris  base 
NaHCOo 
HEPES 
Glucose 
Manitol
1.3 Preparation of Buffers
1.3.1 Materials
A ll  chemicals were of ana ly tica l grade supplied by BDH, Poole, Dorset. 
All solutions were made up in water which had been double d is t i l le d  
followed by p u r if ica t io n  using a M i l l i  Q Water system ( M iH i  Q HpO; 
M il l ip o re ,  Harrow, Middlesex).
1 .3 .2  KREBS
The salts were dissolved in M i l l i  Q HpO and the pH adjusted to 7.4 
with 1 M HCl, before making up to volume.
1 .3 .3  KRBG (Krebs Ringer Bicarbonate Buffer)
The salts  were dissolved in M i l l i  Q HpO and f i l t e r e d  though a 0 .4 5 jam 
Nylon 66 f i l t e r s  (Anachem, Luton, Beds.) before making up to volume. 
The buffer was gassed with 95% 02/ 6% COp fo r  20 min p rio r to  use.
1 2 7
1 .3 .4  KRHG (Krebs Rinoer Heoes Buffer)
The salts were dissolved in M i l l i  Q HpO, the pH adjusted to 7 .4  using 
1 M NaOH and the solution was f i l t e r e d  though a 0.45yum Nylon 66 
f i l t e r s  before making up to volume. The buffer was gassed with 100% 
Op/ fo r 20 min p rio r to use.
1 .3 .5 .  PBS (Phosphate Buffered Saline)
The salts were dissolved in M i l l i  Q HpO at the concentration indicated  
to give PBS at pH7.4
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Appendix I I
1 1 .1 Guanvlate Cyclase Assay and cGMP Assay
1 1 .1.1 Reagents fo r  Guanvlate Cvclase Assay
200 mM Theophylline. Stable at room temperature. Heat to redissolve  
before use.
20 mM Isobutylmethylzanthine (IBMX). Stable at room temperature. Heat 
to re-dissolve before use.
1 M Triethanolamine (TEA), pH 7 .4 , Stable at room temperature.
100 mM Phosphocreatine (CP). Store in 19 mg aliquots at -20^0. 
Dissolve in 0.5 ml d is t i l le d  H2O immediately prior to use).
2 mg/ml Creatine phosphokinase (CK). Store in 1 mg aliquots at -20^C. 
Dissolve in 0.5 ml 1% BSA ju s t  p rio r to use.
50 mM Guanosine 5 ' -triphosphate (GTP) See below.
60 mM MnCl2 . Stable at room temperature.
The following solutions are prepared just p rior to use.reagents are 
mixed
Reaction Mix
Reagent______________________ Volume
Theophylline 1
IBMX 2
TEA 1
HoO 2
CP* 1
CK 1
Make sure the solution is cool before addition
''ï
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GTP/MnCU
lOO^ ul GTP
650ul HoO
250>il MnCl2 (Add th is  las t)
1 1 ,1 .2 . i Preparation of GTP Stock Solution
Commercially obtained GTP contains s ign ifican t amounts of cGMP which 
re s u lt  in high blank values being obtained from the guanylate cyclase 
assay. I t  is therefore necessary to purify  GTP p rio r to use.
I I . 1 . 2 . Ü  P u rif ica tio n  of GTP
A 0 .7  x25 cm column was prepared containing Dowex AG 50-W-X8 and 
washed with 2 x 20 ml of 0.1 M HCl. Approximately 500 mg GTP was 
dissolved in 2m1 0.1 M HCl and the solution applied to the column. GTP 
was eluted with O.IM HCl and 12 x 1 ml fractions were collected.  
Aliquots from the fractions were d iluted (1:20,000) and the optical  
density measured at O.D. at 255 nm. The concentration of GTP in the 
frac tions  was calculated from the extinction co e ff ic ien t  as follows :
A = E X [M] X 1 
where A = Absorbance at 255 nm
E = Extinction co e ff ic ien t  = 12,400 at 255 nm 
[M] = Molar concentration 
1 = l ig h t  path length (cm)
The fractions containing GTP were combined and the pH was adjusted to
7.4  with IM TEA and NaOH such that the f in a l  concentrations of GTP 
and TEA were 50 mM.
Store in lOQjul aliquots at -20°C.
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I I . 2 Measurement of cGMP
11. 2 . 1 . Preparation of [^^^I]-Tyros1ne Methyl Ester Succinyl-c GMP 
([125l]-ScGMP)
11.2 .1 .  i.Reagents
Succinyl-cyclic  GMP tyrosine methyl ester (ScGMP-TME) was dissolved in 
0 .5  M potassium phosphate, pH 7.4 , at a f in a l  concentraton of 0.1 
mg/ml. I t  was stored at -20^0 in 20 jal aliquots.
[125_i]_Na (Amersham In te rn ationa l,  radioactive concentration = 100 
mCi [12-5-I] /m l, specific  a c t iv i ty  15 mCi [^^^-I]/jug iodine
QAE- Sephadex (A-25; Sigma) was resuspended 0.1 M ammonium formate, pH 
6.0y 2 to 3 days pr io r  to use and stored at 4°C.
0 .5  M potassium phosphate, pH 7.4 . Make fresh.
0.05  M potassium phosphate, pH 7 .4 . Make fresh.
1 mg/ml chloramine-T in 0.05M potassium phosphate, pH7.4. Made up jus t  
before use.
1 mg/ml potassium metabisulphite in 0.05 M potassium phosphate, pH 
7 .4 .  Made up jus t  before use.
0 .05 M ammonium formate, pH 6.0 . Made freshly.
0 .25 M ammonium formate, pH 6 .0 . Made freshly ,
2 .5  mM sodium iodide, in M i l l i -Q  water. Prepared immediately prior to
use.
1 3 1
11.2 .2 .  Preparation of OAE-25 Column
A 1 X  10 ml p las t ic  p ipette  was plugged with glass wool and f i l l e d  
with preswollen QAE-25 Sephadex in O.IM ammonium formate. The column 
was allowed to equ il ib ra te  at 4°C and then washed with at least 125mls 
of 0.05M ammonium formate, pH 6.0 . I t  was stored at at 4°C un ti l  
required.
Reagents for cGMP Assay
Buffer: 50 mM sodium acetate, pH 4.75 in 0.5% BSA
Antibody: Undiluted stock stored in 100 >il aliquots at -70®C. The 
antibody was diluted 1:1000 with acetate buffer. This could be stored 
fo r  up to 6 months at -20°C. The antibody was f in a l l y  d iluted 1:25 in 
the same buffer fo r  use in the assay.
Radiolabel: [^^^I]-cGMP (approx. 15000 cpm/100>il)
cGMP (2 X  10"^M) was prepared in H2O and stored at -20°C.
1 3 2
Appendix I I I  
I I I  Analysis of Dose Response Curves
I I I . l  Ind irec t H i l l  Plots;
[DR],log - - - - - - - - -  = nlog [ I j  + nlog ECcn
[DR] - [DR];
Where [DR] = amount of binding in the absence of
competitor I 
[DR]j = amount of binding in the presence of 
competitor I 
[ I ]  = concentration of competitor 
n = H i l l  coe ff ic ien t
I I 1 . 1.2 Scatchard p lo t :
B -1 Bmax
F Kp .B Kg
Where B = Bound = concentration of ligand bound to the 
receptor at equilibrium  
Bmax = Maximum number of binding sites  
F = Free = concentration of free  ligand
present in the incubation a t equilibrium  
Kq = Equilibrium dissociation constant
1 3 3
I I I . 1.3 Cheng Prusoff equation;
K ''50Dl =
Kq*
Where Kpj = equilibrium dissociation constant for  
competitor I 
[D*] = concentration of free  radioligand  
Kq*  = equilibrium dissociation constant for  
radioligand.
111.2.1 E n z f i t te r  :
Where possible dose response curves were analysed by E n z f i t te r ,  a data 
analysis package from Elsevier Biosoft (Cambridge, U .K .) .  This 
programme uses non-linear regression analysis to provide the b e s t - f i t  
fo r  a given set of data to a specified equation (R.J. Leatherbarrow, 
1987). In the present studies E n z f it te r  was u t i l iz e d  to f i t  data to 
the following equations:
111.2.2 Ligand binding 1 s i te
Bmax X F 
Kg + F
Where B = Bound = concentration of ligand bound to the 
receptor at equilibrium  
Bmax = Maximum number of binding sites  
Kq = Equilibrium dissociation constant
..
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F = Free = concentration of free  ligand
present in the incubation at equilibrium
I I I . 2 .3 Liaand binding 2 sites
BmaX} X F Bmax2 x F
Kq i + F Ko2 + F
Where B = Bound = concentration of ligand bound to the 
receptor at equilibrium  
Bmaxi = Maximum number of s i te  1 binding s ites  
Bmax2 = Maximum number of s i te  2 binding s ites  
Kqi = Equilibrium dissociation constant fo r  s i te  1 
Kq2 = Equilibrium dissociation constant fo r  s i te  2 
F = Free = concentration of free  ligand present 
in the incubation at equilibrium
I I I . 2 .4  A l lo s te r ic  k inetics ( H i l l  equation)
Vmax X [S]"
Rate ~ ———————————
(Km + [S]")
Where Vmax = Maximum rate
Km = Michael is constant 
[S] = Substrate concentration 
n = H i l l  co e ff ic ie n t
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Appendix IV
Measurement of Cell Volume using a Coulter Counter
The coulter counter estimates the number and volume of ce lls  by 
measuring the change in e le c t r ic a l  resistance caused by the 
displacement of e le c tro ly te  as the ce ll passes through the electrode  
aperture. The resu lt ing  drop in voltage is d ire c t ly  proportional to 
the volume of the c e l l .  For the measurement of ventricu lar myocyte 
number and c e l l  volume the following settings were employed :
Aperture = 4
Attenuator = 256
Window width = 0/70
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Appendix V
Tables containing data from which figures were constructed
Figure 3.1
Measurement of cGMP bv Radio-immunoassay
cGMP
(fmol/tube)
Mean+SEM
cpm
Co/Cs
78
156
313
625
1250
2500
5000
10000
NSB
7370+227
5515+50
4695+11
3848+24
2855+77
2065+10
1495+27
1064+24
772+10
355+20
1.000
1.402
1.698
2.110
2.948
4.310
6.465
10.395
17.674
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Figure 3.3
Measurement of Protein Using the Bio-Rad Protein Assay K it
BSA
(pg/tube)
Absorbance
(595nm)
0 0.000 0.011
1.25 0.079 0.078
2.5 0.140 0.152
5 0.275 0.276
10 0.503 0.518
20 0.920 0.918
Figure 4.1
The E ffect of Protein Concentration on Guanvlate Cvclase A c t iy i tv  in 
Rat Cardiac Sarcolemmal Membranes
Protein
Cug/tube)
cGMP Produced 
(fmol/min per tube)
Basal 10“ M^ ANP
0.525 6.46+0.29 10.3+0.2
1.05 11.9+0.3 15.7+0.6
2.1 21.5+0.7 28.9+1.9
4 .2 26.4+1.0 37.4+0.2
13 8
Figure 4.2
Time Course for Guanvlate Cvclase A c t iv i ty  in Rat Cardiac Sarcolemmal 
Membranes
Time
(min)
cGMP (pmol/mg protein)
Basal 10"^M ANP
1 268 463
2.3 473 804
5 849 1465
10 1414 2012
15 1661 4529
20.3 2593 5149
25 5453 8093
30 6649 8769
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Figure 4.3
The E ffect of Manganese and Magnesium on Guanvlate Cvclase A c t iv i ty
[Cat] cGMP Produced (pmol/min per mg protein)
(mM) Mn%+ MgZ+
Basal 10‘ ®M ANP Basal 10"®M ANP
0 0,44+3.51 1.02+1.45 4.09+1.09 5.14+0.23
0 .5 25.4+1.16 51.5+3.65 4.29+1.09 5.81+1.36
1 83.1+6.53 144+9.93 6.31+0.86 8.81+1.94
2 87.8+6.24 148+9,02 7.08+0.94 10.04+1.81
4 88.0+9.0 147+5.62 8.13+1.14 11.34+0.95
8 57.4+1.56 6 48.3+2,19 7.86+0.96 8.29+1.32
32 27.5+4.38 35.4+0.58 7.19+0.67 7.05+1.00
64 19.9+3.08 24.5+1.56 8.44+0.50 8.01+0.69
Figure 4.4
Dose Response Curve fo r  GTP Stimulation of Guanvlate Cvclase A c t iv i ty
[GTP]
cGMP Produced 
(pmol/min per mg protein)
(M) Basal lO'^M ANP
3x10-6 0.31+0.22 0.53+0.12
10-5 0.28+0.20 0.33+0.17
3x10-5 1.33+0.37 1.69+0.04
10-4 7.76+0.40 11.3+0.38
3x10-4 43.4+1.19 61.0+1.60
10-3 68.2+1.80 97.7+2.45
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Figure 4.5
Dose Response Curves fo r  ANP, ANPg_28 , and ANP^ .g^g Stimulation of 
Guanylate Cyclase Activ i t y
[Peptide] % of Basal A c t iv i ty
(M) ANP ANP5-28 ANPs_25
10-14 96.4+2.6 99.2+0.6 103
10-13 100+3.5 95.8+5.4 98
10-12 99.5+2.2 99.8+2.05 105
10-11 110+6.0 99.8+0.7 102
10-10 127+9.4 108+6.9 101
10-9 147+8.4 128+10 93
10-8 165+13 134+13 105
10-7 180+13 139+10 110
10-6 198+13 145+9 137
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Figure 4.6
Effect of Phosphoramidon on Guanvlate Cvclase A c t iv i ty
[ANP] % of Basal A c t iv i ty
(M) Control Phosphoramidon
10-14 92.0+4.4 97.1+1.7
10-13 104+2.3 103+5.3
10-12 95.0+3.2 95.4+1.75
10-11 104+8.7 111+4.3
10-10 132+6.0 129+4.4
10-9 160+13 161+8.8
10-8 188+12 167+4.9
10-7 206+13 207+14
10-6 209+5.4 223+9.8
Figure 4.7
The E ffec t of Various Peptides and Protease Inh ib ito rs  on Guanvlate 
Cvclase A c t iv i tv
14 2
In h ib ito r (M)
[ANP] (M) 
0 10"^M lO’ M^
None - 124+8 172+9 196+8
Amastatin 10-6 136+6 176+4 186+4
Peptstatin 10-6 136+5 173+2 178+6
Lepeptin 10-6 131+9 169+2 179+5
PMSF 5x10-4 126+4 140+6 158+5
Aprot inin 10-6 133+8 163+7 168+6
E-64 10-6 140+3 164+20 176+2
BPFC 5x10-6 133+4 165±4 184+7
SQ 20881 10-3 143+5 153+10 187+7
Ramipri1 lOug/ml 145+4 166+.6 190+12
Glucagon 10-G 126+3 157+7 178+7
Bradykinin 5x10-5 131+3 158+7 185+3
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Figure 4.8 & Figure 4.11
Effect of Adenosine Phosphates on Mn^*- and Mg^*- Dependent Guanylate
Cyc1 a se Activity
Guanylate Cyclase A c tiv ity
[Mn2+] (3mM) [MgZ+] (2mM)
Addition Basal ANP Basal ANP
None 114+20 187+42 3.2+1.3 11.8+3.4
ATP 104+21 155+39 15.8+4.0 52.9+14.1
ADP 132+48 185+65 5.2+5.0 23.9+13.7
AMP 131+48 172+58 -0 .6+2 .6 3.7+3.1
AMP-PNP 89+30 164+62 6.3+3.7 29.9+9.1
Figure 4.9
Dose Response Curve fo r  the Effect of ATP on Mn^-Deoendent Guanvlate 
Cvclase A c t iv i tv
Mn2+-0ependent Guanylate Cyclase Activity
[ATP] (pmol/min per mg protein) % of Control
(M) Basal lO-^M ANP Basal ICr^M ANP
0 111+4.2 158+14 100 100
10‘ 6 125+0.5 157+15 112+5 99+3
3x10-6 113+5 157+15 102+4 99+2
10-4 126+3 167+19 113+4 105+3
3x10-4 116+8 157+19 104+9 99+3
10-3 84+5 118+14 76+7 74+3
3x10-3 36+4 62+15 33+7 38+7
10-2 9.2+0.4 13+3 8+0 8+1
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Figure 4.10
The Effect of ATP on the Rate of cGMP Production
T ime 
(min)
Guanylate Cyclase A c tiv ity  
(pmol cGMP /mg protein)
Control ImM ATP
Basal 10"5m ANP Basal 10“5m ANP
2 164 359 156 363
4 359 674 265 643
6 565 986 402 861
10 881 1520 624 1298
15 1357 2210 982 1719
20 1774 2608 1466 2401
30 2175 3613 1902 3574
45 2553 4202 3126 5481
60 2865 4545 4693 7722
14 5
Figure 4.12
Dose Response Curve fo r  the Effect of ATP on Mg^^-Dependent Guanylate 
Cyclase A c tiv ity
Mg2+_0ependent Guanylate Cyclase A ctivity
[ATP] (pmol/min per mg protein) % of Control
(M) Basal 10-5m ANP Basal 10“5m ANP
0 4.5+0.5 17.8+4.8 100 100
10‘ 6 5.2+0.1 17.3+6.2 127+27 102+6
3x10-6 8.6+1.0 9.6+6.6 199+21 116+10
10-4 10.7+2.4 28.0+7.3 233+30 178+14
3x10-4 5.4+2.3 52.5+20 362+83 297+39
10-3 24.4+4.7 73.4+32 572+67 396+74
3x10-3 13.0+1.3 47.3+20 303+40 264+37
10-2 7.3+1.3 5 .0_+0.8 160+10 44.5+22
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Figure 4.13
Dose Response Curve for ANP in the presence of ATP and Mg^ ~^
[ANP]
(M)
cGMP
pmol/min
Produced 
per mg protein
0 2.2 + 0 .6
10-14 3.5 0,4
10-13 2.8 + 0.1
10-12 3.5 ± 0.1
10-11 1.9 0.2
10-10 4.3 + 0.2
10-9 9.4 0.3
10-8 23.5 ± 0.6
10-7 24.4 + 0.4
10-6 27.7 0.6
10-6 26.6 + 0,5
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Figure 4.14
Dose Response Curve fo r  ANP Stimulation of Guanvlate Cvclase a c t iv i t y  
in BAC Membranes
[ANP] cGMP Produced
(M) (pmol/min/mg protein)
0 287 + 34
10-12 367 ± 59
10-11 335 28
10-10 374 i 15
10-9 570 + 38
10-8 800 ± 24
10-7 824 + 17
10-6 825 jf 25
Figure 5.1
Time Course fo r  the Binding of [^^^Ij-ANP to Rat Cardiac Sarcolemmal 
Membranes
Time [125i]_ANP Bound (fmol/mg protein)
(min) Total NSB Specific
0 62.6 67 -
5 252 120 132
10 439 126 314
20 641 122 519
30 745 127 618
40 845 171 674
60 842 192 650
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Figure 5.2 & Figure 5.3
In h ib it io n  of [1^^I]-ANP binding in Rat Cardiac Sarcolemmal Membranes 
by ANP
ANP
(M)
[128 i ] - anP Bound 
fmol/mg protein
% Inh ib it io n  
Mean + SEM
0 187 117 212 725 298 835
10-14 - 113 220 753 - - -0 .9 3  ±  3.87
10-13 - 103 213 - - - 2.21 1  11.8
10-12 169 94 205 732 290 676 16.0 ±  6.17
10-11 174 94 187 666 305 6812 15.7 1  6.04
10-10 144 86 190 524 226 681 32.8 ±  4.05
10-9 145 83 169 363 172 608 45.1 + 5.29
10-8 109 82 156 252 154 421 64.3 ±  3.76
10-7 67 76 106 152 97 334 85.0 1  4.36
10-6 35 58 56 98 60 244 100 1  0.62
10-6 - - - 120 55 2479 9 .6  1  0.77
Figure 5.4
Relationship Between Radioactiv ity  Displaced and Concentration of
[ 125i]_anp
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Preparation [125I1-ANP
(pM)
% Displaced
1 43.29 39.0
2 60.6 15.91
3 70.9 11.6
4 81.6 3.3
5* 88.6 27.0
6 90.9 -1 .6
Membranes prepared in the absence of DTT,
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Figure 5.5
Saturation Curve fo r  [125%]_AWP Binding to Rat Cardiac Sarcolemmal 
Membranes
Free
pM
[125j]_^l^p Bound (fmol/mg protein)
Total NSB Specific
2.48 9.53 1  0.36 5.31 1  0.54 4.22
4.15 15.1 1  0.27 6.47 1  0.27 8.64
7.76 21.6 1  0.63 8.77 1  1.35 12.8
14.65 35.1 + 0.45 13.8 1  0.81 21.4
29.18 56.7 1  1.17 24.8 ±  0.63 31.92
56.7 94.7 ±  3.24 47.9 + 3.33 46.76
105 203 1  6.56 99.1 + 2.34 104.3
206 334 1  7.10 195 ±  6.65 139
418 710 ±  39.6 394 ±  16.9 316
706 1101 ±  70.5 765 + 25.5 333
Figure 5.6
The e ffec t  of Phosphoramidon on [125i]_Awp Binding to Rat Cardiac 
Sarcolemmal Membranes
ANP Cpm bound (contro l)  X 100
(M) cpm bound (phosphoramidon) n t
0 104.6 1  1.36 3 3.38
10-12 106.5 1  4.70 3 1.40
10-10 111.6 ±  12.2 3 0.95
10-8 102.8 + 4.79 3 0.58
.4
Figure 5.8
Time Course fo r the Binding of [^^^I]-ANP to BAC Membranes
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Time
(min)
[^^^I]-ANP Bound (fmol/mg protein)
Total NSB Specific
0 .5 5.8 2.3 3.6
5 23.0 3.3 19.7
10 33.3 3.4 28.9
20 33.9 5.3 28.6
30 35.3 4.1 31.1
45 34.8 4.3 30.5
60 36.3 4.2 32.1
90 34.7 5.7 29.0
120 33.4 7.0 26.4
Figure 5.9
Saturation Curve fo r  [^^^I]-ANP Binding to BAC Membranes
Free
[ANP]
(pM)
[125I]-ANP Bound 
(fmol/mg protein)
Total NSB Specific
6.03 22.6 5.3 17.3
12.7 42.5 9 .9 32.7
25.8 78.0 17.6 60.4
51.3 152 28.7 124
105.7 278 63.0 215
226.3 554 127 427
481.3 994 211 783
Figure 5.10
Time Course for the Binding of [^^^I]-ANP to MOCK 
(s t ra in  I )  Membranes
15 2
T ime 
(min)
[125]^ANP Bound 
(fmol/mg protein)
Total NSB Specific
3 66±5 35+5 30
6 74+2 41+5 33
9 84_+l 41+3 43
12 102+5 39+3 63
15 115+11 41+6 74
20 117+2 38+1 79
30 130+2 42+3 88
45 126+4 40+2 86
60 127+2 40+3 88
1 5 3
Figure 5.11
Saturation Curve for [^^^I]-ANP Binding to MDCK 
(S tra in  I )  Membranes
[ANP]
Free
[125l]-ANP Bound 
(fmol/mg protein)
(pM) Total NSB Specific
9.38 62.9 7.5 55.4
18.7 112.5 13.1 99.4
40.4 193.8 23.8 170.0
77.9 275.0 47.9 227.1
155.1 367.8 96.3 271.5
301.4 483.9 182.6 301.3
612.9 689.4 380.1 309.3
1 5 4
Figure 5.12 & Figure 5.13
ANP Displacement of [^^^I]~ANP Binding to MDCK (S tra in  I )  Membranes
Specific [128i ] - anp Bound % Inhibition
ANP (fmol/mg protein) Mean + SEM ■Î
(M) 1 2 3 4
0 58 52 46 171 - 1
10-12 60 44 43 153 7.0+4.0 '
2x10-12 - 52 39 - 7.1+7.1
3x10-12 - - - 129 - 3
5x10-12 - 44 33 21.9+6.7 ■■
10-11 35 31 32 100 38.0+2.7
2x10-11 - 23 14 - 61.7+6.1
3x10-11 - - - 60 -
5x10-11 - 25 8 - 67.6+14.7
10-10 14 18 1 29 80.4+6.7
3x10-10 - 11 0 12 93.7+8.6
10-9 7 8 0 2 97.7+7.5
3x10-9 - 3 0 - 101.6+6.9
10-8 2 4 - 3 95.6+1.7
10-7 0 5 - 0 99.2+9.4 ' 4
1 5 5
Figure 5.14
ANP Displacement of [^^^I]-ANP binding to MDCK (Stra in  I I )  Membranes
ANP
(M)
Total [i^^I]-ANP Bound 
(fmol/mg protein)
0 1.20 0.45
10-12 1.96 1.96
2x10-12 1.11 1.52
5x10-12 0.79 2.24
10-11 0.98 0.35
2x10-11 1.71 0.03
5x10-11 -1 .26 0.54
10-10 -0 .5 0.82
3x10-10 0.32 0.13
10-9 0.29 0.22
3x10-9 0.35 0.44
10-8 0.32 0.19
10-7 -1.01 -0.38
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Figure 8.2
Comparison of the Volume of Rat and Rabbit Mvocvtes with the Number of 
Rods Present in the Preparation
Rabbit Rat
% Cell Vol. % Cell Vol.
Rods (jiim )^ Rods lurn^)
48 18019 64 20704
40 15699 80 21119
37 15277 70 26351
10 15531 79 21590
20 15813 79 18111
28 19268 29 17095
Figure 8.3
Standard Curve for HPLC Determination of ANP
Date ANP 
(nmol)
Area 
(220 nm)
AUFS Ret. Time 
(min)
3-12-87 1.43 1689595 0.2 33.73
4-12-87 1.60 1820294 0.05 33.15
4-12-87 0.80 1092462 0.05 33.15
4-12-87 0.40 618888 0.05 33.18
8-12-87 0.60 857806 0.05 35.06
8-12-87 0,60 820262 0.05 34.18
8-12-87 0.60 875563 0.05 33.44
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Figure 9.1
Degradation of [^^^I]-ANP by Rabbit Ventricu lar Myocytes
Time
(min)
[125ij_ANP Degraded 
fmol/min per 10^ Cells
4°C 20^0
5 3.67+2.68 29.53+0.53
10 5.93+1.33 62.20+1.22
15 10.60+0.92 85.13+1.86
20 15.60+1.50 101.8+1.39
30 19.00+3.06 131.9+3.15
45 30.33+3.01 144.7+4.30
60 31.07+.057 151.0+4.85
Figure 9.2
E ffec t of Preincubation Time on [^^^I]-ANP Degradation by Rabbit 
Ventricu lar Myocytes
Preinc.
(min)
[125 i ]_a (^ P Degraded 
fmol/min per 10^ ce l ls
Cell Suspen. Supernatant
0.5 1.46+0.03 0.82+0.04
10 1.60+0.03 1.21+0.04
30 2.01+0.04 1.49+0.06
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Figure 9.3
The Effect of Homogenization on the Degradation of 
[^^^I]-ANP by Rabbit Ventricu lar Myocytes
Time [125i]_ANP Degraded
(min) fmol/min per 10^ Cells
Cells Homogenate
5 5.28+1.24 11.84+0.02
10 13,28+0.36 23.24+1.12
15 20.28+0.64 35.80+0.36
20 27.36+0.40 45.84+1.20
25 37.36+0.56 56.48_+0.56
30 43.32+0.20 63.08+0.32
45 65.40+0.24 78.08+0.68
60 86.36+1.16 90.76+0.60
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Figure 9.4
The E ffec t of Heat Treatment on [^^^I]-ANP Degradation by Rabbit 
Ventricu1ar Myocytes
T ime 
(min)
[^^^I]-ANP Degraded 
fmol/10^ Cells
Control 60°C
0 0.03+0.72 1.8+3.1
5 116+14 10.0+1.8
10 208+10 16.2+1.6
20 361+7.3 27.9+3.0
40 470+5.3 44.8+1.9
60 559+13 64.3+1.3
Figure 9.5
The E ffec t  of Homogenization on the Degradation of 
[^ ^ I] -A N P  by Rat Ventricular Myocytes
Time
(min)
[125 i ]_anp Degraded 
fmol/ 10^ Cells
Cell Suspen. Homogenate
0 .5 - 73+3.4
30 73+11.2 688+11.2
60 194+4,5 1005+127
90 279+22.7 1443+16.6
120 338+12.1 1565+42.9
1 6 0
Figure 9.6
[125 i ] , anp Degradation by Rat Ventricular Myocytes at 20°C
Cells/ml
[125i]_ANP Degraded 
fmol/min per 10^ Cells
Cells Homogenates
2.6x10^ 7.32 -
4x10* 14.47 -
4xl0'* 5.93 -
2.5x10^ 4.12 22.13
1.3x10® - 9.80
3.4x10^ - 58.45
Mean+S.E.M 7.96+2.27 40.1+10.5
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Figure 9.6
[125i]_ANp Degradation by Rat Ventricu lar Myocytes at 37°C
[125i]_ANP Degraded 
fmol/min per 10^ Cells
Cells/ml Homogenates Sol.Fraction Pel le t
1.3x10^ 61.68 - -
5x15^ 68.7 54.4 -
5x10^ 73.86 48.8 38.0
5x10* - 55.9
SxlO* - 39.0 -
5x10* - 56.7 -
5x10'' - 27.0 -
6.5xl04 - 26.4 -
3.3x10'' - 38.15 -
5x10'' - 26.3 -
2.5x10* - 43.9 -
2.5x10* - 36.5 -
2.5x10* - 34.5 -
5x10* - 25.4 35.3
Mean + S.E.M. 68.1+3.5 39.5+3.2 36.7
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Figure 9.7
The E ffect of Various Protease In h ib ito rs  and Peptides on
In h ib ito r [M] Degradation 
% of Control
No. P<
Casein 10’ * 98.0+13.5 5 NS
PMSF 5x10'* 99.4+7.0 3 NS
Aprotinin 10-6 102.5+3.6 3 NS
Amastatin 10-6 98.9+3.2 5 NS
E-64 10-6 102.2+3.5 6 NS
Phosphoramidon 10-6 99.7+2.2 5 NS
1,10 Phenanthroline 10-6 7.2+2.6 5 0.001
Bacitracin Img/ml 0.89+1.25 3 0.001
EDTA 10-3 15.5+2.95 3 0.01
PCMB 10-6 9.7+3.74 3 0.01
ANP 10-6 6.9+3.97 3 0.01
Glucagon 3x10-6 32.3+8.59 4 0.01
Bradykinin 10-3 6.9+5.48 2 0.01
SQ 20881 10-3 83.7+3.1 3 0.05
BPFC 10-* 95.1+1.8 3 NS
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Figure 9.8
Dose Response Curves for the Inhibition of [^^^I]-ANP Degradation by
ANP, Glucagon, and Bradykinin
% of Control Degradation
Cone (M) ANP Glucagon Bradykinin
3x10-10 - 100.5 -
IQ-9 107.8+0.5 - -
3x10-9 - 100.1+1.3 -
10-8 97.1+0.5 - 106.5
3x10-8 - 103.6+1.7 -
10-7 77.2+4.5 - 107.7+4.1
3x10-7 53.3+2.2 102.7+8.7 -
10-6 29.1+2.4 - 100.7+4.8
3x10-6 13.7+4.0 68.7+7.2 -
10-6 6.9+3.2 78.9+4.0
3x10-6 - 32.3+8.6 -
10 -* - - 36.0+4.8
10-3 - - 5.5+3.9
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Figure 9.9a
The E ffec t  of pH on [^^^I]-ANP Degradation by a Soluble Fraction 
Iso lated  from Rat Ventricu lar Myocytes
pH [125 i ]_anp Degraded 
fmol/min/10® ce lls
4.78 3.39 + 0.65
5.32 3.91 ±  0.35
5.56 5.37 + 0.24
5.46 2.40 1  0.67
6.24 4.74 .+  0.85
6.85 8.49 + 1.18
7.38 19.17 + 0,45
7.86 41.77 1  2.09
8.43 55.16 + 1.45
9.42 57.55 ±  1.58
Figure 9.9b
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I  ime 
min
[125i]_anp Degraded 
fmol/10^ ce lls
pH 6.1 pH 6.1
5 97.1 1  10.9 90.2 1  4.3
10 161 ±  14.7 188 ±  7.3
pH 7.5
15 245 + 9.0 285 + 16.3
20 299 + 14.3 425 1  10.4
25 339 ±  6.0 582 ±  14.8
30 347 1  17.7 730 1  6.3
Figure 9.11
The Degradation of ANP following Incubation with Soluble Fraction from 
Rat Ventr icu lar Mvocvtes
I  ime 
(min)
Peak Area 
(x 10-3)
ANP 
(nmol)
0 858 0.609
2 424 0.175
5 344 0.95
10 N.D. -
20 N.D. -
40 N.D. -
90 N.D. -
N.D. = Not Detected
16 6
Figure 9.12
Time Course fo r  the Degradation Products of ANP
Inc.Time Peak Area xlO”^
(min) 1 2 3 4 5
2 51.5 48.9 - - 0.4
5 47.6 43.6 5.16 25.2 18.7
10 53.2 41.3 15.8 34.3 34.3
20 66.1 36.6 19.7 36.1 24.3
40 99.7 66.9 53.5 30.3 17.1
90 129 67.7 52.9 1.5 3.3
%ACN 19.2 22.8 35.0 43.5 45
Figure 9.13
The E ffect of Various Protease Inh ib ito rs  on [^^^I]-ANP Degradation by 
a Soluble Fraction from Rat Lung
In h ib ito r [M]
% Maximum 
Degradation No. P<
Phosphoramidon 10-5 96.3+11.6 3 NS
PMSF 5x10-4 98.5+2.4 4 NS
Aprotinin 10-5 100.8+1.2 3 NS
Amastatin 10-5 95.5+2.5 3 NS
E-64 10-5 105.2+5.5 3 NS
1,10 Phenanthroline 10-5 35.1+8.0 3 0.02
Bacitracin Img/ml 20.4+3.9 3 0.01
EDTA 10-3 101.5+3.8 2 NS
PCMB 10-5 88.9+4.3 3 NS
1 6 7
Figure 9.14
The E ffec t of Various Protease Inh ib ito rs  on [^^^I]-ANP Degradation by 
a Soluble Fraction from Rat Kidney Cortex
In h ib ito r [M]
% Maximum 
Degradation No. P<
Phosphoramidon 10-5 98.7+6.1 4 NS
PMSF 5x10-4 93.3+1.9 5 0.01
Aprotinin 10-5 99.5+1.3 3 NS
Amastatin 10-5 101.5+10.2 4 NS
E-64 10-5 95.1+7.2 5 NS
1,10 Phenanthroline 10-5 29.7+3.2 4 0.001
Bacitracin Img/ml 25.4+1.9 3 0.001
EDTA 10-3 71.3+6.4 4 0.05
PCMB 10-5 92.0+6.2 3 NS
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Figure 9.15
The Effect of Various Protease Inhibitors on [^^^I]-ANP Degradation by
a Soluble Fraction from Rat Kidney Medulla
In h ib ito r [M]
% Maximum 
Degradation No. P<
Phosphoramidon 10-5 83.8+4.7 3 NS
PMSF 5x10-4 93.9+3.4 4 NS
Aprotinin 10-5 99.5+0.9 3 NS
Amastatin 10-5 96.6+9.9 3 NS
E-64 10-5 102.1+1.7 3 NS
1,10 Phenanthroline 10-5 18.8+4.6 3 0.01
Bacitracin Img/ml 16.2+8.2 3 0.01
EDTA 10-3 72.6+10.7 2 NS
PCMB 10-5 79.7+4.1 3 0.05
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Figure 9.16
Dose Response Curves for the Inhibition of [^^^I]-ANP Degradation by
ANP, Glucagon, and Bradykinin
Cone (M) ANP Glucagon Bradykinin
10-9 98.9 - -
3x10-9 - 97.2+1.0 -
10-8 100+2.1 - -
3x10-8 - 97.9+4.2 -
10-7 81.9+3.6 - -
3x10-7 65.4+0.0 79.5+4.1 -
10-5 45.6+1.0 - 97.6+0.8
3x10-5 27.1+5.4 58.3+9.0 80.4+5.7
10-5 10.6+2.1 - 67.6+2.0
2x10-5 - - 52.6+0.8
3x10-5 - 32.5+5.0-
5x10-5 - 40.2+1.4
10-4 - 32.5+2.0
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Figure 9.17
Dose Response Curves fo r  the Inh ib it io n  of [^^^I]-ANP Degradation by 
ANP, Glucagon, and Bradykinin
Cone (M) ANP Glucagon Bradykinin
10-9 104.2 - -
3x10-9 - 106.7+2.3 -
10-8 103+2.0 - -
3x10-8 - 98.3+3.6 -
10-7 93.6+1.1 -
3x10-7 78.7+4.3 90.6+5.6
10-5 56.6+4.2 - 93.7+2.1
3x10-5 42.7+4.8 81.0+4.7 94.3+1.1
10-5 19.5+7.0 - 77.5+2.6
2x10-5 - - 64 .6±3.6
3x10-5 - 39.6+6.2
5x10-5 - - 55.1+4.7
10-4 - 47.1+8.3
1 7 1
Figure 9.18
Dose Response Curves for the Inhibition of [^^^I]-ANP Degradation by
ANP, Glucagon, and Bradykinin
Cone (M) ANP Glucagon Bradykinin
10-9 95.9 - -
3x10-9 - 97.7+1.8 -
10-8 97.5+18 - -
3x10-8 - 100.6+2.3 -
10-7 85.1+1.1 - -
3x10-7 56.9+3.5 95.1+2.3 -
10-5 36.0+2.8 - 97.1+0.2
3x10-5 19.9+4.4 81.1+4.3 87.9+3.9
10-5 9.6+2.0 - 72.9+2.9
2x10-5 - - 54.8+0.8
3x10-5 - 40.9+6.3 -
5x10-5 - - 36.0+1.1
10-4 - - 23.6+3.6
